

Drug Delivery[®]

Technology

November/December 2006 Vol 6 No 10

Partnerships, Technologies & Pipeline Report

IN THIS ISSUE

**Corporate
Profiles** 16

**Drug Delivery
Technologies** 73

**Excipients,
Polymers,
Liposomes &
Lipids** 90

**Contract
Pharmaceutical
& Biological
Development
Services** 96

**Machinery &
Laboratory
Equipment
and Software** 109

**Technology
Spotlight** 114

The science & business of specialty pharma, biotechnology, and drug delivery

www.drugdeliverytech.com

LEADING THE NEXT GENER

INNOVATIVE
SCIENCE

SUPERIOR
MEDICINES

PASSIONATE
PEOPLE



ATION OF DRUG DELIVERY

ALZA was founded on a vision of improving medicines to enhance patient care worldwide. Today, employees share in this vision and are exploring new ways to advance therapies. Through problem-solving strategies that address unmet patient and technology needs, ALZA is focused on drug delivery and drug targeting as a way to optimize the therapeutic utility of small molecules and biopharmaceuticals.

ALZA's commitment to develop solutions that address unmet patient needs has resulted in the industry's most extensive portfolio of drug delivery-based pharmaceuticals. Through substantial research and development, collaborative partnerships and a dedication to the highest scientific and ethical ideals, ALZA will continue to be at the forefront of novel drug delivery solutions.

AN EXPANDING BREADTH
OF TECHNOLOGIES



OROS®
D-TRANS®

D-TRANS®
STEALTH®

MACROFLUX®
DUROS®
ALZAMER®

www.ALZA.com



INTELLIGENT OUTSOURCING™

DRUG DELIVERY
DEVICE
DEVELOPMENT

&

CLINICAL TRIAL
BUILDS

BCTECH

VALVES & ACTUATORS • DOSE COUNTING
NASAL DEVICES • INFLATION CHECK VALVES
ACCELERATED FEASIBILITY TESTING

MECHANICAL ENGINEERS • ELECTRICAL ENGINEERS • SOFTWARE ENGINEERS
HUMAN FACTORS ENGINEERS • INDUSTRIAL DESIGNERS • REGULATORY AFFAIRS
QUALITY ASSURANCE • DOCUMENT CONTROL SPECIALISTS • MACHINISTS
MANUFACTURING ENGINEERS • CLEANROOM ASSEMBLERS



MEDICAL
DESIGN
EXCELLENCE
AWARDS
2005 WINNER



www.bctechinc.com 831.459.6464

Drug Delivery Technology

November/December 2006 Vol 6 No 10

PUBLISHER/PRESIDENT
Ralph Vitaro

EXECUTIVE EDITORIAL DIRECTOR
Dan Marino, MSc
dmarino@drugdeliverytech.com

CREATIVE DIRECTOR
Shalamar Q. Eagel

CONTROLLER
Debbie Carrillo

CONTRIBUTING EDITORS
Cindy H. Dubin
Debra Bingham
Jason McKinnie

TECHNICAL OPERATIONS
Mark Newland

EDITORIAL SUPPORT
Nicholas D. Vitaro

ADMINISTRATIVE SUPPORT
Kathleen Kenny

Corporate/Editorial Office

219 Changebridge Road, Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937
www.drugdeliverytech.com

Advertising Sales Offices

East & Midwest

Victoria Geis - Account Executive
Cheryl S. Stratos - Account Executive
103 Oronoco Street, Suite 200
Alexandria, VA 22314
Tel: (703) 212-7735
Fax: (703) 548-3733
E-mail: vgeis@drugdeliverytech.com
E-mail: cstratos@drugdeliverytech.com

West Coast

Warren De Graff
Western Regional Manager
818 5th Avenue, Suite 301
San Rafael, CA 94901
Tel: (415) 721-0644
Fax: (415) 721-0665
E-mail: wjdegraff@drugdeliverytech.com

International

Ralph Vitaro
219 Changebridge Road
Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937
E-mail: rvitaro@drugdeliverytech.com

Mailing List Rental

Candy Brecht
Tel: (703) 706-0383
Fax: (703) 549-6057
E-mail: cbrecht@mgilists.com

All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology (ISSN 1537-2898) is published 10 times in 2006, January, February, March, April, May, June, July/August, September, October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville NJ 07045. Subscription rates: \$99.00 for 1 year in the United States, Canada, and Mexico. \$153.00 for 1 year outside the United States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug Delivery Technology LLC subscription Department, 219 Changebridge Road, Montville NJ 07045. Single copies (prepaid) \$15.00, US, Canada, and Mexico; \$24.00 in all other countries. Add \$5.00 per order for shipping and handling. Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address changes to Drug Delivery Technology, 219 Changebridge Road, Montville NJ 07045. All rights reserved under the U.S., International and Pan-American Copyright Conventions. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording, or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery Technology LLC for libraries and other users registered with the Copyright Clearance, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470.

1956 was the year we
invented the world's first
metered dose inhaler,
making medical history
and improving the lives
of many millions of asthma
sufferers worldwide. "

In 2006 put our experience to work for you.

In 50 years we've taken MDI technology from pioneering invention to worldwide recognition with over 60 million metered dose inhalers produced by 3M annually. Our global regulatory experience, time-tested processes and flexible business models help take your molecules from discovery to commercialisation. And we're continually exploring future technologies and formulations, to meet the changing needs of the marketplace.

When you need drug delivery results, experience matters.

www.3M.com/DDS50years

Enabling your success

3M Drug Delivery Systems

© 3M 2006





Hand Off With Confidence

When partnership is
crucial to success

- Full Service cGMP Laboratory
- Analytical Chemistry
- Microbiology
- Clinical (Phase I-III)



800-229-9057
www.bioscreen.com



Table Of Contents

Company Profiles

16

For each participating company, this section presents a special 2-page spread featuring core technologies, capabilities, products, and services as well as visuals and complete contact information. Featured companies include:

3M Drug Delivery Systems	Capsugel	Hovione
ALZA Corporation	Cardinal Health	Huber Engineering
ASSA International	Coating Place	Iomed
BASF	Controlled Release Society	Kurve Technologies
Baxter BioPharma Solutions	Degussa	Lipocine
BC Technology	DPT Laboratories	Loparex Inc.
Bespak	Drug Delivery Partnerships	NOF Corporation
BD	Eurand	PharmaCircle
BioScreen Testing Service	ExcipientFest	PharmaMed Device
BioConvergence	Filtertek Inc.	RDD Europe
	Genzyme Pharmaceuticals	Safety Syringes
	Glatt Pharmaceutical Services	Scolr Pharma, Inc
	Halozyme	Weiler Engineering

Partnerships, Technologies & Pipeline Report

73

This Report, divided into four sections for Drug Delivery, Excipient, Contract Services, and Machinery & Laboratory Equipment & Software, provides a checklist of currently marketed technologies or services and their applications, pipeline/investigational technologies and their applications and stage of development, and partnerships. Technologies include:

Oral	Gene Therapy	Rectal
Inhalation	Mucosal	Vaginal
Transdermal	Capsules	Colon
Parenteral	Intranasal	Liposomes
Implants	Polymers	Lipids
Nasal	Biomaterials	Devices
Topical	Proteins & Peptides	Ocular
Transmucosal	Controlled Release	Excipients

Unique



Unparalleled taste Flexible dose Versatile release Robust tablet

AdvaTab® The next generation ODT

Eurand's AdvaTab is an orally disintegrating tablet (ODT) technology that combines superior taste and mouth feel properties in a robust tablet. AdvaTab is unique, offering both high dose capacity and modified drug release making it the most broadly applicable ODT available. Utilization of standard tableting processes allows for cost-efficient manufacturing and conventional packaging. The next generation ODT is here!



www.eurand.com

USA +01-937-898-9669
EU +39-02-95428-309

ODT

CUSTOMIZED RELEASE

TASTE MASKING

ENHANCED BIOAVAILABILITY

Table Of Contents

Drug Delivery Spotlight 114

To complement the Company Profiles and Special Report, this section examines innovative and emerging technologies, services, and devices, featuring dynamic 4-color visuals and contact information.



Surmount Delivery Barriers



With Our Self Correcting
Oral Systems

Our suite of patented self-correcting oral delivery systems can handle your most challenging drug or nutritional ingredient. CDT®'s simple but elegant technology provides partners with rapid product development and the highest possible success in clinical trials.

- Our **"Dual Polymer"** platform allows production of novel Matrix tablets and capsules regardless of their initial flow properties.
- Our **"Electrolyte"** platform is capable of custom tailored release profiles, including zero order, that can emulate complex delivery systems. (i.e. osmotic pumps, bead systems, layered tablets)
- Our **"Amino Acid"** platform can enhance solubility to allow precision controlled delivery in simple monolithic dosage forms.

SCOLR, CDT Logo & Design are trademarks of SCOLR Pharma, Inc. • CDT is a registered trademark of SCOLR Pharma, Inc.

SCOLR Pharma, Inc.
Self Correcting Oral Delivery Systems

3625 132nd Ave S. E. • Suite 300
Bellevue, WA 98006
425.373.0171
www.scolr.com

The EDITORIAL Advisory Board



Dan Marino, MSc
Executive Editorial
Director
Drug Delivery
Technology



Jack Aurora, PhD
Director, Pharmaceutical
Research & Development
Pharmascience, Inc



John A. Bermingham
President & CEO
Ampad, LLC



Matthew D. Burke, PhD
Investigator,
Pharmaceutical Development
GlaxoSmithKline



Sarath Chandar, MBA
Vice President, Global
Marketing & Commercial
Development
SPI Pharma



**Mahesh Chaubal,
PhD, MS**
Associate Director
Baxter Healthcare



**Gary W. Cleary, PhD,
PharmD, MBA**
President & CTO
Corium International



**Sonya Summerour
Clemmons, PhD, MBA, MS**
Director, Business
Development
MediVas, LLC



James N. Czaban, JD
Attorney at Law
Heller Ehrman White &
McAuliff, LLP



John Fraher
President, North America
Eurand



Philip Green, PhD
Director of Business
Development
Advanced Drug Delivery
BD



Keith Horspool, PhD
Director, Research
Formulations
Pfizer Global Research &
Development



Ravi Kiron, PhD, MBA
Executive Director, New
Technology Assessment &
Planning
ALZA Corporation



David C. Klonoff, MD, FACP
Clinical Professor of
Medicine - UC San Francisco
Medical Director
Mills-Peninsula Diabetes
Research Institute



Uday B. Kompella, PhD
Associate Professor of
Pharmaceutics
University of Nebraska
Medical Center



James W. McGinity, PhD
Professor of Pharmaceutics
University of Texas
at Austin



Nasser Nyamweya, PhD
Technical Service Manager
Degussa



Kinam Park, PhD
President
Akina, Inc



Philip L. Smith, PhD
Investment Manager
S.R. One, Limited,
GlaxoSmithKline



Ronald L. Smith, PhD
Director of Exploratory
Biopharmaceutics &
Drug Delivery
Bristol-Myers Squibb
Research Institute



Cornell Stamoran
VP, Strategy & Business
Process
Cardinal Health, PTS



Tom Tice, PhD
Executive Vice President
and Chief Scientific Officer
Brookwood
Pharmaceuticals



James Vaughan
General Manager
3M Drug Delivery
Systems



Howard S. Wachtler
President & CEO
Actinium
Pharmaceuticals



Henry Y. Wu, PhD, MS
Associate Director
Merck Research
Laboratories



Now open for business.

The power of pulmonary delivery with PROMAXX microsphere technology.

By giving you precise control over microsphere size and uniformity, PROMAXX facilitates development of pulmonary formulations. This versatile platform works with a wide range of compounds, from proteins and peptides to small molecules.

Plus, you can trust the experienced Baxter team to work with you to solve your unique formulation challenge.

Add powerful new potential to your drug pipeline with PROMAXX. To learn more, visit www.baxterbiopharmasolutions.com. For specific requests, send an e-mail to PROMAXX@baxter.com, or call 1-800-422-9837.



PROMAXX microsphere technology delivers unique particle size control ideal for inhalation therapies.

BioPharma Solutions

Baxter

Connect to the resources you need.



*Plan
ahead
for...*

**Ninth International
Workshop**

IWPCPS®-9

**June 24 - 29, 2007
Crowne Plaza Boston Natick, USA**

- Information exchange about cutting edge methods for solid state characterization;
- Review of most recent regulatory issues;
- Presentation of the latest research results in drug development and future outlooks.

**The Most Advanced Workshop
in Pharmaceutical Sciences**

Space is limited!

For more information please check

www.assainternational.



©2006 assa Inc.

MARKET NEWS AND TRENDS

Tris Pharma Unveils Expansion of State-of-the-Art Research Facility

Tris Pharma, a privately owned specialty pharmaceutical company, recently unveiled a new state-of-the-art research and manufacturing facility at a South Brunswick, New Jersey, campus. These expanded capabilities are a result of the company's success with its innovative drug delivery technologies.

This 30,000-square-foot expansion adds a state-of-the-art, FDA-compliant cGMP facility and marks the transition of Tris Pharma to a technology firm that has all the capabilities, including manufacturing, in one facility. The company can provide its partners clinical supplies, submission batches, eCTD filing, and medium-scale commercial production of tablets, capsules, liquid suspensions, and oral solutions, and packaging for the finished products.

"This facility enhances our manufacturing capabilities and also enables us to continue to invest in our drug development," said Ketan Mehta, CEO and Founder of Tris Pharma. "This is the final piece of the puzzle for our first phase of growth and keeps our operations scalable to keep pace with several more deals and new technologies in the pipeline."

Tris Pharma envisioned a cutting-edge manufacturing facility and set out to build it. Rather than rely on outside contractors, the company hired top experts in the field to design and build the plant from scratch. The result is 15 cGMP suites that are completely flexible, with end-to-end in-built utilities and features that streamline the drug production process. The new facility also expands the company's current capabilities by including a commercial-size vault for DEA controlled substances with manufacturing license of Schedules I to IV.

"The relationship between Interpharm and Tris Pharma has been an important partnership for the development of our joint products," added Cameron Reid, CEO of Interpharm. "As we move toward commercialization, Tris will bring their manufacturing capability to the table for our liquid products."

Tris Pharma is a privately owned product-focused specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. The company's proprietary technologies enhance solubility and bioavailability, provide controlled-release formulations for solid and liquid dosages, and offer orally disintegrating tablets for immediate and controlled release.

AVEVA

DRUG DELIVERY SYSTEMS

A Nitto Denko Company

Aveva Drug Delivery Systems is recruiting for the following positions:

Sr. Quality Control Supervisor
Analyst II, Quality Control
Analyst II, Analytical Development
Analyst III, Analytical Development

Please visit our website at www.avevadds.com for more details.

MARKET NEWS AND TRENDS

Study Shows Patient Preference for Gonal-f® RFF Pen to Treat Infertility

Serono recently announced the results of a Phase IIIb, prospective, open-label study in which patients reported that they preferred the Gonal-f RFF Pen (follitropin alfa injection) to their previous fertility treatment with conventional vials/ampules and syringes. The study was published by the peer-reviewed journal Current Medical Research and Opinion

“Patient satisfaction is a critical component to infertility treatment success,” said Stephen G. Somkuti, MD, PhD, the lead author and coordinating investigator from Abington Reproductive Medicine, Abington, PA. “By providing products that patients prefer, fertility centers may minimize treatment dropout rates while increasing the chance of a positive outcome.”

All participants who stated an injection preference (n = 61/61) found use of the Gonal-f RFF Pen to be less stressful than methods involving vials/ampules and syringes (95% confidence interval [94.1%, 100.0%]) and would recommend it to other women considering gonadotropin treatment (p < 0.001). In addition, 89% (n = 54/61) of patients found instructions for using the Pen very easy to understand compared with 29% (n = 17/59) who found the same for vials/ampules and syringes. When using the Pen, a significantly smaller proportion of patients contacted their healthcare provider two or more times to ask questions about dose preparation (3%, n = 2/61) compared to when using vials/ampules and syringes (19%, n = 11/59, p = 0.007).

“Serono is committed to advancing the field of reproductive health by improving the patient experience,” said David Stern, Executive Vice President, Endocrinology, Serono, Inc. “This study strongly supports the use of the Gonal-f RFF Pen, which was designed to be quick and easy for patients to use. Through other research, we also know that support services, such as Fertility LifeLines also help people manage their experience with infertility.”

The most prescribed gonadotropin in the world, Gonal-f is a highly consistent recombinant form of human follicle stimulating hormone (r-hFSH) prescribed to supplement or replace naturally occurring FSH, which stimulates the development of follicles in the ovaries. A prefilled and ready-to-use multi-dose device, Gonal-f RFF Pen delivers a liquid formulation of Gonal-f RFF without needing to mix medications or load cartridges.

About 12% of women (7.3 million) in the US aged 15 to 44 had difficulty getting pregnant or carrying a baby to term in 2002, according to the National Center for Health Statistics of the Centers for Disease Control and Prevention. The majority of patients who complete treatment eventually succeed in having a child. The Phase IIIb, prospective, open-label study was conducted at nine fertility centers in the US and included 62 premenopausal women ages 18 to 40 years undergoing ovulation induction for oligoanovulatory infertility. Using the Gonal-f RFF Pen, patients administered a fixed dose of recombinant follitropin alfa for 5 days followed by dose adjustment if necessary until a lead follicle reached a mean diameter K 14 mm. Eligible patients had undergone at least one treatment cycle of gonadotropin therapy administered with vials/ampules and syringes within the past 6 months. Patient satisfaction with prior gonadotropin therapy was measured using a pre-treatment questionnaire while patient satisfaction with the Gonal-f RFF Pen was measured using an in-treatment questionnaire as well as a post-treatment interview that asked participants to compare their treatment experiences and choose a preferred injection method. The primary endpoint was the proportion of patients who preferred the Gonal-f RFF Pen to vials/ampules and syringes. All patients who completed the primary endpoint (61/61, 100%) preferred the Gonal-f RFF Pen. The majority of women ovulated (79%) and pregnancy was achieved in 12 women (20%). Of these 12 pregnancies, eight were clinical (fetal sac), three were biochemical, and one was ectopic. No patients withdrew from the study due to adverse events.



Bespak: The critical component in device development

You make a significant financial, intellectual and emotional investment in your device programmes. To ensure you have the best possible chance of success, you deserve a strong, experienced and expert device development partner.

At Bespak we work hard to be that partner for the world's pharmaceutical, biotechnology, medical device and diagnostics companies; one that can add value at every stage of the product life-cycle to bring about faster development times, thorough regulatory conformance, improved processes and effective risk management.

Our proven track record, robust and flexible methodologies combined with a deep understanding of what it takes to deliver even the most complex devices, means we are well placed to be the partner of choice for your next programme.



+44 (0)1553 691000 • www.bespak.com

bespak



PharmaCircle LLC
Tel: (847) 729 2960
email: tkararli@pharmacircle.com

<http://www.pharmacircle.com>

COMPREHENSIVE AND UP-TO-DATE ANALYSIS

... of companies, drug delivery technologies, pipeline, products, deals, patents, and more.

- > Fully searchable and detailed info about formulation, dosing, pharmacokinetic and physical-chemical properties for products and molecules
- > Facilitates technology selection, formulation development, product lifecycle management (LCM), partnering, licensing and CI efforts
- > Saves time and resources while supplementing internal expertise and efforts
- > Easily accessible on the Web

<http://www.pharmacircle.com>

Endo Pharmaceuticals Acquires RxKinetix; Deal Worth Potentially \$95 Million

Endo Pharmaceuticals Holdings Inc. recently announced its wholly owned subsidiary, Endo Pharmaceuticals Inc., has acquired all of the outstanding stock of RxKinetix, Inc., a privately held company headquartered in Boulder, Colorado, that develops new formulations of approved products for oral mucositis and other supportive care oncology conditions. The company and its 21 employees will now operate as part of a newly created wholly owned subsidiary of Endo Pharmaceuticals Inc.

The transaction includes an up-front payment of up to \$20 million, with the potential for up to an additional \$95 million in earn-out payments based on clinical development and regulatory milestones. The acquisition is expected to be dilutive to Endo's 2006 adjusted earnings by approximately \$0.02 per adjusted diluted share based on incremental research and development expense. This excludes transaction-related expenses and the one-time charge for the write-off of acquired in-process R&D expense of approximately \$26 million, subject to final purchase price allocation, to be taken in the fourth quarter of 2006.

RxKinetix's lead product is RK-0202, a topical oral-rinse with the active ingredient formulated in its proprietary ProGelz drug delivery platform. RK-0202 is in clinical Phase II for the prevention of oral mucositis (OM), painful mouth sores that often occur in cancer patients undergoing radiation and chemotherapeutic treatment. RxKinetix also has other products in early stage development based on the ProGelz technology.

"The acquisition of RxKinetix is consistent with our strategic goal of expanding into therapeutic areas that are complementary to pain," said Peter A. Lankau, President and Chief Executive Officer of Endo. "Endo has expanded its

commercial presence among oncologists with the recent launch of Opana ER and Opana tablets, and Rapinyl, our quick-dissolving fentanyl tablet in development for breakthrough cancer pain, is currently in Phase III trials. A product such as RK-0202, if approved, would be a natural extension of this franchise, and we look forward to working with our new colleagues in the development of this and other cancer-related palliative care treatments in the RxKinetix pipeline. We intend to continue to seek similar specialist-focused opportunities in supportive care oncology and other complementary therapeutic areas." Endo plans to conduct additional Phase II trials of RK-0202 to continue to characterize the clinical profile of the product in the intended patient population - head and neck cancer patients undergoing combination treatment of radiation and chemotherapy. During the course of high-dose cancer therapy and bone marrow transplantation, patients often develop painful and debilitating oral inflammation, or mucositis, in the mouth. The resulting weight loss, dehydration and, in some cases, infection often lead to dose-limitation of chemotherapy and radiation therapy, and contribute considerably to cancer and transplant-related morbidity and mortality. Further, these side effects add to related medical costs by prolonging hospital stays, increasing antibiotic, fluid, and analgesic use, and requiring patients to receive parenteral nutritional support. Of the estimated 900,000 chemotherapy-treated patients in the US, 400,000 may develop the debilitating complications of oral mucositis as a result of their treatments.

Endo Pharmaceuticals Holdings Inc. is a fully integrated specialty pharmaceutical company with market leadership in pain management products. Through its Endo Pharmaceuticals Inc. subsidiary, the company researches, develops, produces, and markets a broad product offering of both branded and generic pharmaceuticals, meeting the needs of healthcare professionals and consumers alike.

MARKET NEWS AND TRENDS

Eurand Announces License Agreement With GlaxoSmithKline

Eurand recently announced it has entered into a development and license agreement with GlaxoSmithKline whereby Eurand will use its Microcaps taste-masking and AdvaTab oral disintegration tablet technologies to develop a new formulation of an undisclosed GlaxoSmithKline (GSK) product. Under the terms of the agreement, GSK will fund the development of the product, and Eurand will receive royalties on product sales. GSK will have exclusive rights in the US to commercialize the new product, and GSK and Eurand each have certain rights to commercialize the product outside of the US. Eurand will retain exclusive, worldwide manufacturing rights. It is expected that the companies will commence clinical trials under the agreement in 2006 and apply for marketing authorization in the US by the end of 2007.

GSK will pay Eurand aggregate payments of up to \$42 million based upon achievement of certain development, regulatory, and sales milestones. Additional terms of the agreement have not been disclosed.

"We are delighted that GSK has chosen Eurand for this important project; we believe it further confirms our market-leading position in the fields of taste-masking and oral disintegrating tablets," said Gearóid Faherty, Chief Executive Officer of Eurand. "The combination of our Microcaps and AdvaTab technologies has received an enthusiastic reception from industry leaders, such as GSK, and we are currently in advanced contract negotiations with companies in Japan, Europe, and the US for a range of different products."

Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug delivery technologies. The company has had three products approved by the FDA since 2000 and has an extensive pipeline of products in development for itself and its partners. The company's most advanced development product, a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and other diseases, is currently undergoing Phase III clinical trials in the US. Eurand's technology platforms include: bioavailability enhancement of poorly soluble drugs, customized release, taste-masking/fast-dissolving formulations, and drug conjugation. Eurand is a global company with research, development, and manufacturing facilities throughout the world.

SPI Pharma's Pharmaburst? Patent Issued!

SPI Pharma's novel excipient system, Pharmaburst, was granted a US patent on October 10, 2006. (US Patent No. 7118765; Issued: 10/10/2006; Co-processed carbohydrate system as a quick-dissolve matrix for solid oral dosage forms):

"The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity shall dissolve or disintegrate, preferably within about 60 seconds."

Since the introduction of this novel drug delivery platform by SPI in 2002, several Pharmaceutical (Rx, OTC) and Nutraceutical products based on Pharmaburst technology have been successfully launched in the US, Europe, Asia, and South America. Several NDA, ANDA, and European applications have been filed for "Orally Dispersible" drug formulations that use Pharmaburst as their primary platform. Also, SPI has filed a new drug application patent, on a co-ownership basis, with a major pharmaceutical company. Given the fact that there is a minefield of patents in the field of "Orally Dispersible" dosage forms, using the patented Pharmaburst platform will give SPI customers a "peace of mind."

SPI Pharma is a world wide leader in custom formulation solutions for pharmaceutical and nutraceutical manufacturers. By offering raw materials, processing capabilities, and advanced application technologies, the company has become a valued source for complete custom delivery systems. This provides a competitive advantage for its customers' formulations.

What if ...

**your contractor
performed like part
of your company?**

BioConvergence works with you like a colleague down the hall, operating much like a department within your operation. Our secure extranet allows you to monitor the latest developments, activities, and reports for your project.

Parenteral Development

- Lyophilization cycle development/ optimization
- Formulation development
- Analytical development/validation
- GLP toxicology batch manufacturing

Storage and Logistics

- 20,000 SF of 2 to 8° C
- 10,000 SF of 15 to 25° C
- Additional storage for -20 to -80° C
- For API, Finished Product, and WIP

Consulting Services

- Person-in-the-plant
- Quality assurance auditing
- Engineering

Women-owned business

- Experienced staff with 70+ years of experience
- New state-of-the-art facility
- Headquartered in Bloomington, Indiana

BioConvergence
LLC

Call us. We answer.

Allisa Wright
CEO

Jennifer Winders
Business Development Mgr

1-800-978-2462

www.bioc.us

COMPANY PROFILE

Enabling your success

3M Drug Delivery Systems

3M DRUG DELIVERY SYSTEMS

3M Center, Bldg. 275-3E-10

St. Paul, Minnesota 55144-1000

T: (800) 643-8086 • F: (651) 737-5265

Website: www.3M.com/DDS



3M Drug Delivery Systems is a global leader and innovator for inhalation and transdermal drug delivery. Between drug discovery and commercialization, 3M Drug Delivery Systems offers...

- Innovative and proven technology
- Product development services
- Global regulatory expertise
- Commercial manufacturing
- Broad range of customizable system components

Our technology, expertise and experience can provide pharmaceutical and biotech companies with:

- Differentiated products
- Speed to market
- Increased probability of technical and commercial success

3M's proven track record includes development of the first metered-dose inhaler (MDI), development of the first HFA MDI, and the development of the first stand-alone 7-day transdermal system. Products manufactured by 3M Drug Delivery Systems are currently sold in more than 60 countries on six continents.


We combine the agility of a leading drug delivery company with the resources of a major, multinational corporation. 3M provides expertise in product development, regulatory and manufacturing to enable you to get to market sooner.

Our expertise increases your opportunity for success. www.3m.com/dds

When you need drug delivery results

experience matters

3M has been developing and manufacturing successful drug delivery solutions for more than 50 years. Put our experience to work for you.



Inhalation and transdermal solutions from 3M

Product development services

Pilot and commercial scale manufacturing

Global regulatory expertise

Dedicated program and alliance management

Broad range of customizable metered dose inhaler and patch components

Partner with 3M to enable your success.



For more information on how 3M can enable your success, visit our **NEW** Web site at 3m.com/ddsadv.

1-800-643-8086 ext. 700 U.S. | 44 (1509) 613626 U.K.

(81) 3-3709-9671 Japan

Enabling your success
3M Drug Delivery Systems



COMPANY PROFILE



The Chemical Company

BASF CORPORATION


100 Campus Drive
Florham Park, NJ 07932

Tel : (800) 443-0627 - Fax : (973) 245-6763

Web: www.pharma-solutions.basf.com - Email: pharmasolutions@basf.com

KEY CONTACTS

Key contacts for BASF Pharma Solutions in North America: Folker Ruchatz, Director; Javier Beeck, Marketing Manager
Anisul Quadir, Technical Services Manager



Company Description

BASF helps pharmaceutical companies to be successful with:

- a broad portfolio of excipients and active ingredients;
- contract manufacturing services including pharmaceutical finishing and exclusive custom synthesis;
- the services of an experienced technical staff with industry-specific formulation expertise.

BASF offers excipients and active ingredients with proven quality and reliability, and expertise in chemistry that dates back to 1865.

Products and Services

BASF offers excipients such as Kollidon® binders and disintegrants, Ludipress® direct tableting aids, Lutrol® and Cremophor® solubilizers and emulsifiers, and Kollicoat® coatings. Actives include ibuprofen, pseudoephedrine, ephedrine, caffeine, theophylline, and retinols. BASF's Shreveport, La., pharmaceutical finishing plant is a flexible, high capacity site for the manufacture of solid and semi-solid tablets, capsules, liquids and creams.

What's New

Ibuprofen DC 85* can help pharmaceutical companies to eliminate steps associated with wet granulation and compaction processes currently employed for typical ibuprofen powders. Using a proprietary nanoparticle crystal coating, Ibuprofen DC 85 grade does not require the addition of a lubricant to prevent sticking. As a result, it permits up to 85% API in formulations, which enables the production of smaller, easier-to-swallow tablets. It blends well with excipients, so it can also be diluted to formulations with lower API concentrations.

Services: BASF's Shreveport, La., contract manufacturing facility is a flexible, high capacity site able to handle the manufacturing of solid and semi-solid dosage forms of tablets, capsules, liquids and creams. The site has been producing quality pharmaceuticals for nearly two decades and is among the leading U.S. manufacturers of prescription-strength ibuprofen tablets. The facility meets cGMP and is able to handle up to Schedule II compounds, from raw materials through packaging of finished product. Our capabilities include: manufacturing of solid dosage forms: aqueous and solvent granulations, compression, coating, printing, manufacturing of creams and liquids and packaging.

On the exclusive custom synthesis side, BASF is building a new, multi-product plant for pharmaceutical active ingredients – an expansion of our current production site in Minden, Germany.

BASF's Technical Service Center in Ledgewood, N.J. houses laboratory equipment used for dosage-form formulations and physical/chemical analysis. Our pharmacists and chemists provide specialized expertise to assist customers with their product and process developments. One of the main advantages of this facility is its New Jersey location – which is close to many pharmaceutical companies and their research and development laboratories.

*New product pending US FDA approval



Helping Make
Pharmaceuticals Better™

 **BASF**

The Chemical Company

Kollidon® is well known as a universal excipient range for more than 60 years.

New: 4 dimensions of Kollidon® CL – standard, fine (CL-F), superfine (CL-SF) and micronized (CL-M) for your individual needs.

Kollidon® CL, the cross-linked PVP, is not only one of the three “superdisintegrants.”

Kollidon® CL accelerates dissolution and improves bioavailability, thanks to its power to form complexes with insoluble actives.

Pharma Solutions by BASF:

- **Excipients**
- **Actives**
- **Contract Manufacturing**
- **Value Added**

BASF Corporation
100 Campus Drive
Florham Park, NJ 07932

- Tel. (800) 443-0627
- Fax (973) 245-6763
- Technical Services (800) 469-7541
- www.pharma-solutions.basf.com
- pharmasolutions@basf.com

Accelerators

Kollidon® CL
Kollidon® CL-F
Kollidon® CL-SF
Kollidon® CL-M

Superdisintegrants and dissolution enhancers.

COMPANY PROFILE

Baxter

BAXTER HEALTHCARE CORPORATION

US: (800) 422-9837

Direct: (847) 948-4770

F: (847) 948-3642

E: onebaxter@baxter.com

Website: www.baxterbiopharmasolutions.com



Baxter Healthcare Corporation's award-winning BioPharma Solutions business is dedicated to pharma and biopharma customers, offering contract services and proprietary technologies focused on parenteral (injectable or pulmonary) delivery. Contract services include: development, form/fill/finish into syringes, vials, and cartridges, lyophilization and cytotoxics manufacturing. Proprietary technologies include NANOEDGE dispersion and PROMAXX microsphere formulation technologies and enhanced packaging.

Contract Services - Recipient of the 2006 pharmaceutical Facility of the Year Award, Baxter's Bloomington facility has expanded capacities for syringe and vial filling/finishing, making Baxter the global SCF leader in prefilled syringes. We have added new capability in cartridge filling/finishing, as well as a fully automated kitting line. Our newest lyophilization and vial-filling lines are specifically designed for biologics; lyophilization capacity has increased along with the advancement of the Lyophilization Center of Excellence. Baxter can also provide analytical and microbiological services as well as validation and regulatory assistance.

In our German facilities, we can take you from scale-up to commercial production for dedicated cytotoxic contract services. Our state-of-the-art facility features advanced aseptic processing using barrier isolator technology. Our technologies include lyophilization, aseptic liquid vial filling, dry powder vial filling and sterile crystallization. Other services include stability storage, validation and documentation, and analytical services.

Baxter is a proven CMO provider offering best-in-class parenteral outsourcing solutions including:

- Reliable supply – complete contract manufacturing resources
- Expertise – highly skilled solutions for a streamlined path to market
- Bottom-line results – lower expenses and increased revenue.

Proprietary Formulation Technologies - NANOEDGE dispersion technology offers innovative formulations for your solubility challenges and is applicable for multiple routes of administration. It reduces the particle size of most drugs to nanometer size, which can enhance a drug's saturation solubility and dissolution rate and eliminates the need for undesirable cosolvents.

The PROMAXX microsphere technology is a unique, elegant and cost effective formulation platform, tailored to fit your specific requirements. It is applicable to a broad range of molecules- from small molecules and nucleic acids to peptides and proteins. PROMAXX technology can offer high drug loading and precise particle size control and enable dosing flexibility across various administration routes.



You've invested many years
in your biologic molecule.

We've invested more than
\$300 million to help it succeed.

Discover Baxter's specialized contract services for vial filling and lyophilization.

Getting your biologic to market is a long, complex process. And the commercial development phase can make a critical difference in its final success.

Baxter's newest lyophilization and vial-filling lines in Bloomington, Indiana, are designed to help your molecule succeed. Specifically developed for biologics, they utilize 100% in-line, nondestructive check weighing with automated process-control feedback to significantly reduce waste.

Our lines include highly sophisticated temperature control systems for complete cold-chain filling—from tank to filling head and from accumulation table to automated lyophilization loading and unloading. State-of-the-art processing is available for nonbiologic manufacturing as well.



Our award-winning facility is supported by a dedicated scientific team with in-depth large molecule experience and industry-leading lyophilization expertise. Find out today how we can help reduce your risks and speed your success on the path to market.

Connect with us today at www.baxterbiopharmasolutions.com or call 1-800-4-BAXTER.



BioPharma Solutions

Baxter

Connect to the resources you need.

COMPANY PROFILE



Blackhill Drive, Featherstone Road, Wolverton Mill South
Milton Keynes, Buckinghamshire MK12 5TS - United Kingdom
T: +44(0)1908 552600 F: +44(0)1908 552613
E: bizdev@bespak.com - Website: www.bespak.com



Bespak plc is a global leader in specialty medical devices, developing delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings. Bespak has an unrivalled ability to take devices safely to market.

- Bespak offers its customers expertise at every stage of the product life-cycle from concept creation to manufacturing.
- Bespak has developed a range of value-added services that assist in getting products to market. Our laboratories are frequently audited by US and European regulatory bodies and ensure conformity throughout the development and marketed life of the product.
- Bespak has developed Metered Dose Inhaler (MDI) valves for more products currently marketed with hydrofluoroalkane (HFA) formulations than any other manufacturer.
- Bespak has industrialized more Dry Powder Inhalers than any other company.

The group has facilities in Indianapolis, IN, and Kent, OH, in the US, King's Lynn and Milton Keynes in the UK, and a liaison office in Mumbai, India. Bespak's own product range includes:

- MDI Valves • Dose Counter & Regime Assurance Devices • Breathing Circuits • Laryngeal Tubes
- Actuators • Disposable Face Masks • Nasal Delivery Systems • Medical Check Valves

The company also develops and manufactures some of the world's most successful devices for major global pharmaceutical and healthcare companies. Products include:

- Dry Powder Inhalers for Respiratory Drugs • Dry Powder Inhalers for Protein & Peptide Delivery
- Needle-free Injection Devices • Diagnostics Components & Products

Bespak plc operates three complementary business units.

Device Manufacturing Services

For more than 40 years, Bespak has contributed to the design, development, and industrialization of leading medical devices. Bespak provides the capability and expertise to minimize time to market, allowing products to be created, tested, and manufactured faster and with less risk. Through an in-depth understanding of design for manufacture and a robust continuous improvement approach, Bespak offers an unrivalled ability to manage a device throughout life.

Bespak Respiratory Products

Bespak's MDI valves ensure precise dose delivery of some of the world's most prescribed respiratory drugs. Bespak offers a broad portfolio of patented valves, actuators, and accessories as well an intellectual property portfolio, including intelligent devices, such as dose counters and nasal devices.

Anesthesia & Critical Care Products

Through a wholly owned subsidiary, King Systems, Bespak is a custom manufacturer of anesthesia and respiratory care products, offering full research and development, quality assurance, marketing, and sales operations. King Systems now offers more than 3,500 different circuit configurations, four product lines of face masks, and hundreds of other products.

PLEASE MARK YOUR CALENDARS AND PLAN TO ATTEND!

We are pleased to announce:

RDD EUROPE 2007


Respiratory Drug Delivery



APRIL 17 - 20 , 2007
Novotel Paris-Tour Eiffel
Paris, **FRANCE**

Information: www.rddonline.com
www.pfeiffer.de
www.valoispharma.com

Consider submitting a poster abstract? The deadline is January 8, 2007



RDD Europe is a conference jointly organized by



COMPANY PROFILE



Helping all people
live healthy lives

BD MEDICAL - PHARMACEUTICAL SYSTEMS

1 Becton Drive
Franklin Lakes, NJ 07417
T: (800) 225-3310
F: (201) 847-4847

E-Mail: BDPS_marketing@bd.com
Website: www.bdpharma.com



BD Medical - Pharmaceutical Systems is dedicated to developing prefilled drug delivery systems designed to fit the needs of the pharmaceutical industry.

Whether a glass or plastic prefilled syringe, a nasal spray system, a dry drug

reconstitution system, an injection or self-injection device, BD Medical - Pharmaceutical Systems provides the expertise and experience required by the pharmaceutical industry in a packaging partner. We deliver cost-effective alternatives to conventional drug delivery methods, which differentiate pharmaceutical products and contribute to the optimization of drug therapy. All our prefilled devices are designed to meet healthcare professionals' demands for safety and convenience and to fulfill patients' needs for comfort.

With a broad range of innovative devices and services, BD Medical - Pharmaceutical Systems provides pharmaceutical companies with support and resources to help them achieve their goals. Our worldwide presence, market awareness and pharmaceutical packaging know-how allow us to propose suitable solutions for all regional markets and parenteral drug delivery needs.

BD Hypak™

Glass Prefillable Syringes



Customizable Solutions & Unparalleled Support

Strategic Marketing

- An understanding of market trends for parenteral delivery systems
- Recognized leader in safety solutions
- Capable of adapting your product to meet regional needs in a global world

Quality and Regulatory Specialists

- BD Hypak Syringe materials conform to US, European, and Japanese pharmacopoeias
- Drug Master File and a Technical Dossier for product registration worldwide
- Our regulatory experts are ready to assist you



Helping all people
live healthy lives

Technical Expertise

- Partnering with machine manufacturers to meet all your processing requirements
- Our Technical Support Team is ready to assist you during any phase of processing
- Expert project teams are ready to propose innovative solutions to meet your specific drug-delivery needs

**For more information, please call 800.225.3310
or visit www.bdpharma.com**

BD Medical
Pharmaceutical Systems
1 Becton Drive
Franklin Lakes, NJ 07417
BDPS_marketing@bd.com

COMPANY PROFILE

BioConvergence™

BIOCONVERGENCE LLC

Business Development

4320 West Zenith Drive

Bloomington, IN 47404

T: 812.961.1700 - F: 812.961.1733

E: info@bioc.us - Website www.bioc.us



Corporate Description: BioConvergence is an experienced contract service provider offering cGMP parenteral product development, cGMP materials management (including cold chain storage), and consulting services to the pharmaceutical industry. Our e-transparency solution, which is the first of its kind, provides clients real-time secure access to their data found in our research scientists' laboratory notebooks, ERP material transactions, and SOPs. Located in Bloomington, Indiana, BioConvergence is a women-owned business dedicated to providing best-in-class outsourcing services. Our scientific expertise, substantial development experience along with our quality-by-design strategy contribute to the development of safe, effective, and stable products meeting regulatory requirements.

Technical Services: BioConvergence offers solutions to meet your parenteral product development needs for solutions, suspensions, emulsions, and lyophilized formulations for both small and large molecules. In addition, we have unique expertise in formulating and processing molecules that are unstable in solution. Our research scientists have developed more than 20 commercial products. Our services include:

- Pre-formulation & Formulation Development
- Process Development
- Analytical Method Development & Validation
- Lyophilization Cycle Development & Optimization
- Stability Storage & Testing
- Pre-clinical & Toxicology Batch Manufacture
- Technology Transfer Support to Clinical & Commercial Manufacturing Sites
- Other: • GMP materials management
- Consulting

Facilities: BioConvergence's new 50,000-sq-ft state-of-the-art facility houses a 30,000-sq-ft cGMP warehouse and 2,500-sq-ft cGLP laboratory with:

<i>General</i>	<i>Analytical</i>	<i>Specialized for Lyophilization</i>
<ul style="list-style-type: none">• Purified Water System• Laminar Flow Hood• Glove Box for Containment & Inert Atmospheric Requirements• Autoclave• Environmental Chamber• Formulation, Filling, Freeze Drying & Capping Equipment	<ul style="list-style-type: none">• LC Mass Spectrometry• X-ray Powder Diffraction• FTIR, Including Protein Secondary Structure Analysis• HPLC, Including UV & PDA Detection• CE, Including CZE, CGE & cIEF• ELISA• Electrophoresis, Including SDS-PAGE, IEF, Western Blot• Plate-based Protein Assays• UV-Vis	<ul style="list-style-type: none">• Differential Scanning Calorimetry• Freeze-Dry Microscopy• Development-scale Freeze Dryer• Karl Fischer Moisture Analysis• XRPD Data Collection In Situ During Lyophilization

Markets: BioConvergence partners with biotech and pharmaceutical companies worldwide to create solutions to meet their growing demands for formulation and analytical development. We utilize our electronic laboratory notebook (ELN) system and enterprise resource planning (ERP) system to allow our clients real-time access to their information and data. This enables worldwide clients' access to BioConvergence as if they were located next door – reducing both travel costs and time away from the office for each client.

LONG BEACH

CALIFORNIA



**The Place to Be for
Industry News, Research,
and Connections**

**34th Annual Meeting & Exposition
of the Controlled Release Society**

*Advancing Science, Technology, and Education
in the Field of Controlled Release and Delivery*

July 7–11, 2007

**Long Beach Convention Center
Long Beach, California U.S.A.**

Did We Mention the Perfect Weather, Sandy Beaches,
and Beautiful Vistas of the Pacific Ocean?

Mark Your Calendars Today!

Call for Papers Opens in 2006

Interested in Exhibiting?

Visit the Website for More Information.



www.controlledreleasesociety.org/meeting

COMPANY PROFILE

CAPSUGEL®

CAPSUGEL GLOBAL HEADQUARTERS

100 Route 206 North
Peapack, NJ 07977
Website: www.capsugel.com

U.S. CONTACT INFORMATION

535 North Emerald Road
Greenwood, SC 29646
T: 888-783-6361
F: 888-783-6360



CAPSUGEL's capsule products, in both gelatin and non-gelatin grades, are globally recognized for their high-quality performance throughout the pharmaceutical industry. Capsugel also offers liquid formulations services to help address the challenge of poorly soluble drug compounds.



Products / Services

If your company is working with lipid-based formulations, then the new CFS 1200™ liquid filling and sealing machine is a must for your R&D lab. The successor to the highly successful CFS 1000, this development-scale machine will help get your product to market faster with a host of impressive features:

- Liquid fill and seal 1,200 capsules/hr
- Product integrity ensured with gentle handling of capsules before sealing and during the drying cycle
- A robust filling pump with highly accurate temperature control

Need to reduce the time-to-market for your latest drug?



Utilize capsules.

Pharmaceutical companies are taking months off the first-in-man timeline by micro-dosing API directly into capsules. But that's only one way capsules help gain time in the race to market. Capsule formulations require fewer processing steps, meaning less time for process optimization, documentation and equipment validation. And when early-phase clinical trials are conducted in capsules, there is no need for the time-consuming bioequivalence testing that would be needed to develop the commercial dose in a tablet. Finally, capsule formulations require fewer excipients than tablets, resulting in less time to select, evaluate, and validate raw materials.

This time saved during development translates directly into more selling time under patent protection, making the capsule dosage form decision not only simple, but smart.

For more information, visit www.capsugel.com

CAPSUGEL®
Quality
People and Products Working Together™

COMPANY PROFILE



CardinalHealth

CARDINAL HEALTH

14 Schoolhouse Road

Somerset, New Jersey 08873

T: (866) 720-3148 • F: (732) 537-5949

E: pts@cardinal.com

Website: www.cardinal.com/pts

Cardinal Health provides its pharmaceutical and biotechnology customers integrated, enabling technologies, and services that help bring quality products to market faster and deliver greater value. From laboratory to launch and beyond, Cardinal Health offers an unmatched range of world-class technologies and services to help our customers accelerate drug development, streamline the supply chain, and grow market share. Serving the pharmaceutical and biotechnology industries, Cardinal Health is a global leader in development, drug delivery technologies, contract manufacturing, packaging, and product commercialization services. With several decades of experience and more than 1,500 patents and patent applications, Cardinal Health brings its customers innovative expertise throughout a drug's development, launch, and entire life cycle. Cardinal Health also offers the broadest range of dose form development and manufacturing options in the industry - from traditional and proprietary oral technologies to sterile products, inhaled forms, and topicals - in 37 facilities on 5 continents.

Drug Delivery Systems

Sometimes the right dosage form makes all the difference. A significant factor in the marketing success of a new drug is how much it improves results for patients. Even the most sophisticated new compound can benefit from a formulation that will optimize bioavailability or enhance patient compliance. Cardinal Health has a track record of improving the success of many products by developing dosage forms that offer reduced side effects or have broadened acceptance among different patient types. Zydis® fast-dissolve technology, for example, improves patient compliance for children or older patients who may have difficulty swallowing a traditional tablet. Trust the precision, speed, and ingenuity of Cardinal Health to engineer a more efficient, patent-protected formulation or dose form for your product.

Streamlining the Supply Chain

In every technology that we offer, we have experience in helping our customers resolve quality, formulation, and supply issues. By integrating dose form development, manufacturing, and packaging, Cardinal Health can reduce time - and often total cost - to shipment. And by integrating Cardinal Health's launch acceleration services, we can help you get to pharmacy shelves quicker, with greater visibility to prescribers, pharmacists, and patients. We provide the right capacity - when and where you need it. Through our global network of facilities, Cardinal Health provides our customers the manufacturing capacity and support required to meet even the most challenging launch planning requirements. And through creative arrangements for back-up manufacturing sites and dedicated capacity, Cardinal Health provides a range of creative options.

"Bioavailability issues with one of our critical care drugs had forced a manufacturing shutdown. To recover the business, we needed to find a formulation solution fast."

"One call to Cardinal Health put us back in business."



"Using one of Cardinal Health's proprietary technologies, we were able to quickly develop an alternative delivery form that solved the bioavailability issues and put product manufacturing back on line."

Drug Delivery is just one area where Cardinal Health can help you conquer your business challenges. You can trust the pharmaceutical outsourcing expertise of Cardinal Health for other phases of your business as well, including:

- Drug Development
- Manufacturing
- Packaging
- Commercialization

For capabilities that meet your needs, and outcomes that exceed your expectations, call on Cardinal Health.



For more information, visit www.cardinal.com/pts or call toll-free at **1.866.720.3148**.

COMPANY PROFILE



Coating Place Inc.

THE ORIGINAL WURSTER TECHNOLOGY SOURCE

THE COATING PLACE, INC.

200 Paoli Street

Madison, WI 53593

T: (608) 854-9521 • F: (608) 845-9526

E: info@encap.com

Website: www.encap.com



Coating Place Inc. specializes in Wurster fluid bed microencapsulation of fine powders, granules, crystals, and beads. We provide contract formulation development, technology transfer, scale-up, and commercial manufacturing in a GMP environment with analytical support. Coating Place formulation chemists have been able to apply this process to particles ranging from less than 50 μm up to several centimeters in diameter. Our facility has organic solvent capabilities that allow formulations to be developed in either solvent or aqueous coating processes. Coating properties can be optimized with formulation, coat percent thickness, and other processing parameters.

Our new ion resin drug-release system allows us to create 12-hour time-release liquid suspensions that can match the profiles of sustained-release solid dosage forms. These easy-to-swallow liquids make it simple to take your medicine wherever you go.

The original management, with 34 years of Wurster coating experience, remains active in the development of formulations and new technology. Our production staff includes numerous employees with more than 20 years of coating experience. Our history and expertise in this coating technology is unmatched in the industry.

Coating Place provides Wurster coating and other manufacturing services to the following markets:

- Rx, Branded, and Generic
- OTC
- Controlled Substance (Schedule II –V)

Services offered include tablet compression, capsule filling, and pan coating for both R&D and commercial manufacturing. Coating capabilities include softgels, hard shell capsules, and tablets. Development applications include controlled oral delivery, such as enteric, delayed, or sustained release. Other coating applications include moisture or oxygen barrier and taste-masking.

Our 110,000-sq-ft FDA-registered facility is located in Verona, Wisconsin. Production suites are equipped with a range of Wurster fluid bed coating units that will accommodate batch sizes ranging from 0.010 to over 600 kg. Coating Place Inc. continues to develop, manufacture, and operate proprietary cutting-edge Wurster coating equipment for our operations. Our chemists have successfully developed a wide range of formulations and applied them to an equally wide range of core materials. Our formulations are designed for a wide variety of desired outcomes, including improved stability, shelf life, taste, or odor masking, enteric delivery, controlled release, sustained release, delayed release, and surface property modification. The possibilities are almost limitless. The innovative, creative staff of the Coating Place is prepared to take on all your particle, bead, or tablet coating needs. Every project is handled in a confidential manner and scheduled to meet your needs. Honest and confidential research and manufacturing services have made us the leader and most trusted in the industry.



Coating Place Inc.

THE ORIGINAL WURSTER TECHNOLOGY SOURCE



Drug Delivery Systems.

And formulation development, contract manufacturing...

For over 30 years Coating Place Inc. has brought innovative ideas to the marketplace. This time is no different....

People will tell you that it is impossible to create a 12 hour time released suspension... not any more. Introducing 12 hour time re-



Dr. Dale Wurster - Inventor

lease suspensions that actually taste good. Our new ion resin drug delivery system allows us to create liquid suspensions with custom-release

profiles much like solid dosage forms. These good tasting liquids make medicine easier to swallow.



We have experience in other types of formulation development as well; taste masking, enteric, and delayed or sustained release coatings. These applications are available in both aqueous or organic solvent systems.

From development through commercial manufacturing in a cGMP environment, Coating Place has you covered.

The Original Wurster Technology Source for more than 30 Years.

August, 1953
First Wurster coating patent by WARF

January, 1970
Harlan Hall joins WARF lab

December, 1976
Harlan Hall founds CPI via WARF technology

December, 1982
CPI introduces first Micro-Wurster (<20g cap.)

June, 1989, CPI adds 7 nozzle Wurster production unit

July, 1997, CPI develops first 3 nozzle Wurster with linear scalability

2006, CPI achieves 3 million kilos capacity


PRODUCT PROFILE

DEGUSSA CORPORATION
Pharma Polymers
2 Turner Place
Piscataway, NJ 08855
T: (732) 981-5383 Option 4
F: (732) 981-5371
E: eudragit.usa@degussa.com
Website: www.pharma-polymers.com


DEGUSSA AG - PHARMA POLYMERS
Röhm GmbH
Kirschenallee 45
64293 Darmstadt, Germany
T: +49-6151-18-4019
F: +49-6151-18-3520
E: eudragit.germany@degussa.com

degussa.
creating essentials


Diltiazem granulated with 10 & 20% NM 30D in Fluid Bed



Storage Stability of Diltiazem 20% NM 30 D Matrix Tablets, done by Fluid Bed



Diltiazem granulated with 10% NM 30D in Fluid Bed or High Shear Mixer



EUDRAGIT® NM 30 D is very effective as a sustained release polymer. Only 10% of polymer in the tablet formulation is sufficient to generate a very strong sustained release effect even for a highly water-soluble drug like diltiazem. Naturally, a higher amount of incorporated polymer will reduce the release. Thus, the desired release profile can be controlled by different amounts of polymer in the formulation.

EUDRAGIT® NM 30 D based matrix tablets show good storage stability. In the case of diltiazem matrix tablets, the final release profile is reached and stable after a short phase of polymer relaxation, even under accelerated ICH conditions.

EUDRAGIT® NM 30 D is suitable for wet granulation in either high shear mixer or fluid bed system. The tablets show good sustained release properties with both manufacturing techniques. Due to the better distribution of the polymer in the granule, the tablets manufactured by using fluid bed granulation show a stronger sustained release behavior.

Visit: www.eudragit.com/nm30d

degussa.

creating essentials

EUDRAGIT[®] NM 30 D

Acrylic Alternative for Matrix Modified Release

- Excellent Sustained-Release Performance
- Easy Processing
- Good Tablet Properties
- High Flexibility for Modifying Drug Release



For more information call:

US: 001-732-981-5383

Germany: 0049-6151-18-3567

www.eudragit.com/nm30d

COMPANY PROFILE



A DFB COMPANY

DPT LABORATORIES, LTD.

318 McCullough

San Antonio, TX 78215

T: (210) 476-8159 F: (210) 829-8733

E: confidence@dptlabs.com

Website: www.dptlabs.com

Year Founded: 1990

Number of Employees: 1,500

Key Personnel: Paul Johnson, President; Paul Josephs, Vice President Sales & Commercial Operations; Marc Iacobucci, Vice President Project Management & Marketing

Who We Are

DPT, a DFB Pharmaceuticals, Inc. company, is a contract development and manufacturing organization (CDMO). DPT provides pharmaceutical, biotechnology, and consumer healthcare companies the best solutions to their drug development and manufacturing needs through innovation, technology, and service. Specializing in semi-solid and liquid dosage forms, DPT has a reputation for quality, unmatched technical expertise, virtually unlimited manufacturing capabilities, and an exemplary regulatory compliance record.

Customers choose DPT as a strategic partner because of our ability to provide fully integrated drug development and manufacturing solutions. DPT customers have confidence that their formulations, from concept to commercial manufacturing, will be handled by professionals with unparalleled knowledge and experience, using state-of-the-art equipment and processes.

The ability to develop, manufacture, and commercialize products in semi-solid and liquid dosage forms makes DPT unique. To get your next product to market fast and with confidence, call DPT – *The Industry Source for Semi-solids and LiquidsSM*.

Drug Development Solutions

- Pre-formulation and formulation
- Biopharmaceutical development
- Analytical and bioanalytical method development and validation
- Stability studies under ICH conditions
- Process development and validation
- Pilot and proof-of-concept batches from 0.3 kg
- Clinical trial materials Phase I-IV

Packaging Solutions

- Identification and sourcing of relevant packaging options
- Packaging specification development
- Formulation and package compatibility assessment
- Packaging equipment sourcing, design, and engineering services
- Turnkey sourcing services for unique and specialized packaging

Manufacturing Solutions

- Four cGMP facilities
- cGMP batch sizes from 25 kg to 22,000 kg
- Controlled substances Schedules II-V
- Extensive packaging capabilities for semi-solids and liquids
- Specialized equipment installation, operational qualification, and validation services

Facilities

Headquartered in San Antonio, TX, DPT has four facilities there and two in Lakewood, NJ, with more than 1 million square feet of state-of-the-art development, manufacturing, packaging, and distribution space.

1-800-we-need-a-company-that-
will-take-our-molecule-and-develop-
a-unique-formulation-and-delivery-
system-then-another-company-that-
will-scale-up-and-manufacture-it-
and-get-it-to-market-fast

< or >

1-866-CALL-DPT

When it comes to sourcing, it's hard to find one company that matches DPT's range of services. From concept to commercialization, leading pharmaceutical, biotech, and healthcare companies choose DPT for fully integrated drug development and manufacturing services.

Pre-formulation and formulation. Analytical method development and validation. Stability studies. Process development. Clinical trial materials. Commercial manufacturing. Get it all with DPT – *the industry source for semi-solids and liquids.SM*



A DFB COMPANY

SOURCE WITH CONFIDENCE™
CONTRACT DRUG DEVELOPMENT AND MANUFACTURING SOLUTIONS
1.866.CALL.DPT • WWW.DPTLABS.COM

© Copyright 2006 DPT Laboratories, Ltd. All rights reserved.

Drug Delivery Partnerships™

708 Third Ave., 4th Floor • New York, NY, 10017

Event Director: Miriam Glick

T: (212) 661-3500 Ext 3709 F: (212) 599-2192 • E: mglick@iirusa.com

Website: www.drugdeliverypartnerships.com

COMPANY PROFILE

The Drug Delivery Partnerships (DDP) event is the world's largest Drug Delivery & Specialty Pharma event for the Pharma, Biotech & Generics Industry. DDP 2007 is dedicated to answering your voiced concerns on competitive intelligence, strategic business transactions, innovation, product differentiation and life cycle management strategies, for ultimate business sustainability and growth.

The event provides a forum for bringing potential and existing partners together to initiate and expand deals that further their business. DDP has grown to an event with more than 90 speakers and 500 delegates expected in January 2007. The event draws a highly senior-level audience composed of licensing, business development, marketing, legal, and R&D executives from pharma, biotech, specialty pharma, drug delivery and generic companies.

PROGRAM HIGHLIGHTS

Keynote Address

Create and Sustain a Competitive Advantage by Identifying & Utilizing Undervalued Assets

Billy Beane, General Manager, OAKLAND A's and the subject of the best selling book, *Moneyball*

Keynote Panel

How the End-User Can Inspire New Opportunities: Bridging the Patient, Physician and Payer

Moderator: Hamilton Jordan, White House Chief of Staff under President Carter, Best Selling Author, *No Such Thing As a Bad Day*, and four-time cancer survivor.

Senior Executive Keynote Panel

How Are We Creating Sustainable Business Models Out of Evolving Technology Companies?

Cynthia Robbins-Roth, *Featured Columnist*, BIOWORLD
Peter Stein, *Chief Executive Officer*, NORGINE
Michael Step, *Senior Vice President, Corporate Development*, SANTARUS
Joseph P Cooper, *Executive Vice President*, MEDICIS
James Vaughan, *General Manager*, 3M DRUG DELIVERY SYSTEMS
James Gale, *Managing Partner*, SANDERS MORRIS HARRIS

Wall Street Address

BACK BY POPULAR DEMAND

Stock Updates, Market Trends & Key Technologies to Watch

David M. Steinberg, *Managing Director, Equity Research, Specialty Pharmaceuticals and Drug Delivery*, DEUTSCHE BANK

Featured Presentations

Growth Opportunities for Drug Delivery Systems: Development Trends for New Drugs in the Pipeline

Dr. Joseph Dimasi, *Director of Economic Analysis*, TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

What's Your Value Proposition? Demonstrating the Value of Your Partnerships in a Complex World

David Flores, *Co-founder, Chief Executive Officer & President*, BIOCENTURY

Drug Delivery Partnerships Trend Report 2007 - What's Fueling Market Changes?

Roger Longman, *Managing Partner*, WINDHOVER INFORMATION

Strategically Position Your Product for Optimal Candidacy for Reimbursement & Pricing

Cynthia Tudor, *Acting Director*, CENTERS FOR MEDICARE AND MEDICAID SERVICES

Mention Registration Code **P1225DDT2** and
recieve a 15% Discount

11th Annual
**Drug Delivery
Partnerships™**



**JANUARY 22-24, 2007
RED ROCK CASINO, RESORT & SPA
LAS VEGAS, NV**

***The Event that Gets You
One Step Closer to the Deal***



***The World's LARGEST Drug Delivery & Specialty
Pharma event for the Pharma, Biotech & Generics Industry***

www.drugdeliverypartnerships.com


COMPANY PROFILE



Via M. Luther King, 13
20060 - Pessano con Bornago
(Milan) Italy
T: +39-02-95428-309
F: +39-02-95745018/12

845 Center Drive
Vandalia, Ohio 45377
T: (937) 898-9669
F: (937) 898-9529

E: bizdev@eurand.com
Website: www.eurand.com



Eurand is a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products using our innovative technologies. Eurand is dedicated to the continued development and commercialization of breakthrough technologies and products that better satisfy patients' needs. To this end, the Company develops treatment options with superior safety, enhanced efficacy, and convenient dosing.

For more than 30 years, Eurand has been a world leader in drug delivery. We offer comprehensive technology platforms designed to optimize the delivery of drug substances. Using these technologies, Eurand turns difficult drug candidates into easy-to-administer, successful pharmaceutical products. Additionally, our technologies can be used to enable the creation of innovative and effective products for life-cycle management. Eurand has a well-established technology

portfolio that is one of the broadest in the industry. The Company's drug development efforts are based on three commercialized technology platforms:

- **Bioavailability Enhancement of Poorly Soluble Drugs**
- **Customized Release**
- **Taste-Masking & Orally Disintegrating Formulations**

Our commercialized technology platforms are made up of multiple novel drug delivery technologies that can be used alone or in tandem to provide unique drug delivery solutions. Eurand has a fourth technology platform, drug targeting, that, once commercialized, can be applied to small molecule and biotechnology derived products for improved drug delivery. The breadth of our technology platforms enables us to have more than one solution for any drug delivery problem.

We are experts in using our technologies to solve the most difficult drug delivery challenges and to develop novel pharmaceutical products. To date, more than 40 products, marketed by Eurand customers in over 50 countries, have been developed using our technologies.

Eurand is a global company with more than 500 employees. Its principal operating offices are in Milan, Italy. The Company has research, development, and manufacturing facilities throughout the world, including sites in Milan and Trieste, Italy; Dayton, Ohio (US) and Paris, France. For more information, please call us or visit our website, where you will find detailed technical information on our drug delivery systems.

Depth

USA +01-937-898-9669
EU +39-02-95428-320

www.eurand.com

4 platforms 13 core technologies 100 marketed products 500 resourceful minds

The **Depth** to deliver success. Both yours and ours.

Eurand works with the world's leading pharmaceutical and biotechnology companies to develop innovative pharmaceutical products based on our proprietary drug delivery technologies. These technologies can be used alone or in tandem, providing cost effective, patentable and therapeutically effective solutions to the most challenging drug delivery problems.



ENHANCED BIOAVAILABILITY

DRUG TARGETING

CUSTOMIZED RELEASE

TASTE-MASKING

COMPANY PROFILE



FILTERTEK INC.

11411 Price Road
Hebron, Illinois 60034

T: (800) 648-0791 (Main)

T: (815) 648-2416

E: cmaar@filtertek.com

Contact: Chris Maar, Marketing Specialist

Website: www.filtertek.com

Pinpoint precision and strict attention to details keep Filtertek medical filters, valves, and critical components in line with leading edge medical technology and the needs of our customers. Filtertek develops and manufactures a full range of products for use in the medical industry including products for drug delivery, respiratory therapies, surgical preparation, pharmaceutical processing, and equipment protection. Meeting the needs of large and small OEM's, the company has developed and produced hundreds of product innovations designed to provide high-performance results for our customers. Filtertek has cost-effective, high-quality products for any medical application from simple, traditional components to highly sophisticated devices. If the right product is not yet available, we have the expertise to design custom parts from basic specifications, such as flow rate, pressure drop, and application to better serve the needs of the ever-evolving medical market.

Filtertek is committed to proactive, solution-driven product development to help our customers achieve optimal results. A close collaboration with our suppliers and customers keeps Filtertek in pace with "tomorrow's" medical technology. With our wide range of product applications expertise, medical clean rooms, and strategic manufacturing locations, Filtertek is uniquely positioned as a global partner in the development of advanced products. Customers' growing desire for "turn-key" projects affords Filtertek the opportunity to quickly and efficiently offer finished products and services tailored to our customers unique business needs.

With so much riding on product quality and performance, designing and developing components for critical medical applications takes design ingenuity, technical knowledge, and manufacturing precision. By choosing Filtertek to produce your drug delivery components, you're assured of partnering with a source that puts as much into the development of your product as you do.

Filtertek, a worldwide leader in the design and manufacture of filters, fluid control components, and technically molded assemblies, has nearly 1000 employees located across three continents and annual revenues of over \$95 million. The company, recognized for its innovation in the medical industry, designs custom solutions that meet or exceed customer requirements for performance, durability, delivery and cost.



**TO STAY AHEAD OF YOUR COMPETITION,
IT PAYS TO HAVE THE
RIGHT CONNECTIONS.**



When the patent on your drug expires, so do many of your hopes for maintaining market share. But Filtertek gives you the edge you need. The first of its kind, and the last word in needle-safe drug transfer, our breakthrough technology eliminates the potential for needlesticks, contamination and waste by combining venting and transfer into one safe, spill-proof action—providing unmatched protection for those administering and receiving your drug. And unmatched protection for your bottom line. Because when your customers know they won't get stuck by a needle, they'll be more likely to stick by your drug. For more information, call 1-800-648-0791 and connect with us today.

 **FILTERTEK**
An ESCO Technologies Company

COMPANY PROFILE



Americas
Genzyme Pharmaceuticals
675 West Kendall Street
Cambridge, MA 02142

T: 800-868-8208 (US & Canada) or 617-374-7248
F: 617-768-9765 - E: pharmaceuticals@genzyme.com

Rest of the World
Genzyme Pharmaceuticals
Eichenweg 1

CH-4410 Liestal, Switzerland
T: +41 (0)61 906 5959 or F: +41 (0)61 906 5958
E: pharmaceuticals.swiss@genzyme.com

Website: www.genzymepharmaceuticals.com

Genzyme Pharmaceuticals is a distinct business unit within Genzyme Corporation, one of world's foremost biotechnology leaders in developing and applying advanced technologies in the life sciences to address a broad range of unmet medical needs. With our commercial headquarters in Cambridge, MA and our manufacturing facility in Liestal, Switzerland, Genzyme Pharmaceuticals strives to be a premier business partner in the development and manufacturing of specialty pharmaceutical materials and value-added technologies, products and services with an immediate focus in the lipid, peptide, amino acid derivative, and drug delivery markets.

Technology Description

Genzyme Pharmaceuticals offers two novel drug delivery technologies: LipoBridge® and LipoMask™.



LipoBridge® is an innovative technology specifically designed to facilitate transport of drug compounds across the blood brain barrier (BBB) and into the central nervous system (CNS) by temporarily and reversibly opening tight junctions. Over 100 model compounds including small molecules, peptides, and antibodies ranging from 100 to 155,000 Daltons have been successfully delivered across the BBB using this technology. Applications include the treatment of brain cancer, Alzheimer's, stroke, trauma, Parkinson's and multiple sclerosis.

Advantages of LipoBridge®:

- The BBB naturally limits most molecules from entering the CNS, especially those greater than 600 Daltons. Due to this limitation, many potentially important drug compounds are discarded during the R&D process.
- Easily formulated by mixing drug and excipients
- Improves solubility
- Is not metabolized and is rapidly excreted



LipoMask™ increases the circulation half life of lipid particles in blood, thereby tailoring drug pharmacokinetic profiles, improving drug efficacy, and decreasing drug toxicity. Due to their unique surface properties, nanoparticles formed with LipoMask™ evade the RES (reticuloendothelial system) uptake normally seen with conventional lipids and consequently have more chances to get to the desired site of pharmaceutical action. LipoMask™ is designed to extend the circulation time of both small and macromolecules, while reducing their toxicity. Drug therapy is usually administered parenterally.

Advantages of LipoMask™:

- Increased circulation time
- Extended degradation time
- Reduced toxicity
- Increased loading capacities
- Sustained release
- Tissue targeting

Partnerships

By combining LipoBridge® with the CNS assessment services of its partner Pharmidex, Genzyme Pharmaceuticals offers CerenseSM, a complete solution to deliver and assess poorly brain penetrant drug compounds in the CNS. The Brookwood – Genzyme Pharmaceuticals Collaboration offers customized solutions for peptides formulations through Design for Peptide DeliverySM.

Lipid Based Drug Delivery Technologies

LIPOBRIDGE™

Compounds that facilitate drug transport across the blood-brain-barrier into the CNS



LipoBridge™

LIPOMASK™

Compounds that increase the circulation time of lipid particles, improving drug efficacy and safety



LipoMask™

ACTISOLV™

Compounds that solubilize hydrophobic drugs normally insoluble in aqueous media



ActiSolv™

Contract Manufacturing
of APIs, Intermediates and
Critical Excipients

CUSTOM PEPTIDE MANUFACTURE

SYNTHETIC LIPID DEVELOPMENT
AND MANUFACTURE

AMINO ACID DERIVATIVES

genzyme
Pharmaceuticals

Genzyme Pharmaceuticals
500 Kendall Street
Cambridge, MA 02142, USA
Tel 800 868 8208; 617 374 7248
Fax 617 768 6433
Email pharmaceuticals@genzyme.com

www.genzymepharmaceuticals.com

Genzyme Pharmaceuticals,
Sygena Facility
Eichenweg 1, CH-4410 Liestal, Switzerland
Tel +41 (0)61 906 5959
Fax +41 (0)61 906 5958
Email pharmaceuticals.swiss@genzyme.com

COMPANY PROFILE



GLATT PHARMACEUTICAL SERVICES

20 Spear Road

Ramsey, New Jersey 07446

T: (201) 825-8700

F: (201) 825-0389

E: pharmaceuticalservices@glattair.com

Website: www.glattpharmaceuticalservices.com

Vital Statistics: Year Founded: 1954

Number of Employees: Glatt Air Techniques, Inc., USA ~ 150 - Glatt Group, Worldwide ~ 1500

Who We Are: Glatt Pharmaceutical Services is the leading provider of solid dosage form product development, drug delivery technology, and contract manufacturing to the pharmaceutical industry. With over thirty years of experience and innovation, this division of Glatt Air Techniques, Inc., in collaboration with its global Glatt Group affiliates, continues to successfully partner with pharmaceutical companies to bring their immediate release and complex controlled release products to market. All of our services are provided with the greatest attention to quality and customer service.

Services Offered:

Product Development - We feature a highly experienced and accomplished group of scientist that participate in a teamwork focused environment in the development of your products. Our R&D team has succeeded in developing products from a broad list of categories including New Chemical Entities, Product Line Extensions, Over-the-Counter, and Generic Drug Products. Our R&D services are supported by a complete line of analytical capabilities in our newly expanded laboratory.

Building on our expertise in fluid bed and solid dosage technology, we deliver a complete R&D program including:

Formulation Development

Process Development (Aqueous and Organic Solvent Processing)

cGMP Clinical Trial Material Production

Process Scale-Up

Technology Transfer for Manufacturing

Drug Delivery Technologies - With a focus on controlled release, Glatt offers new and novel enabling proprietary technologies for both ANDA and NDA products.

CPS Technology™ - Controlled Release Pellet System

- Direct Pelletization

- High Drug Loading (up to ~ 90%)

- Dense, Spherical, and Uniform Pellets

ZRx™ Technology - Zero-Order Release Tablet System

- Extended Release Tablet Matrix System

- Zero or First-Order Release Characteristics

- Once-per-Day Dosing

MicroPx Technology™ - Direct Pelletization

- High Drug Loading (up to ~ 90%)

- Dense, Spherical, and Uniform Pellets

- Continuous Processing

Contract Manufacturing: Our experienced staff provides first-class cGMP manufacturing of both bulk intermediates and final solid dosage form products. We are committed to a schedule of up to 24 hours/7 days a week to meet the market demands placed on the supply of your products.

Our pellet manufacturing capabilities are expanding to further focus on Wurster HS drug layering and functional film coating and direct pelletization using our CPS Technology™.

Facility Expansion- Glatt Pharmaceutical Services announces the inauguration of its new solid dosage facility in Ramsey, NJ. Our expanded capability concentrates on complex controlled-release R&D and manufacturing, including organic solvent coating capacity, our proprietary CPS™ pellet system, fluid bed and high shear granulation, and Glatt's unsurpassed Wurster HS technology.

To learn more about how we're expanding, please contact us to schedule a visit.

Unleashing The Knowledge

Product Development

Drug Delivery Technology

Contract Manufacturing

Glatt Pharmaceutical Services, the global leader in modified release technology, announces the expansion of our world renowned staff with the addition of key positions in R&D, Manufacturing, Quality Assurance, and Project Management. The depth of our knowledge, coupled with our newly completed facility in Ramsey, NJ, assures unrivaled development and manufacture of complex solid dosage products.



A Division of Glatt Air Techniques, Inc.

www.glattpharmaceuticals.com
201.825.8700

E x p e r i e n c e t h e G l a t t E x p a n s i o n

To learn more about how we're *Unleashing the Knowledge*, contact us to schedule a visit.

COMPANY PROFILE



HALOZYME THERAPEUTICS

11588 Sorrento Valley Road, Suite 17

San Diego, CA 92121


T: (858) 794-8889

F: (858) 259-2539

Contact: Mark Wilson - E: mwilson@halozyme.com

Website: www.halozyme.com

3-Dimensional Model of Human PH20



Halozyme Therapeutics is a biopharmaceutical company developing and commercializing recombinant human enzymes (rHuPH20) for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity.

The company has received FDA approval for two products: Cumulase[®], the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and HyleneX for use as an adjuvant to

increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.

Enhance Technology

Enhance Technology is Halozyme's proprietary drug delivery technology based on rHuPH20, a recombinant form of the naturally occurring human enzyme being investigated for its ability to break down hyaluronic acid (HA), the space-filling "gel"-like substance that is a major component of tissues throughout the body. When combined or co-formulated with certain injectable drugs, Enhance Technology can act as a "molecular machete" to facilitate the penetration and dispersion of these drugs by temporarily opening flow channels under the skin. Molecules as large as 200 nanometers may pass freely through the perforated extracellular matrix, which recovers its normal density within approximately 24 hours, leading to a drug delivery platform that does not permanently alter the architecture of the skin.

Recent pharmacology studies with Halozyme's rHuPH20 enzyme demonstrate increased dispersion of locally injected molecules across a broad range of molecular weights and sizes without tissue distortion. In particular, rHuPH20 changed the pharmacokinetic profiles and significantly augmented the systemic bioavailability of locally injected large protein therapeutics, such as cytokines and therapeutic antibodies, in animal models.

Halozyme is seeking partnerships with pharmaceutical companies that market drugs requiring or benefiting from injection via the subcutaneous or intramuscular routes that could benefit from this technology, and is actively focused on a number of discrete product opportunities.

Enhance™ Technology

from Halozyme

A Revolution in Drug Dispersion

Would you like to convert your drugs from IV to subcutaneous (SC) delivery or enhance the dispersion of your existing SC compounds? With Enhance™ Technology, microgram quantities of a fully human recombinant enzyme act as a “molecular machete” to clear the subcutaneous “jungle.” Based upon this mechanism of action, co-delivery with Enhance is anticipated to permit the SC administration of large volumes of antibody drugs, speed onset of action relative to SC delivery without Enhance, and improve patient comfort. Backed by a robust IP portfolio, Enhance may extend a compound’s patent life and potentially reduce COGS for products that are expensive to manufacture.

Enhance Technology employs the first and only human recombinant enzyme for injectable drug dispersion. The enzyme in Enhance has been used in two FDA-approved formulations. Enhance is being developed to deliver an optimized pharmacokinetic profile and thus offers a potential competitive advantage for partners’ products. Potential benefits of this technology include:

- Enhancing the dispersion and absorption of other injected drugs
- Allowing SC injection of up to 10 mL in a single push or a mean infusion rate of ~500 mL/hour
- Dispersing drugs away from injection site, potentially reducing concentration-dependent injection site reactions
- Compared to SC administration without Enhance, reducing T_{max} and increasing bioavailability for large molecule compounds
- Enabling conversion of certain IV drugs to SC self-delivery



Learn how Enhance Technology might revolutionize your drug delivery by contacting Mark Wilson, Vice President of Business Development at mwilson@halozyme.com or (858) 794-8889.

COMPANY PROFILE



HOVIONE

HOVIONE
40 Lake Drive
East Windsor, NJ 08520
T: (609) 918-2600 F: (609) 918-2615
E: hello@hovione.com
Website: www.hovione.com



Exclusively Focused on Pharmaceutical Fine Chemicals

Hovione is a world-class company dedicated to the cGMP development and manufacture of APIs both as a CMO and API supplier. With FDA approved plants in Europe and Asia and a Technology Transfer Centre in New Jersey, HOVIONE is committed to superior customer service, quality, and regulatory support. Our capabilities include process chemistry, analytical development, worldwide regulatory affairs, particle design, and kilo to multi ton manufacture of APIs under FDA and ICH cGMP standards. We offer APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. With a 50 year track record in API development, our ability to provide customers with timely and reliable solutions that are dependable and economical has given us a worldwide reputation for quality products, superior customer service, and regulatory compliance.


Particle Design Technologies & cGMP Spray Drying

Building on our accumulated expertise in all major areas of API development and manufacture, HOVIONE also has extensive expertise in particle design and engineering. Spray-drying, spray-congealing, freeze-drying, micronization and cryomilling capabilities allow us to offer a wide range of solutions to modify the API particle characteristics. From lab to industrial scale, our installations are designed to support both API synthesis and drug product formulations. No manufacturing partner is better equipped to meet the challenges of bringing new APIs to market quickly, while ensuring "right first time" delivery. Our aim is to do well what is difficult, to give our customers what they cannot find elsewhere.

For further information please visit www.hovione.com.

Better formulations.
Better bio-availability.
Better stability.

Introducing cGMP Spray Drying from Hovione.
Simply better.



The world of API development and manufacturing is constantly evolving. With our innovative particle design and engineering technologies, Hovione is a partner fully equipped to meet your most challenging drug development and manufacturing requirements. From lab scale, to pilot scale through to full cGMP compliant production, we provide you with the quantity you need together with the quality you expect. Call +1 609 918 2600 in the USA or +351 21 982 9451 in Europe or visit our website hovione.com.



COMPANY PROFILE



HUBER ENGINEERED MATERIALS, PART OF J.M. HUBER CORPORATION

907 Revolution Street
Havre de Grace, MD 21078
T: (410) 939-7228 E: hubermaterials@huber.com
Website: www.rxipients.com or www.hubermaterials.com



Huber Engineered Materials, a division of the J. M. Huber Corporation, provides highly functional excipients, granulated powders, and contract manufacturing for oral dosage tablets and formulated powders. Huber's portfolio includes RxCIPIENTS® excipients for rapid disintegration, glidant, and carrier applications; Hubercal® calcium carbonate for antacid and inert filler applications; and custom processing capability.

EXCIPIENTS

Huber's RxCIPIENTS rapid disintegration technology (FM1000) enables the creation of high dose, robust tablets that disintegrate in less than 30 seconds in the mouth. Tablet formulations containing FM1000 have a pleasant mouth feel, are produced on standard tablet presses, and can be packaged in standard bottles. Additionally, FM1000 is sold as an excipient without royalty or milestone payments.

Huber's glidants (GL 100 & 200) provide excellent glidancy while being dense and easy to handle. When compared to alternative glidants, Huber's glidants are twice as dense, allowing for smaller, more efficient packaging and storage. Functionally, Huber's glidants are less prone to adhesion to glass or metal surfaces and much less prone to dusting in plant operations, allowing for more even distribution and material transfer.

Huber's high loading carriers (Silicon Dioxide & Calcium Silicate) have been utilized in numerous formulations carrying up to 70% by weight. Not only do Huber's products absorb the liquid actives, more importantly, they efficiently and effectively release the liquid active ingredient to deliver required potency.

CALCIUM CARBONATE

Huber's HuberCal calcium carbonates provide a cost effective and natural alternative for pharmaceutical applications. With years of history in mining natural calcium carbonate and a Certificate of Suitability for Europe, Huber provides a fantastic product for antacid and filler applications.

PROCESSING

Huber is taking large strides in its development of blending, granulation, and encapsulation services for the pharmaceutical industry. With cGMP facilities and innovative technologists dedicated to your formulation success, Huber is a proud collaborator with companies looking for advanced excipient and drug delivery options.

LOCATIONS


Havre de Grace –
Excipients,
Sales & Service
907 Revolution Street
Havre de Grace, MD 21078

Benicia Plant –
Granulations, Manufacturing
3909 B Park Road
Benicia, CA 94510

Modesto Plant –
Granulations, Triturations, Microencapsulations,
Blending, Packaging, Contract Manufacturing
700 D Kiernan Avenue
Modesto, CA 95356



HuberCal® is a registered trademark of J.M. Huber Corporation for calcium carbonate. RxCIPIENTS® is a registered trademark of J.M. Huber Corporation for pharmaceutical excipients.



Introducing RxCIPIENTS® FM1000 from Huber Engineered Materials, an excipient that enhances tablet disintegration. It's **fast**, with tablet disintegration in 5-30 seconds. It's **strong** – low tablet friability allows for standard packaging. It provides **consistent tablet disintegration**. It's the excipient you can **formulate in house** without need for a drug delivery company. Request a sample or learn more at www.rxciipients.com or by calling Huber Engineered Materials at 866-881-6480.

 **rxciipients**
Advanced Pharmaceutical Excipients


HUBER ENGINEERED MATERIALS
Collaborative Genius™

COMPANY PROFILE



IOMED, INC.

2441 South 3850 West
Salt Lake City, Utah 84120

T: (800) 621-3347 or (801) 975-1191 F: (801) 972-9072

E: info@iomed.com

Website: www.iomed.com



IOMED, Inc. is a leader in developing, manufacturing, and selling active drug delivery systems that employ iontophoresis. Our versatile transdermal and trans-scleral technology allows for custom delivery profiles for local and systemic applications. These innovative systems allow systemic or site-specific delivery, rapid onset, and therapeutic control not possible with other delivery methods. We are actively pursuing opportunities to utilize our non-invasive drug delivery systems in combination with specialty pharmaceuticals to offer unique products designed to satisfy unmet medical needs. Licensing, co-development, and marketing agreements are available.

IOMED's active drug delivery systems use iontophoresis technology, a non-invasive method of enhancing and controlling the transport of water-soluble ionic drugs using low-level electrical current. Our technology and products are used in situations when it is advisable to avoid the pain from needle insertion and drug injection, to minimize the infiltration of carrier fluids, and/or to avoid the damage caused by needle insertion. Iontophoresis is applicable to a broad range of compounds and can transport drugs significantly faster than passive transdermal patches. Our proprietary technology has also been shown to effectively transport compounds through other body tissue, including the sclera in ophthalmic applications.

Transdermal Drug Delivery

Our current products are used primarily for site-specific corticosteroid therapy in clinics nationwide to treat a variety of local inflammatory conditions, including those suffered by top Olympic athletes and professional athletes in football, baseball, basketball, hockey, and golf. Clinicians have administered over 28 million patient treatments using our current systems. We offer the most comprehensive line of iontophoretic products available on the market.

We are developing and marketing "next-generation" products for use in treating acute local inflammatory conditions, including enhancing our reusable dose controllers, improving our disposable electrode patches, and developing new products. IontoDex™ is a proprietary application of a miniaturized, integrated version of our active drug transport system designed for patient in-home use. IontoDex could address a significant unmet medical need by offering patients the anti-inflammatory benefits of dexamethasone while avoiding all of the gastrointestinal (GI) and other systemic side effects of oral drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), including Cox-II inhibitors.


Ophthalmic Drug Delivery

Using our proprietary technology, we have developed an ocular drug delivery system that seeks to address the safe and effective administration of therapeutics to the back of the eye. Our delivery system, trademarked OcuPhor™, allows for non-invasive, site-specific administration without the collateral tissue damage associated with surgery, lasers, needle injections, or implants. OcuPhor has been designed as a platform technology to deliver therapeutic compounds to posterior segments of the eye. Through both collaborations and internal research efforts, we have made significant advancements with the OcuPhor System. Feasibility studies confirmed OcuPhor's ability to deliver a broad range of anti-angiogenic drugs to the back of the eye. Preliminary clinical studies in human volunteers have shown that the OcuPhor System is both safe and well tolerated. Additionally, the Company has demonstrated that the OcuPhor System is capable of delivering anti-angiogenic, anti-inflammatory, antibiotic, and antiviral compounds.

First in Iontophoresis . . .

Trans-scleral

The OcuPhor[®] delivery system dispenses medication to difficult to reach areas of the eye



Transdermal

The PM2000[™] delivery system provides timed released and bolus delivery capabilities



Drug Delivery Systems Partnership Opportunities

IOMED, the first company to commercialize iontophoretic products, continues as a leader in developing new, non-invasive technologies and products that deliver drugs safely to areas of the body.

Iontophoresis Applications

- Transdermal
- Ocular
- Systemic
- Local

Expertise

- Electrical and mechanical engineering
- Analytical chemistry
- Biological sciences
- Material sciences

Milestones

- First commercial iontophoretic product
- First NDA approved for an iontophoretic system
- Substantial U.S. and foreign patents and others pending

Research and Development

- Prototype design
- Radio-labeled material handling
- Clinical and regulatory
- In vitro and in vivo drug screening

Manufacturing

- Flexible and efficient processes
- State of the art automated equipment
- Compliant with FDA QSR and ISO 13485

IOMED[®]
First in Iontophoresis

IOMED, Inc.
Phone: 801 975 1191
Fax: 801 972 9072
info@iomed.com
www.iomed.com
AMEX: IOX

COMPANY PROFILE



KURVE TECHNOLOGY, INC.
19805 North Creek Parkway
Bothell, WA 98011
T: (425) 640-9249 F: (425) 673-5783
E-mail: info@kurvetech.com - Website: www.kurvetech.com

Key contacts for Kurve Technology, Inc.
Michael Rackley, VP Business Development mrackley@kurvetech.com
Robert Kamp, VP Corporate Development rkamp@kurvetech.com



Kurve Technology, Inc. develops nasal drug delivery device systems for local, systemic and nose-to-brain medical therapies.

Superior Nasal Drug Delivery with Controlled Particle Dispersion (CPD)[®]

Kurve Technology's flexible technology platform can deliver a wide range of formulations with greater efficacy and efficiency than traditional devices. Clinical results show that the average area of intranasal deposition was significantly greater for CPD compared to spray pumps, with CPD reaching the olfactory region and paranasal sinuses. CPD:

- saturates the entire nasal cavity;
- minimizes peripheral deposition to lungs and stomach;
- improves patient compliance;
- delivers a wide range of formulations.

ViaNase ID[™] Electronic Atomizer

Incorporating CPD technology and electronic intelligent delivery, ViaNase ID[™] Electronic Atomizer offers superior efficacy, rapid onset of action, counterfeit/competitor lockouts, compliance monitoring and abuse control.

Corporate Relationships Sought

Kurve Technology offers global, exclusive licenses in topical, systemic and nose-to-brain therapy areas to pharmaceutical companies.



Still relying on yesterday's technology?



Yesterday's spray bottles are no match for today's drug formulations. Deliver your drug therapies with the most cutting edge nasal drug delivery device available today – ViaNase ID.™


ViaNase ID stands alone as an electronic atomizer that saturates the entire nasal cavity to deliver topical, systemic and nose-to-brain formulations with greater efficacy and efficiency than traditional nasal delivery devices. The first nasal drug delivery device to incorporate drug pedigree confirmation, lock-out technology, and an electronic display, ViaNase ID helps curb counterfeit drug use and abuse. ViaNase ID also improves patient compliance – users see the drug name, number of doses delivered and a dose timer.

Combining Controlled Particle Dispersion™ and intelligent nasal drug delivery technologies, ViaNase ID delivers on the promise of your advanced drug therapies.

Find out more about the ViaNase family of electronic atomizers. Contact Kurve Technology at (425) 640-9249 or info@kurvetech.com.

www.kurvetech.com





Lip'ral™-SSR

FOR SUPERIOR CONTROLLED ORAL THERAPEUTICS

*Superior
bioperformance*

*Faster onset
coupled with
controlled release*

*More consistent
therapeutics*

*Improved patient
compliance*

*Refractory to
food effects*

*Robust to
pH changes*

Conventional controlled release technologies, traditionally designed for water soluble drugs, have inherent inefficiencies in the delivery of intrinsically poorly water soluble drugs due to inadequate solubilization/release, pH sensitive solubility, and/or absorption "window" limitations. These result in sub-optimal bioperformance due to compromised bioavailability.


Lip'ral Synchronized Solubilizer Release (SSR) is an extension of the Lip'ral technology platform to superimpose controlled release aspects while preserving the solubilizing power and absorption improvement aspects of the Lip'ral technology. Lip'ral-SSR synchronizes the release of the poorly water soluble drug and lipidic solubilizers to achieve controlled release of both agents and is ideally suited for drugs that require solubilization and controlled release. The release profiles can be modulated for delayed, pulsatile or sustained release without compromising therapeutic bioavailability.

Lip'ral-SSR comprise a wide range of proprietary compositions of bioacceptable lipid excipients for the optimal delivery of poorly water soluble drugs. Lip'ral-SSR technologies use conventional manufacturing processes that are easy to scale-up and commercialize, thus reducing time to market. Lip'ral-SSR enables development of superior controlled release products with higher solubilization and improved bioavailability leading to reduced dose, improved compliance, targeted absorption and chronotherapeutic release.

Lip'ral™-SSR vs. Conventional Controlled Release			
Technical Attributes	Product Attributes	Lip'ral-SSR	Conventional Controlled Release
Synchronized Release of Drug and Solubilizer	Superior Bioperformance	Yes	No
Controlled Drug Solubilization	More Consistent Therapeutics	Yes	No
High Drug Loading	Smaller Dosage Form	Yes	?
Reduced Dosage Frequency	Improved Patient Compliance	Yes	?
Target to Absorption Window	Better Safety, Lower Dose	Yes	?

Lipral-SSR is well suited for drugs with poor or pH sensitive water solubility. Consider Lipocine's LipidScreen® services for your target compound.

For more information, contact:
Jerry Simmons at gts@lipocine.com or (801) 994-7372 ext 2110.



If water solubility is your challenge...

Whether you are trying to enhance your drug discovery effort or commercialize your new drug or a line extension of your existing drug, Lipocine can help overcome absorption challenges associated with too little or too much water solubility.

Products based on Lipocine technologies are: easy to manufacture, comprised of bioacceptable materials, amenable to diverse patient dosing needs, and offer added exclusivity.

Lipocine currently has a portfolio of superior differentiated products for branding opportunities available for partnering.

...Let's Talk



675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 • (801) 994-7383 • www.lipocine.com

COMPANY PROFILE

LOPAREX

LOPAREX

7700 Griffin Way

Willowbrook, IL 60527

T: (630) 734-2700 F: (630) 734-2690

E: info@loporex.com - Website: www.loporex.com

Contact: Steve Saunders, Market Manager



Medical device manufacturers have specialized needs for release liners, including consistent release, cleanliness, and traceability. Loparex, the world's leader in the manufacture of silicone-coated papers and films, serves the medical industry with a variety of release liners to meet those needs. Our customized products are designed with these applications in mind:

EKG/ECG Electrodes & Electro-Medical Devices

Important requirements include cleanliness, thermoformability, die-cutability, and consistent release, particularly with gel adhesives. To meet these needs, Loparex offers polyester, polystyrene, and polyethylene film release liners. Our POLY SLIK® brand release liners, bleached kraft papers extruded with low- or high-density polyethylene, are used for electro-surgical grounding pads.

Transdermal Drug Delivery Systems (TDDS)

Cleanliness and consistent release are to be expected for TDDS patches. Polyester film, in smooth and matte finishes, is used for processing and protecting drug-loaded adhesives until applied to the patient. Loparex maintains Drug Master Files on many of our products to assist in the development of New Drug Applications (NDAs).

Wound Coverings & Bandages

A common bandage application consists of an adhesive tape, an absorbent pad, and a release liner. Cleanliness and consistent release after sterilization are key. STICK-NOT® brand release liners, manufactured from supercalendered kraft papers and easy release silicone coatings, are suitable, as well as our in-line paper-making and siliconizing capability (ESP) and one-side polycoated and one-side silicone coated (Polyinter). STICK-NOT, ESP, and Polyinter are available in a wide variety of basis weights.

Ostomy Devices

Self-adhering ostomy bags, worn over an abdominal opening or stoma, utilize a one-side polycoated, one-side easy release silicone-coated POLY SLIK product to protect the adhesive. POLY SLIK provides the stiffness, cleanliness, and consistent release demanded by these devices. Polystyrene film-based release liners can be thermoformed to adapt to convex-shaped appliances.

Process Liners

Loparex manufactures reliable and economical release liners that are also used in process (i.e., curing the pressure sensitive adhesive) to assist in the manufacture of medical devices.

Loparex has paper and film substrates, global extrusion processes, slitting, printing, and several silicone-coating chemistries that can be used to design the right release liner for your medical device.

Look to Loparex for Drug Delivery and Medical Release Liners

As Transdermal Drug Delivery Systems (TDDS) continue to grow, so has the need for release liners that can satisfy the demanding requirements of both the manufacturer and the end-use customer.

Loparex is the world's leading manufacturer of release papers and films with sales and service around the world. Our continuing commitment to leading-edge technologies in both chemistry and substrate development make Loparex uniquely qualified to help in selecting the best release liner for your drug delivery device needs. We can also develop a custom release liner designed for your unique application requirements.

Loparex maintains Drug Master Files on many of our products to assist in the development of New Drug Applications (NDA). We also offer a Medical Binder of our most common medical release products and sample rolls for evaluation. Look to Loparex for all your drug delivery and medical release liner needs.


LOPAREX

Consistent. Quality. Release.

7700 Griffin Way, Willowbrook, IL USA 60527

Phone: **888-327-5454** (U.S. toll-free)

www.loparex.com



COMPANY PROFILE

NOF CORPORATION

NOF CORPORATION
20-3, 4-chome
Ebisu, Shibuya-ku, Tokyo 150-6019 - Japan
T: +81-3-5424-6741
F: +81-3-5424-6769

NOF AMERICA CORPORATION - US CONTACT
11 Martin Avenue, Suite 1170
White Plains, NY 10606
T: (914) 681-9790
F: (914) 681-9791

E: ddsinfo@nof.co.jp - Website: www.nof.com.jp/dds



Promoting Innovative Drug Delivery Systems

As an integrated chemical manufacturer featuring all kinds of human activity from Biosphere to Outer Space, NOF CORP. is focused on the development on innovative drug modifiers, carriers and solubilizers, such as PEG, phospholipids, highly purified oleic acid nonionic surfactants, cholesterol pullulan, MPC polymers, and chitosan. As a worldwide leader for DDS, NOF provides excellent quality products for the pharmaceutical industry.

1. PEGYLATION TECHNOLOGY

We produce not only excellent purity of methoxypolyethylene glycols ranging from 200 to 30,000 molecular weight, but also activated PEG derivatives, such as methoxy-PEG amines, maleimides, and carboxylic acid. By arranging the terminal group of PEG, various kinds of customers' drugs can be modified. In addition, the half-life of drugs in the bloodstream can be lengthened when our PEG modified phospholipids are injected as a liposomal formulation.

2. PHOSPHOLIPIDS & EMPTY LIPOSOMES

We have successfully supplied our GMP-grade of phospholipids for worldwide drug products since the 90s and have a good reputation amongst our customers. We not only develop new types of phospholipids, but also formulate and develop lyophilized liposomes, called EMPTY LIPOSOME (EL-series), with which customers can easily encapsulate their drugs. Special cationic type EL-01-D is recently commercialized for gene delivery in which better transfection efficiency can be obtained.

3. Ultra-Pure Polysorbate 80 & PEG 200, 300 & 400

NOFABLE ESO-9920 (Polysorbate 80) of NOF CORPORATION, which consists of ultra-purified Oleic Acid (99% up) and an extremely low impurity profile, provides the following great features of Polysorbate 80:

- Low Degranulation (Low Allergic Reaction)
- Low Cell Toxicity
- Low Hemolysis
- Multi-Compencial-ND, EP, JP

Ultrapurified PEGs and PEG 200, 300, and 400 are only available at NOF CORPORATION, and feature extremely low impurities (EG and DEG) and low POV. NOF's PEG 200, 300, and 400 meet with multi-compencial of NF, EP, and JP.

4. Novel Solubilizing Kit for PUREBRIGHT SL Series

PUREBRIGHT SL Series is a Novel Solubilizing Kit for any Hydrophobic Drugs (Protein, Peptide, and small molecular etc.)

- | | | | |
|--|--|--|--|
| 1. PUREBRIGHT SL-100 series MPC polymer base formulation | 2. PUREBRIGHT SL-200 series PEG Phospholipids base formulation | 3. PUREBRIGHT SL-300 series Cholesterol PEG base formulation | 4. PUREBRIGHT SL-400 series Phospholipids mixture base formulation |
|--|--|--|--|


World-wide leader in DDS

NOF CORPORATION provides outstanding quality, innovative drug modifiers, carriers and emulsifiers. NOF has an excellent reputation producing these products in their cGMP facilities.


Activated PEGs

- Outstanding Quality PEGs and Activated PEGs
- Narrow Polydispersity & Low Diol content
- cGMP production
- New Branched PEGs and Multi-arm PEGs

NOF Activated PEG




New GMP Plant & DDS R&D



cGMP Facility

PEGylation

- Wide Range Selection of Activated PEGs
- Advanced PEGylation Technology
- PEGylation of protein, peptide, nucleic acid, etc.
- Prolonged blood circulation of the Drug



PEG-DRUG




Empty-Liposome Kit



- Outstanding Quality & GMP production
- Numerous Drug Master Files
- Ready-to-use freeze-dried liposome kit
- PEGylated & Targeting Liposome Technology

Phospholipids and Liposome



NOF Others

- Outstanding Quality
- Multi-Compendial NF, EP, and JP
- Low Impurities and Peroxide
- Low Toxicity & Hemolysis
- Low Degranulation (Low Allergic Reaction)

Ultra-pure Polysorbate 80

NOF CORPORATION

DDS Development Department
Yebisu Garden Place Tower
20-3, Ebisu 4-Chome
Shibuya-ku, Tokyo 150-6019 JAPAN

NOF America Corporation
11 Martine Avenue, Suite 1170, White Plains, NY 10606, USA
TEL: +1-914-681-9790 FAX: +1-914-681-9791
E-mail: info@nofamerica.com

NOF Europe (Belgium) NV
Bouwvelven 1, Industriezone Klein-Gent, B-2280 Grobbendonk, Belgium
TEL: +32-14-230001 FAX: +32-14-224563
E-mail: takuya.saigo@nofeurope.com

<http://www.nof.co.jp/dds/> E-mail: ddsinfo@nof.co.jp
Tel: +81-3-5424-6741 Fax: +81-3-5424-6769

You can't be a
leader
without **thinking**
ahead.



COMPANY:

SafetySyringes, Inc.™

CORPORATE HEADQUARTERS:
Carlsbad, CA

PHONE:
760.918.9908

FAX:
760.918.0565

WEB:
www.safetysyringes.com

*Christer Andreasson, Chairman
and CEO of Safety Syringes, Inc.*



Continuous New Product Development

Time and again, the world's leading pharmaceutical manufacturers choose the UltraSafe® brand for their prefilled syringe presentations. Since the first pharmaceutical launch of the UltraSafe® needle guard in 2000, followed by our UltraSafe Passive® delivery system in 2002, we have continued on our path of innovation. Our latest devices highlight tamper evident features to combat drug counterfeiting, while others are suited for use with an autoinjector, serving the growing needs of the self-administration market. We will not stop there.

The Choice of Pharmaceutical Leaders

Today, we anticipate the needs of our partners and increase the capacity to do more each and every day. We have become an intuitive and dependable partner to over a dozen leading-edge pharmaceutical companies who will supply over 20 injectable drug products to the market in the very near future.

Newly Expanded Operations

Our recent expansion into a larger and more advanced facility adds another location to our network for device manufacturing and assembly. Our state-of-the-art facility takes automated assembly of our devices to an unprecedented level and allows us to develop a comprehensive business continuity plan for each pharmaceutical partner. Moreover, our ever-growing network of automation builders and packaging experts still ensures you the fastest time to market with your blockbuster drug.

Leading the Industry into the Future

Our commitment to improving drug delivery for prefilled syringes is proven – and remains our core competency. Our partners' products that are already available on the market demonstrate our leadership position. The UltraSafe Passive® delivery system is the most widely used and accepted device of its kind on the market today.



UltraSafe®
Needle Guard

2000



UltraSafe Passive®
Delivery System

2001




Tamper Evident UltraSafe
Passive® Delivery System

2002



Luer Lock UltraSafe
Passive® Delivery System

2003



Autoinjector with
UltraSafe Passive®
Delivery System

2005

Time and Again the World's Leading Pharmaceutical Companies Choose UltraSafe®.

Seven of the top ten pharmaceutical companies have chosen the UltraSafe® family of products and have proven them safe and effective with well over 150 million used worldwide. The UltraSafe Passive® Delivery System is easily integrated into existing production lines, enabling the fastest possible time to market. And as our product line evolves, it will continue to provide compelling competitive advantages that can make a real difference on your bottom line. Visit us today at www.safetysyringes.com or contact your local representative.

United States

Alex Jaksch Tel 760 918 9908
ajaksch@safetysyringes.com

Europe

Michel Guillory Tel +33 4 76 40 06 14
mguillory@safetysyringes.com



The preferred choice

COMPANY PROFILE



SCOLR Pharma, Inc.

SCOLR PHARMA, INC.

3625 132nd Avenue SE, Suite 300
Bellevue, Washington 98006

T: (425) 373-0171 • F: (425) 373-0181

E: productdevelopment@scolr.com

Website: www.scolr.com



Background

Based in Bellevue, Washington, **SCOLR Pharma** is a specialty pharmaceutical company that leverages its formulation expertise, and its proprietary and patented drug delivery technologies to introduce distinctive and novel pharmaceutical, Over-the-Counter, and nutritional products.

The Company enjoys a significant differentiated intellectual property position in drug delivery consisting of four (4) young and broadly applicable patents. Its first unique robust technology was licensed from Temple University in 1998. Since then, SCOLR has expanded its intellectual property to include a full platform of related delivery technologies capable of handling challenging classes of

drugs and nutritional ingredients. The Company believes its lead OTC pharmaceutical product candidate to be the only 12-hour extended-release ibuprofen formulation currently in clinical evaluation for the US OTC market. It also believes that its lead prescription drug candidate also in clinical evaluation, an immediate-release CDT-Raloxifene formulation for osteoporosis, will potentially be easier to manufacture, and use less drug than currently approved formulations.

In the area of dietary supplements, the Company's efforts are concentrated on meaningful improvements and value-added formulations for human nutritional product applications. The Company has successfully created multiple private label products for large retailers that generate a source of royalty revenues.

Technology Summary

- Electrolyte Platform (US Patent No. 6,090,411-Issued July 18, 2001)
"Salt Patent" allows for simple two step processing and uses ionic interactions to correct for limitations in other first generation matrix-based systems.
- Dual Polymer Platform (US Patent No. 6,337,091-Issued January 8, 2002)
"Dual-Polymer Patent" allows for simple production of tablets and capsules and uses ionic and anionic polymers to correct for limitations in other biphasic/triphasic systems.
- Amino Acid Platform (US Patent No. 6,517,868 – Issued February 11, 2003, US Patent No. 6,936,275 – Issued August 30, 2005)
"Amino Acids Patents" allows for simple production of tablets and uses hydrophobic/polar interactions to facilitate solubility and potentially permeability.

Overcome Delivery Barriers



With Our Self Correcting Oral Systems

Our suite of patented self-correcting oral delivery systems can handle your most challenging drug or nutritional ingredient. CDT®'s simple but elegant technology provides partners with rapid product development and the highest possible success in clinical trials.

- Our **"Dual Polymer"** platform allows production of novel Matrix tablets and capsules regardless of their initial flow properties.
- Our **"Electrolyte"** platform is capable of custom tailored release profiles, including zero order, that can emulate complex delivery systems. (i.e. osmotic pumps, bead systems, layered tablets)
- Our **"Amino Acid"** platform can enhance solubility to allow precision controlled delivery in simple monolithic dosage forms.

SCOLR, CDT Logo & Design are trademarks of SCOLR Pharma, Inc. • CDT is a registered trademark of SCOLR Pharma, Inc.

SCOLR Pharma, Inc.
Self Correcting Oral Delivery Systems

3625 132nd Ave S. E. • Suite 400
Bellevue, WA 98006
425.373.0171
www.scolr.com

COMPANY PROFILE



WEILER ENGINEERING, INC.
Global Sales & Service Department
1395 Gateway Drive
Elgin, Illinois 60123
T: (847) 697-4900
E: solutions@weilerengineering.com
Website: www.weilerengineering.com



The corporate focus of Weiler Engineering, Inc. is to provide the most advanced aseptic liquid processing technology available through the application of customized ASEP-TECH® Blow/Fill/Seal machinery and integrated services. Weiler's unique combination of world-class engineering and cutting-edge technical expertise helps ensure its continuing world-wide leadership position, serving the marketplace with the latest in advanced, sterile, aseptic liquid packaging technology.

Weiler's manufacturing facilities and corporate offices are conveniently located near Chicago's O'Hare International Airport. ASEP-TECH® Blow/Fill/Seal machines are designed and built in a 120,000-sq-ft, state-of-the-art manufacturing plant. All equipment is designed and manufactured in the USA. Approximately 100 people are involved in the design and construction of these machines, providing 21st Century Solutions® for parenterals, ophthalmics, respiratory drugs, biologicals, nutraceuticals, and other complex solutions.

Weiler began manufacturing BFS machines more than 30 years ago under the Bottlepack® brand, continued with the ALP® trademark and is now building the latest generation of ASEP-TECH® Blow/Fill/Seal Systems. The Weiler design incorporates the three-step process of blow molding, aseptic filling, and hermetic sealing of liquid products in one sequential operation on a compact machine frame. The ASEP-TECH® brand identity provides increased focus for future development and advancement of Blow/Fill/Seal technology as a core competency.

Weiler's patented electronically controlled fill system, automatic sterilization system with integral data collection, and filter integrity test system are provided as standard equipment for each machine configuration. Each machine is also equipped with a HEPA air shower to ensure a Class 100 environment under dynamic conditions in the nozzle shroud area. Optional parison shrouding is available to ensure a Class 10,000 environment under dynamic conditions in the extrusion zone and the critical transport area.

Weiler Engineering continues to place a strong emphasis on the science of Blow/Fill/Seal technology as it relates to the optimization of machine design to enhance process capabilities relating to sterility assurance. These efforts are recognized by the worldwide regulatory community and will change the future of aseptic manufacturing. Weiler's proactive stance has positioned it prominently at the forefront of these developments. We are continually applying the results of our scientific research to the design of our next-generation Blow/Fill/Seal machines, firmly setting the standards to the highest level of sterility assurance for aseptic technology.

Our customer commitment extends beyond that of typical machine builders, providing expertise and support derived from years of design and manufacture of high quality, automated equipment. Weiler has the ability to integrate complete finishing lines with its Blow/Fill/Seal systems for deflashing, leak detection, labeling, and final packaging.

Our Technical Services staff is available to assist with container design and development, and technical support. Our R&D department can assist with prototyping, product trials, and outsourcing of key support functions, such as process validation to help complete your project package.

KISS YOUR GLASS GOODBYE...

WITH THE ADVANTAGES OF PLASTIC USING ASEP-TECH® BLOW/FILL/SEAL TECHNOLOGY



ASEP-TECH® Blow/Fill/Seal packaging machines from Weiler Engineering are simply the better alternative to conventional filling of glass vials for parenteral (injectable) products. This advanced aseptic technology is also widely used to package ophthalmic and respiratory therapy products.

Check the ASEP-TECH® Blow/Fill/Seal Advantage:

- ✓ Increased safety for both the patient and healthcare provider
- ✓ Lower product to market cost
- ✓ "Green" container manufacturing – recyclable container materials
- ✓ Improved product quality – no aluminum leaching issues
- ✓ Less material handling reduces probability of product contamination
- ✓ Fewer packaging steps
- ✓ Reduced raw material inventory

Now is the time to kiss your glass goodbye and switch to ASEP-TECH® Blow/Fill/Seal packaging machines from Weiler Engineering. To learn more, visit our website at www.weilerengineering.com or call 847-697-4900.



Driven by Science and Technology



VISIT US AT INTERPHEX BOOTH # C347

1395 Gateway Drive • Elgin, Illinois 60123 • Phone: 847-697-4900 • Fax: 847-697-4915
E-mail: solutions@weilerengineering.com • Website: www.weilerengineering.com

COMPANY PROFILE



XCELIENCE

5415 West Laurel Street

Tampa, FL 33607

Phone: (813) 286-0404 Fax: (813) 286-1105

E: Info@xcelience.com

Contact: Randall Guthrie, Vice President

Website: www.xcelience.com

Xcelience, a Tampa-based pharmaceutical contract research organization, is the premier source for unsurpassed quality in drug development. We consistently and efficiently move our sponsors' APIs through the drug formulation process, getting them to clinic and market faster. By combining the industry's top-performing formulation development scientists, with state-of-the-art equipments, you have the end result Xcelience - Xcelling the Science of Formulation Development.

Xcelience's Core Services

Led by a dedicated project manager, our scientific teams work as an extension of your organization throughout the drug development process. Using the latest technologies gives us unparalleled speed to market without compromising our absolute commitment to quality.

Xcelience offers the following services:

Preformulation: Xcelience's range of preformulation studies allows us to optimize your dosage form at the earliest stage of drug development. Our scientists have experience in preformulation of new substances, generics, and reformulation of new products.

Formulation: The scientific team creates options for formulation to meet your dosage range and preferred route of delivery. We are able to formulate the following dosage forms:

- Solids:
 - Tablet formulation
 - Hard gelatin capsule formulation
 - Granules
 - Powders
- Liquids:
 - Oral and topical liquids
 - Suspensions
 - Emulsions
- Semi-solids:
 - Creams
 - Ointments
 - Gels

Analytical: State-of-the art facilities and instrumentation provide an optimal environment for stability studies, including a full range of temperature and relative-humidity conditions.



Manufacturing: Our scientists are the industry's most respected in the field of formulation development. Contact us for:

- Manufacturing batches for stability testing
- Scaling up and production of pilot batches
- Manufacturing of clinical trials supplies from Phase I through to Phase III, including individual capsule filling of API, tableting, encapsulation, placebo matching, over-encapsulation, or coating of comparators
- Process validation and technology transfer

Xcelience's capabilities include the patented precision micro filling of API into capsules Xcelodose™ 600 system. It creates manufacturing batches for clinical trials in an easier, more precise, and cost-efficient manner: with no need for filling excipients and full traceability of the API's weight, "Time to man" clinical trials is considerably reduced.

Facility Overview

Xcelience's 24,000-sq-ft Tampa laboratories are fully cGMP compliant and registered with the FDA and DEA. The facility is also ISO 9001 certified. We are very proud of our world-class scientists and unparalleled environment breeding excellence.

*Send us your challenge today - Xcelience
Xcelling the Science of formulation development*



The Future of Medical Devices is Now!

PharmaMedDevice™ is the only comprehensive event that fully illuminates the convergence of the medical device, pharmaceutical, and biologic industries. This event provides a dynamic platform for education, partnering, sourcing and discovery of innovative, new products which are transforming the healthcare industry – and provides a unique opportunity for cross-sector collaboration across these industries.



PharmaMedDevice will showcase a range of state-of-the-art technologies from industry-leading medical device suppliers and service providers that will help to advance the commercialization of life-enhancing combination products, such as cardiovascular drug-eluting stents, novel orthopedic implants and implantable insulin pumps. Exhibitor categories will range from contract services, automation systems and components to drug delivery systems, coating and surface treatments, sterilization equipment, and testing and inspection services.

PharmaMedDevice has partnered with *FDC Reports' The Gray Sheet, The Silver Sheet, and The Pink Sheet* and BEACON, the producers of *MEDi2005*, to co-produce a conference program that will address the needs of the

emerging combination products market, biomedical engineering community, and the exciting innovations taking place in drug delivery technology and healthcare. The conference program will provide life science companies with a roadmap for speeding new combination products to market and extend product lifecycles.

Plan to be there! Innovative professionals including scientists, academics, executives from R&D and business development, product managers, manufacturing engineers,



QA/QC personnel and regulatory specialists will gather to network, develop new partnerships and address the challenges of developing and bringing combination products to market. Don't be left behind, you can **register now!**

PHARMA **MedDevice™** 2007

April 24-26, 2007 Jacob K. Javits Center, New York, NY
Co-located with INTERPHEX

www.PharmaMedDevice.com/print

Sponsored by:



Special Report

A close-up, high-angle shot of a microscope's objective lenses and eyepiece, set against a dark blue background. The lighting is dramatic, highlighting the metallic surfaces of the instrument.A glowing blue world map is overlaid with a bright, neon-colored ECG (heart rate) line. The map shows the outlines of continents, and the ECG line pulses across the globe, symbolizing global health and pharmaceutical activity.

Partnerships, Technologies & Pipeline Report

FEATURING:

- Drug Technologies
 - Excipients, Polymers, Liposomes & Lipids
 - Contract Pharmaceutical & Biological Development Services
 - Machinery & Laboratory Equipment & Software
- 
- A close-up of a hand wearing a white nitrile glove, holding a small, clear glass vial. The vial contains a clear liquid and has some text on it, though it's not legible. The background is a soft, out-of-focus blue.

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

3M Drug Delivery Systems



Bldg 275-3E-10
St. Paul, MN 55110
Phone: (800) 643-8086 Fax: 651-737-5265
www.3m.com/ddsadv

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Inhalation Drug Delivery Systems and Components</i>	Systemic/Pulmonary	Schering-Plough Corporation, Forest Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, GlaxoSmithKline, Sepracor, IVAX
<i>Transdermal Drug Delivery Systems and Components</i>	Transdermal	Schering AG, Berlex Laboratoriess, Inc.
<i>Microstructured Transdermal Systems</i>	Proteins & Peptides, Vaccines	
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Novel Excipients</i>	Transdermal, Pulmonary/Nasal	

Contact: Brian Gabrio, bjgabrio@mmm.com

DRUG DELIVERY TECHNOLOGIES

AEROVECTRX CORPORATION
Suite 1500 3003 Summit Blvd. N.E.
Atlanta, GA 30319
Phone: (404) 460-5450 Fax: (404) 460-5001
e-mail: info@aerovectrx.com
Website: www.aerovectrx.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Aerocurrent</i>	Self-administered aerosol drug delivery	Under development
<i>Aerolife</i>	Mass-immunization for aerosolized vaccines for infectious diseases in developing countries	CONFIDENTIAL
<i>Aerolife</i>	Aerosol drug delivery	Under development
<i>Aerocell</i>	Disposable mesh/drug cartridge for use with Aerocurrent and Aerolife	Under development

Contact: Matthew Kim, CEO

DRUG DELIVERY TECHNOLOGIES



AKINA, INC.
Business & Technology Center
1291 Cumberland Avenue, E130
West Lafayette, IN 47906-1385
Phone: (765) 464-0501 Fax: (765) 464-0820
e-mail: kp@akinainc.com - www.akinainc.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Frosta</i>	Oral Fast Melting Tablets	Samyang Corp.
<i>HydroCelle</i>	Delivery of poorly soluble drugs (oral and parenteral)	
<i>PollyShell</i>	Delivery of protein drugs (parenteral)	
<i>Aquagel</i>	Gastric retention devices and diet control	Kos Pharmaceuticals
<i>Stentrix</i>	Drug delivery from stents	

Contact: Kinam Park, PhD, (765) 464-0390, kp@akinainc.com

DRUG DELIVERY TECHNOLOGIES

ALKERMES, INC.
88 Sidney Street
Cambridge, MA 02139
Phone: (617) 494-0171 Fax: (617) 494-9263
e-mail: busdev@alkermes.com
www.alkermes.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Medisorb® Technology</i>	Proprietary, injectable extended-release technology to encapsulate small molecules, peptides, and proteins in microspheres made of biodegradable polymers. With extended-release profiles lasting from days to months, these microspheres eliminate the need for frequent dosing and may be used for SQ or IM delivery.	Confidential
<i>AIR® Technology</i>	Pulmonary technology offers unique, proprietary system for optimized delivery. System can provide efficient dry-powder delivery of small molecule, peptide, protein, and other macromolecule drug particles to the deep lung.	Confidential

Contact: Ken Andrews, Chief Commercial Officer

DRUG DELIVERY TECHNOLOGIES

ALTEA THERAPEUTICS CORPORATION
2056 Weems Road
Tucker, GA 30084
Phone: (678) 495-3100 Fax: (678) 495-3130
e-mail: businessdevelopment@alteatherapeutics.com
www.alteatherapeutics.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>PassPort™ System - Altea Therapeutics new transdermal technology enables the sustained transdermal delivery of water-soluble drugs, peptides, proteins, and nucleotides from a convenient and cost-effective skin patch.</i>	Altea Therapeutics is currently developing a fentanyl citrate patch for management of moderate-to-severe pain, a basal insulin patch for treatment of diabetes, an apomorphine hydrochloride patch for treatment of Parkinson's disease, and an influenza vaccine patch.	In January 2006, Altea Therapeutics and Teikoku Seiyaku Co. Ltd. of Japan signed an exclusive licensing agreement for Japan to develop and commercialize a transdermal patch therapy for the treatment of advanced Parkinson's disease.

Contact: Steven P. Damon, VP Business Development

DRUG DELIVERY TECHNOLOGIES

AMERICAN PEPTIDE COMPANY, INC.
777 East Evelyn Avenue
Sunnyvale, CA 94086
Phone: (408) 733-7604, x204
www.americanpeptide.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Catalog Peptide, Custom Peptides, CGMP Peptides, Oligo-Nucleotides, Dye Products, Process Development</i>	Research in Cell Biology, Microbiology, Immunology and Drug Discovery. Clinical trial and new drug applications	Biotechnology and Pharmaceutical companies; as well as Diagnostic and Antibody companies

Contact: Gary Hu, (800) 926-8272, x204

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

ANTARES PHARMA, INC.
707 Eagleview Boulevard, Suite 414
Exton, PA 19341
Phone: (610) 458-6200
Fax: (610) 458-0756
www.antaespharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Medi-Jector VISION® needle-free injectors</i>	Insulin, growth hormone	Ferring, JCR, SciGen
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Antares Pharma Vibex™ mini-needle injectors - single-dose, disposable</i>	Large and small molecule delivery	Clinical trials
<i>Needle-free injection technology</i>	Diabetes, obesity	Lilly
<i>ATD™ Advanced Transdermal Gel</i>	Transdermal delivery	Clinical trials
<i>Easy Tec™ Oral Dissolving Tablet</i>	Oral delivery	Pre-clinical

Contact: Mike Kasprick: mkasprick@antaespharma.com, Jim Hattersley: jhattersley@antaespharma.com

DRUG DELIVERY TECHNOLOGIES



ALZA CORPORATION
1900 Charleston Road
Mountain View, CA 94043
Phone: (650) 564-5000
www.alza.com



Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>OROS®</i>	Oral	Pharmacia Corporation (Covera-HS®), Novartis (DynaCirc CR®), Pfizer (Cardura® XL, Glucotrol® XL, Procardia XL®, Sudafed® 24 Hour), Muro Pharmaceutical, Inc. (Volmax®), Ortho-McNeil Pharmaceutical (Ditropan XL®), McNeil Consumer & Specialty Pharmaceuticals (Concerta®)
<i>D-TRANS®</i>	Transdermal	GSK (Nicoderm® CQ® and Clear Nicoderm® CQ®), Boehringer Ingelheim Pharmaceuticals (Catapres-TTS), Janssen Pharmaceuticals Inc. (Duragesic®), Novartis (Transderm-Nitro®, Transderm Scop®, Estraderm®), Ortho-McNeil Pharmaceutical (Testoderm®)
<i>DUROS®</i>	Implant	Bayer (Viadur®)
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Macroflux®</i>	Transdermal/Theratechnologies Collaboration	Pre-clinical
<i>DUROS® Omega</i>	BMI Collaboration for hepatitis	Pre-clinical
<i>STEALTH® her2</i>	Liposomal targeted oncology	Pre-clinical
<i>STEALTH® CKD 602</i>	Liposomal oncology	Pre-clinical
<i>E-TRANS® fentanyl</i>	Transdermal, Acute pain in post operative setting	Phase II
<i>L-OROS™</i>	Liquid formulation OROS, oral delivery	Actively Seeking Partner
<i>ALZAMER®</i>	Depot	Actively Seeking Partner

- ALZA is actively seeking partners for all of its technology platforms -

Contact: busdev@alza.com (for business development/partnership inquiries)
(650) 564-5555 (for business development/partnership inquiries)

DRUG DELIVERY TECHNOLOGIES

ARADIGM CORPORATION
3929 Point Eden Way
Hayward, CA 94545
Phone: (510) 265-9000 Fax: (510) 265-0277
www.aradigm.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>AERx Pulmonary Delivery System</i>	Insulin Asthma Anthrax Cystic Fibrosis Pulmonary Hypertension	Novo Nordisk APT Pharmaceuticals Canadian Gov't Proprietary United Therapeutics

Contact: Tom Chesterman, Chief Financial Officer, BD@aradigm.com

DRUG DELIVERY TECHNOLOGIES

AVEVA DRUG DELIVERY SYSTEMS, INC.
3250 Commerce Parkway
Miramar, Florida 33025
Phone: (954) 430-3340 Fax: 954-430-3390
www.avevadds.com



Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Gel Matrix Adhesive Transdermal Patch</i>	Once-a-day Isosorbide Dinitrate	• Teva
<i>Crystal Reservoir</i>	Chrono-Controlled Release, Sustained Release, Immediate Release	• Pfizer
<i>Volatile Drug System</i>	Smoking Cessation	• Perrigo
<i>Membrane Controlled Systems</i>	Weight Loss, HRT, Antiemetics, Bronchodilators, CNS Stimulants, Antimigraine	• Watson
<i>Unique Matrix Technology</i>	Analgesics, Weight Loss HRT, Antiemetics, CNS Stimulants, Antimigraine	• Toa Eryo
<i>Liquid/ Semisolid Formulations</i>	Analgesics, Hypoglycemics	• BioDelivery Sciences International
<i>Dissolvable/ Aqueous Films</i>	Analgesics, Antiemetics, CNS Stimulants, Hypoglycemics	
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Mucosal</i>	Breakthrough Pain	Clinical Trials
<i>Transdermal</i>	Asthma	Preclinical
<i>Transdermal</i>	Asthma	Clinical Trials
<i>Transdermal</i>	Pain Management	Clinical Trials

Contact: Bob Bloder/ Brian Guy

DRUG DELIVERY TECHNOLOGIES



BAXTER HEALTHCARE CORPORATION
Route 120 & Wilson Roads
Round Lake, IL 60073
T: (800) 422-9837 (domestic) or (847) 948-4770
F: (847) 948-3642
e-mail: onebaxter@baxter.com
www.baxterbiopharmasolutions.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Enhanced Packaging (Ready-to-Use Systems; Ready-to-Mix Systems)</i>	Premixed, Parenteral Formulations	
<i>PROMAXX Microsphere Technology</i>	Protein/Peptide/DNA/Organic Drugs; Injectable Drug Delivery; Inhalable Drug Delivery; Ophthalmic; Nasal	
<i>NANOEDGE Dispersion Technology</i>	Lyophilized; Aseptic & Terminally Sterilized Parenterals; Direct Homogenization; Microprecipitation	Not disclosed
<i>Cytotoxic Contract Services</i>	Lyophilization; Aseptic Liquid Vial Filling; Dry Powder Vial Filling; and Sterile Crystallization	
<i>Parenteral Contract Services</i>	Prefilled Syringes; Lyophilization; Aseptic Liquid Vial Filling; Cartridge Filling; Labelling/Packaging; R&D Services; Biologic Manufacturing; Kitting	

Contact: Kim Thomas, (847) 270-5072



DRUG DELIVERY TECHNOLOGIES



BD MEDICAL - PHARMACEUTICAL SYSTEMS
1 Becton Drive, Franklin Lakes, NJ 07417 MC: 407
T: (201) 847-4672 F: (201) 847-4847
e-mail: Jennifer_Zolot@bd.com
www.bd.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>BD Hypak SCF™; Glass Prefillable</i>	Parenteral	Many
<i>BD™ Pens: Customized Self-Injection Devices</i>	Parenteral	
<i>BD Accuspray™; Nasal Spray System</i>	Nasal	
<i>BD Uniject™; Prefill Injection Device</i>	Parenteral	
<i>BD Preventis™; Automatic Needle Shielding System</i>	Parenteral	

Contact: Jennifer Zolot, Jennifer_Zolot@bd.com



DRUG DELIVERY Technologies

See Company Profile



DRUG DELIVERY TECHNOLOGIES

BESPAK PLC

Blackhill Drive, Featherstone Road, Wolverton Mill South
Milton Keynes, Buckinghamshire MK12 5TS
United Kingdom

Phone: +44(0)1908 552600 - Fax: +44(0)1908 552613
e-mail: bizdev@bespak.com - www.bespak.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>BK357 HFA MDI Valve</i>	MDI: Suspension & Solution HFA Formulations	GSK, Teva, Sepracor, Cipla, Boehringer Ingelheim, Sanofi-Aventis, Chiesi, Valeas, Merck Generics
<i>BK361 Easifill</i>	MDI: Suspension & Solution HFA Formulations	Confidential
<i>Mechanical Dose Counter</i>	MDI Dose Counting	Confidential
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>UniDose DP</i>	Nasal Delivery of Powder Formulations	Preclinical
<i>Nasal Cast</i>	Modelling Drug Deposition in Nasal Cavity	Lab Trials

Contact Person: Joe Keenan, joe.keenan@bespak.com

DRUG DELIVERY TECHNOLOGIES



BIODELIVERY SCIENCES INTERNATIONAL, INC.

2501 Aerial Center Parkway, Suite 205
Morrisville, NC 27560

Phone: (919) 653-5160 Fax: (919) 653-5161
email: bds-info@bdsinternational.com
www.bdsinternational.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Biora® cochleate technology for oral delivery of products not normally available orally (hydrophobic drugs, nucleotides, vaccines, etc.)</i>	Oral delivery	Sigma-Tau Accentia Biopharmaceuticals
<i>BEMA™ technology for transmucosal membrane administration of drugs</i>	Transmucosal delivery	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>BEMA™ Fentanyl</i>	Breakthrough Cancer Pain	Phase III
<i>BEMA Long Acting Analgesic</i>	Pain	Phase I
<i>Biora® Amphotericin B</i>	Oral Antifungal	Preclinical
<i>BEMA™ Zolpidem</i>	Insomnia	Preclinical
<i>Biora® siRNAs</i>	Oral delivery	Preclinical

Contact: Evan Gothard, egothard@bdsinternational.com

DRUG DELIVERY TECHNOLOGIES

BIOJECT INC.

20245 SW 95 Avenue
Tualatin, OR 97062

Phone: (800) 683-7221 Fax: 503-692-6698

e-mail: customerservice@bioject.com
www.bioject.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Bio.Jector® 2000</i>	IM & SQ delivery	Trimeris/Roche
<i>Vitajet</i>	SQ delivery	Serono, Merial
<i>Needle-free Vial adapter</i>	reconstitution	Ferring, Amgen
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>IJECT pre-filled Multi-dose injector</i>	Self injection SQ multi-dose	Clinical trials In Development

Contact: Mike Redmond

DRUG DELIVERY TECHNOLOGIES



BROOKWOOD PHARMACEUTICALS, INC.

756 Tom Martin Drive
Birmingham, AL 35211

Phone: (205) 917-2200 - Fax: (205) 917-2205
www.brookwoodpharma.com



Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Long-acting Parenterals - Microparticles</i>	Microparticle formulations for delivery of small molecules, peptides, proteins, nucleic acids, and biological macromolecules by various routes of administration (systemic and local delivery) and duration of release of days, weeks, and months.	
<i>Nanoparticles</i>	Manufacturing of liposomes, polymeric nanoparticles, and lipid nanoparticles for clinical trials and commercial supply.	
<i>Long-acting Parenterals - Injectable Solid Implants</i>	Injectable rods of resorbable polymer and drug for systemic or local delivery with duration of release of days, weeks, or months.	Undisclosed
<i>VAXCAP™ Vaccine Delivery</i>	-Therapeutic & prophylactic vaccines -Mucosal & systemic responses -Antibody & cell-mediated responses -Auto-boosting with single administration	
<i>Modified Polymer Surfaces</i>	-Covalently linking moieties, such as peptides, proteins, and polysaccharides, to biodegradable polymer matrices, such as microparticle rods, fibers, meshes, and other three dimensional shapes. -Applicable to drug delivery formulations or medical devices	
<i>Long-acting, Injectable Hydrophobic Drug Particles</i>	-Drug delivery through the use of injectable, hydrophobic drug particles -Synthesis and particle size control -cGMP clinical lot manufacturing up to the 75-kg scale	
<i>Drug-Eluting Devices</i>	Design, development and manufacturing of biodegradable drug-eluting devices, e.g., for local drug delivery.	

Contact: Kelly Arlnt, (205) 917-2239

SPECIALTY PHARMA

Strategies For Business Development

FREE SUBSCRIPTION OFFER!

Become a regular subscriber! Visit us at www.specialtypharma.com simply fill out the subscription offer.

ADVERTISING

12,000 subscribers - senior level executives, business development professionals, and R&D directors/managers, working in this highly active marketplace of licensing, alliances and outsourcing.

MORE INFO:

EAST/MIDWEST

Victoria Geis
Cheryl Stratos
783-212-7735
vgeis@specialtypharma.com
cstratos@specialtypharma.com

WEST

Warren DeGraff
415-721-0644
wjdegraff@specialtypharma.com

INTERNATIONAL


Ralph Vitaro
973-299-1200
rvitaro@specialtypharma.com

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

CAPSUGEL®

CAPSUGEL
535 North Emerald Road
Greenwood, SC 29646
Phone: (888) 783-6361 Fax: (888) 783-6360
email: Glenda.oliver-smith@pfizer.com
www.capsugel.com


Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Capsules</i>	Hard gelatin, HPMC and pullulan	Undisclosed 
<i>PCcaps®</i>	Capsules & dosing syringe system ideally suited for oral dosage to rodents in pre-clinical studies	
<i>DBCaps®</i>	Capsules designed for overencapsulation in double blind clinical studies	
<i>Licaps®</i>	Empty capsules designed for liquid-in gelatin and HPMC	

Contact: Glenda Oliver-Smith

DRUG DELIVERY TECHNOLOGIES



CARDINAL HEALTH
14 Schoolhouse Road
Somerset, New Jersey 08873
Phone: (866) 720-3148 Fax: (732) 537-5949
email: pts@cardinal.com
www.cardinal.com/pts

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Zydis®</i>	Oral (fast-dissolve tablets)	Undisclosed 
<i>Capsules</i>	Soft gelatin & hard-shell gelatin	
<i>Microsponge®</i>	Topical (Cross-linked polymethacrylate copolymer particles)	
<i>EnSol®</i>	Oral Modified Release	
<i>EnCirc®</i>	Oral Modified Release	
<i>EnVe®</i>	Oral Modified Release	

Contact: (866) 720-3148 (toll-free) or pts@cardinal.com

DRUG DELIVERY TECHNOLOGIES

CELSION CORPORATION
10220-L Old Columbia Road
Columbia, MD 21046
Phone: (410) 290-5390 Fax: (410) 290-5394
email: celsion@celsion.com
www.celsion.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Adaptive Phased Array Treatment</i>	Focused microwave heating (Breast Cancer)	MIT
<i>Thermodynamic Therapy Drug Delivery System</i>	Focused delivery of encapsulated drugs using thermosensitive liposomes (Prostate, Liver,	Duke University (in Phase I for Prostate Cancer and entering Phase I for Liver Cancer)
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Targeted Gene Therapy Technology</i>	Heat-activated Gene Expression	Preclinical (Memorial Sloan Kettering)

Contact: Anthony Deasey, EVP & COO, (410) 290-5390 x4899

DRUG DELIVERY TECHNOLOGIES

CHR. HANSEN
9015 W. Maple Street
Milwaukee, WI 53214
Phone: (800) 558-0802 Fax: (414) 607-5959
email: Innovations@chr-hansen-us.com
www.chr-hansen.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Chr. Hansen Sugar Spheres NF</i>	Timed release	

DRUG DELIVERY TECHNOLOGIES

CHRYSALIS TECHNOLOGIES (DIVISION OF PMUSA)
7801 Whitepine Road
Richmond, VA 23237
Phone: (804) 864-4325 Fax: (804) 864-4443
busdev@Chrysalis-technologies.com
www.chrysalis-technologies.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Capillary Aerosol Generation</i>	Pulmonary Drug Delivery	Discovery Labs
Contact: Dr. Patrick D. Lilly		

DRUG DELIVERY TECHNOLOGIES

CIMA LABS INC.
10000 Valley View Road
Eden Prairie, MN 55344
Phone: (952) 947-8700
www.cimalabs.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>OraSol®</i>	An orally disintegrating tablet that combines taste masked active drug ingredients with a low effervescence system; blistered	Bristol-Meyers Squibb (Tempra Firstabs), Novartis (Triaminic Softchews), Organon (Remeron SolTab) Alamo (FazaClo), Schering-Plough (CLARINEX Reditabs)
<i>DuraSol®</i>	An orally disintegrating tablet that combines taste masked active drug ingredients with or without a low effervescence system; blistered or bottled	AstraZeneca (Zomig-ZMT), Schwarz-Pharma (NuLev), Wyeth (Alavert & Dimetapp ND), Schwarz-Pharma (NuLev, Parcopa, Niravam)
<i>PakSol®</i>	Light and moisture proof proprietary packaging system; also physically protects ODTs	All partners utilize PakSol as either product or trade sample packaging
<i>OraVescent®</i>	Enhanced-absorption drug delivery system intended to improve the transport of active drug ingredients across mucosal membranes; may improve bioavailability and accelerate the onset of action of some active drug ingredients	Cephalon (fentanyl)

Contact: Business Development, (952) 947-8700

DRUG DELIVERY TECHNOLOGIES

CIRRUS PHARMACEUTICALS, INC.
P.O. Box 14748
Research Triangle Park, NC 27709-4748
Phone: (919) 884-2064 Fax: (919) 884-2075
email: info@cirruspharm.com
www.cirruspharm.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Dry Powder Inhaler Formulation & Development</i>	Inhalation	Confidential
<i>Meter Dose Inhaler Formulation & Development</i>	Inhalation	
<i>Nasal Spray Formulation & Development</i>	Inhalation	
<i>Nebulizer Solution Formulation & Development</i>	Inhalation	
<i>Parenteral Formulation & Development</i>	Parenteral	
<i>Oral Drug Formulation & Development</i>	Oral	
<i>Topical Formulation & Development</i>	Topical, Transdermal	
<i>Peptide & Protein Formulation & Development</i>	Various	

Contact: Michael Branciforti (919) 321-4043

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES



CORIUM INTERNATIONAL
2686 Middlefield Road, Suite G
Redwood City, CA 94063
Phone: (650) 298-8255 Fax: (650) 298-8012
email: debfox@coriumtech.com
www.coriumgroup.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Corplex™ Hydrogel</i>	Transdermal, mucosal, wound care, device, and diagnostic products	Pharma, specialty, generic, wound care, and device companies
<i>MicroCor™ Micro Delivery System</i>		
<i>Delivery Modifiers/Permeation Enhancers</i>		

Contact: Deb Fox, PhD, V.P. of Business Development, (203) 775-7124, email: debfox@coriumtech.com

DRUG DELIVERY TECHNOLOGIES

CP KELCO
8355 Aero Drive
San Diego, CA 92123
Phone: (858) 292-4900 Fax: (858) 292-4901
email: solutions@cpkelco.com
www.cpkelco.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>KELTROL® xanthan gum</i> <i>XANTURAL® xanthan gum</i> <i>KELCOGEL® gellan gum</i> <i>GELRITE® gellan gum</i> <i>GENUP® pectin</i> <i>GENUP® carrageenan</i>	Oral drug delivery systems Mucosal drug delivery Transdermal drug delivery Controlled & sustained drug release Colonic drug delivery Edible film delivery systems	

Contact: Anne Sinha, (858) 467-6615

DRUG DELIVERY TECHNOLOGIES

CYDEX, INC.
10513 West 84th Terrace
Lenexa, KS 66214
Phone: (913) 685-8850 Fax: (913) 685-8856
email: cd_info@cydexinc.com
www.cydexinc.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>CAPTISOL® β-Cyclodextrin Sulfobutyl Ethers, Sodium Salts) drug delivery technology</i>	Parenteral, Oral, Inhalation, Ophthalmic, Other	Allergan, Inc.; Bristol-Myers Squibb; Daiichi Asubio Pharma Co., Ltd.; Merck & Co., Inc.; Pfizer Inc.; Pfizer Animal Health; Taisho Pharmaceutical Co., Ltd.; TargeGen, Inc.; Teva Pharmaceutical Industries, Ltd.; Genentech Inc.; AstraZeneca UK Limited; Gilead Sciences, Inc.; Array BioPharma Inc.

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Captisol-Enabled® Formulations:</i> • <i>Amiodarone – Licensed Worldwide</i> • <i>Budesonide – Licensed in the U.S.</i> • <i>Fexofenadine</i> • <i>Fosphenytoin</i> • <i>Melphalan – Licensed in the U.S.</i> • <i>Propofol</i> • <i>Sertraline</i>	-IV Antiarrhythmic -Respiratory -Oral Antihistamine -IV Anti-epilepsy -IV Oncology -IV Anesthetic -Oral Antidepressant	Preclinical – Clinical; Seeking development/marketing partners

Contact: Jose L. Rodriguez

DRUG DELIVERY TECHNOLOGIES

DELSITE BIOTECHNOLOGIES, INC.
1505 Walnut Hill Lane
Irving, TX 75038
Phone: (972) 717-5009 Fax: (972) 831-1132
email: info@delsite.com
www.delsite.com

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>GelVac™ Nasal Powder System</i> <i>GelSite® Polymer Injectable System</i>	Vaccine delivery Injectable delivery of protein & peptide drugs	Phase I completed Pre-clinical

Contact: Jean Anne Mire, Director, Business Development, (972) 650-7320, email: jamire@delsite.com

DRUG DELIVERY TECHNOLOGIES

DENDRITIC NANOTECHNOLOGIES, INC.
2625 Denison Drive
Mount Pleasant, MI 48858
Phone: (989) 774-6565 Fax: (989) 774-2322
email: hayes@dnanotech.com
www.dnanotech.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>STARBURST™ Dendrimer Platform</i>	Drug Delivery, Imaging Enhanced Drug Solubility	Large Pharma Companies Actively Seeking Partner
<i>Priostar™ Dendrimer Platform</i>	Drug Delivery, Imaging Enhanced Drug Solubility	Actively Seeking Partner Actively Seeking Partner

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>MRI Agent undisclosed</i> <i>Cisplatin-Dendrimer formulation</i> <i>Drug Formulation undisclosed</i> <i>siRNA Formulation</i>	Blood pool, targeted organs Ovarian cancer Oncology Transfection	Pre-clinical Ovarian cancer Late Development Pre-clinical

Contact: Ryan Hayes, PhD, Director of Business Development, (989) 774-6565

DRUG DELIVERY TECHNOLOGIES

DEPOMED, INC.
1360 O'Brien Drive
Menlo Park, CA 94025
Phone: (650) 462-5900
www.depomed.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Gastric Retention (GR) System</i>	Proprietary, oral, controlled-release drug delivery system	Biovail, Inc., ActivBiotics and AVI BioPharma

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Metformin GR</i> <i>Ciprofloxacin GR</i> <i>Gabapentin GR</i> <i>Furosemide GR</i> <i>Metformin/Sulfonylurea GR combo</i> <i>NEUGENE product</i> <i>Rifalazil GR</i>	Type II diabetes (oral) Urinary Tract Infection (oral) Seizures/Pain (oral) Diuretic (oral) Type II diabetes (oral) Undisclosed GI Infection (oral)	Conducting second phase III Phase III Phase I completed Phase I completed Preclinical Preclinical Preclinical

Contact: Thadd Vargas, (650) 462-5900

DRUG DELIVERY TECHNOLOGIES

DOW CORNING CORPORATION
PO Box 994
Midland, MI 48866
Phone: (989) 496-6000 Fax: (989) 496-6731
email: lifesciences@dowcorning.com
www.dowcorning.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Transdermal Drug Delivery</i>	Pressure Sensitive (PSA) and Soft Skin (SSA) adhesives; excipients; elastomeric matrices; in situ film-forming materials; coatings; fluids; and emulsions	
<i>Controlled Release Devices</i>	Adhesives, Medical-Grade Elastomers	Many
<i>Excipients for Topical Pharmaceutical Applications</i>	Ointments, Emulsions, Gels, Sprays, Sticks, Delivery of Actives	
<i>Topical excipients</i>	Volatile excipients, fluids, blends, waxes and emulsifiers to aid the delivery of topical forms and actives	

Contact: Stacey Chapin

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES



A D F B COMPANY

DPT LABORATORIES, LTD.
307 East Josephine Street
San Antonio, TX 78215
Phone: (210) 476-8159 Fax: (210) 829-8733
e-mail: confidence@dptlabs.com
www.dptlabs.com

Current Technologies/Platforms:

Advanced formulation expertise, including multivesicular emulsions, liposomes, microemulsions, anhydrous aerosol foams, low surfactant and surfactant-free formulations

Application(s):

Aerosols, Creams, Foams, Gels, Lotions, Ointments, Solutions, Suspensions, Nasal Sprays

Current Partner(s):



Contact: Roxanne Barr

DRUG DELIVERY TECHNOLOGIES

DURECT CORPORATION
10240 Bubb Road
Cupertino, CA 95014
Phone: (408) 777-1417 Fax: (408) 777-3577
email: IR@DURECT.COM
www.durect.com

Current Technologies/Platforms:

DUROS®

systemic and site-directed implantable

Endo Pharmaceuticals

SABER®

parenteral, oral, dermal and others

Cardinal Health, BioPartners, Pain Therapeutics

DURIN™

biodegradable implant

Voyager Pharmaceuticals

MICRODUR™

microsphere injectables

LACTEL®

biodegradable polymers

Various

Contact: Schond Greenway, (408) 777-1417

DRUG DELIVERY TECHNOLOGIES

EASTMAN CHEMICAL COMPANY
200 S Wilcox Drive, Box 431
Kingsport, TN 37662
Phone: (800) 327-8626 Fax: (423) 229-2707
www.eastman.com

Current Technologies/Platforms:

C-A-P NF

Enteric coating

Current Partner(s):

Eastacryl™ 30D NF acrylic coating material

Enteric coating

Eastman CA-398-10 NF

Sustained/Controlled Release; Taste Masking; Semi-Permeable Films

Eastman CAB-171-15-PG

Sustained/Controlled Release; Taste Masking; Semi-Permeable Films

Eastman Vitamin E TPGS NF

Absorption Enhancer, Solubilizer, Bioavailability Enhancer

Contact: Carolyn Baker, (423) 229-2987

DRUG DELIVERY TECHNOLOGIES

E.I. DUPONT DE NEMOURS COMPANY
DuPont Fluorochemicals, Chestnut Run Plaza
Wilmington, DE 19880-0711
Phone: (302) 224-0426 Fax: (302) 224-0427 www.dupont.com/dymel

Current Technologies/Platforms:

Technical Service Assistance (i.e. Basic Propellant Properties and Characteristics, Formulation Properties Data, Formulation Testing, Analytical Services, Toxicity Information, Regulatory Assistance, Safe Storage and Handling

Application(s):

Metered Dose Inhalers, Dry Powder Inhalers and other medical aerosols

Current Partner(s):

Confidential

Particle Science Technology, Engineering Evaluations for Heat, Mass & Momentum Transfer, Quality Management and Technology, Chemical & Reaction Engineering, Electrical & Energy Engineering, Environmental and Process Safety

Metered Dose Inhalers, Dry Powder Inhalers and other medical aerosols

Confidential

Contact: Mr. Joe Creazzo, email: Joseph.A.Creazzo@usa.dupont.com

DRUG DELIVERY TECHNOLOGIES

EGALET
Lejrvej 37- 41 Kirke Vaerloese
DK - 3500 Vaerloese - Denmark
Phone: +45 4447 8080 Fax: +45 4447 2425
www.egalet.com

Current Technologies/Platforms:

Egale®

Oral Sustained Release

Current Partner(s):

Parvulet®

Pediatrics

Pipeline Technologies/Platforms:

Cardiovascular Morphine

Application(s):

Development stage:

Phase III
Phase II

Contact: Ken Downie

DRUG DELIVERY TECHNOLOGIES

ELAN DRUG TECHNOLOGIES
Monksland - Athlone, Co Westmeath - Ireland
Phone: +353 90 64 95000 Fax: +353 90 64 95807
e-mail: operations@elan.com
Website: www.elan.com/EDT

Current Technologies/Platforms:

NanoCrysta® Technology (for poorly water-soluble compounds)

Oral: enhanced bioavailability, rapid absorption, decreased fed/fasted variability. Solid oral dosage forms, waterless tablets, oral liquids

Current Partner(s):

Number of clients including commercialized products with Merck, Wyeth, Fournier/Abbott and Par.

Parenteral: low volume, high dose aqueous formulations for IV, IM and Sub-Q administration

Respiratory: liquid and dry powder formulations for upper respiratory or deep lung delivery; sterile, preservative-free aqueous nasal spray suspensions

Pipeline Technologies/Platforms:

NanoCrysta® Technology

IM formulation of NCE

Development stage:

Phase III

NanoCrysta® Technology

Inhalation reformulation of marketed product

Phase II

NanoCrysta® Technology

Oral liquid NCE

Phase II

NanoCrysta® Technology

Tablet NCE

Phase I

NanoCrysta® Technology

IM depot

Phase I

NanoCrysta® Technology

Tablet reformulation of marketed product

Phase I

Contact: Sarah Carty, sarah.ccarty@elan.com

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

EMISPHERE TECHNOLOGIES, INC.
765 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: (914) 347-2220
www.emisphere.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Eligen Oral Drug Delivery Technology</i>	Oral delivery of macromolecules and other non-orally available therapeutics	Proprietary Technology
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Oral Heparin Solid Dose</i>	Cardiovascular	Phase III - Self Developed
<i>Oral LMWH Solid Dose</i>	Cardiovascular	Phase I - Undisclosed partner
<i>Oral Salmon Calcitonin</i>	Osteoporosis/Osteoarthritis	Phase III - Novartis
<i>Oral Recombinant Parathyroid Hormone 1-34</i>	Osteoporosis	Phase I - Novartis
<i>Oral Insulin</i>	Diabetes	Phase II - Self Developed
<i>Oral Cromolyn Sodium</i>	Asthma/Allergies	Phase II - Self Developed
<i>Oral Recombinant Human Growth Hormone (somatropin)</i>	Growth disorders	Phase I - Novartis
<i>Oral Acyclovir</i>	Anti-viral	Phase I - Undisclosed
<i>Oral Gallium</i>	Oncology	Pre-clinical - Genta
<i>Other Feasibility Projects</i>	Various	Pre-clinical

Contact: Business Development (914) 347-2220

DRUG DELIVERY TECHNOLOGIES

ETHYPHARM
194 Bureaux de la Colline
92213 Saint-Cloud Cedex - France
Phone: +33 1 41 12 17 20
www.ethypharm.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Oral Modified Release</i>	Oral, site-specific, sustained, delayed	Biovail, Astra
<i>Taste-Masking, Orodispersible</i>	Oral, rapid dispersion	Jansen, BMS
<i>Oral Enhanced Absorption</i>	Oral, pulmonary (macromolecules)	Novartis, Sanofi
<i>Injectable Modified Release</i>	Parenteral / implantation parenteral	
<i>Vaccine Delivery/Cancer & Adjuvants</i>	Parenteral	

Contact: Bruno Delie, Senior VP, Business Development, +33 1 41 12 17 20

DRUG DELIVERY TECHNOLOGIES



EURAND, INC.
845 Center Drive
Vandalia, OH 45377
Phone: (937) 898-9669 Fax: (937) 898-1093
email: bizdev@eurand.com
www.eurand.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>AdvaTab™</i>	Taste-masking, Fast Dissolve	
<i>Biorise®</i>	Bioavailability Enhancement	Multiple International Partners
<i>Diffucaps®</i>	Customized Release	
<i>Diffutabs®</i>	Customized Release	
<i>Liquitard</i>	Taste-masking/Suspension	
<i>Microcaps®</i>	Taste-masking/Fast-dissolve	
<i>Minitabs®</i>	Customized Release	
<i>Orbexa™</i>	Customized Release	
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Drug Targeting/Drug Conjugation</i>	Parenteral	Pre-Clinical

Contact: Troy Harmon

DRUG DELIVERY TECHNOLOGIES

FERRIS PHARMACEUTICALS INC.
16W300 83rd Street
Burr Ridge, IL 60527-5848
Phone: (630) 734-7810 Fax: (630) 887-1008
email: info@ferrispolymem.com
www.FerrisCares.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Polyurethane matrix (contains absorbent starch, glycerol, surfactant) drug free</i>	Wound dressings	Marketed by Ferris Mfg. Corp.
<i>Polyurethane matrix containing antimicrobial (nanocrystalline silver)</i>	Antimicrobial dressings	Marketed by Ferris Mfg. Corp.
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Loaded foam and gel formulations to which drugs, carriers, biologicals, or cosmetics (dry or liquid form) can be added without heat/shear degradation, sterile/non-sterile</i>	Transdermal - healthy or injured skin/tissue Mucosal - (mouth, nose, rectum) healthy/injured	

Contact: Paul Kay

DRUG DELIVERY TECHNOLOGIES

FERTIN PHARMA A/S
Industrivej 8
DK-7120 Vejle
Denmark
Phone: (+45) 72 15 13 00 Fax: (+45) 72 15 13 01
email: fertin@fertin.com
www.fertin.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>MediChew®</i>	Oral, Buccal	Novartis, GlaxoSmithKline

DRUG DELIVERY TECHNOLOGIES



FILTERTEK INC.
11411 Price Road
Hebron, IL 60034
Phone: (800) 648-0791 Fax:
(800) 648-2929
www.filtertek.com

See Company Profile

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Needles Access Products</i>	Drug Delivery/Transfer	Various
<i>Various Filters and Fluid Control Components</i>	Intravenous Drug Delivery	Various
<i>Air and Liquid Filters</i>	Pharmaceutical/Laboratory Processing	Various

Contact: Bruce Daniels, VP Medical Marketing

DRUG DELIVERY TECHNOLOGIES

FLAMEL TECHNOLOGIES S.A.
Parc Club Du Moulin à Vent
33, Avenue du Docteur Georges Lévy
69693 Vénissieux Cedex - France
Phone: (+33) 4-72-78-34-34
www.flamel.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>MicroPump MEDUSA</i>	Oral (MicroPump) Parenteral	GSK, Servier Monde, Merck & Co. (all with MicroPump)
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Genvir (MicroPump)</i>	Oral	Phase III
<i>Metformin XL (MicroPump)</i>	Oral	Phase I
<i>Ace Inhibitor (MicroPump)</i>	Oral	Confidential
<i>Augmentin SR (MicroPump)</i>	Oral	Confidential
<i>Basulin (MEDUSA)</i>	Parenteral	Phase I (completed)
<i>Various Drugs</i>	Various	Preclinical

Contact: Frederick Simonin, (+33) 4-72-78-34-34

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

GENEREX BIOTECHNOLOGY CORPORATION
33 Harbour Square, Suite 202
Toronto, Ontario, Canada M5J 2G2
Phone: (800) 391-6755 Fax: (416) 364-9363
email: info@generex.com
www.generex.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
RapidMist™	Buccal Mucosa	Not Disclosed
Pipeline Technologies/Platforms:	Application(s):	Development stage:
Generex Oral-lyn™ - Oral insulin spray for the treatment of diabetes	Buccal Mucosa	Approved in Ecuador
Glucose RapidSpray™		
Metformin Gum		Not Disclosed
Fentanyl Spray		

Contact: Business Development (800) 391-6755, info@generex.com

DRUG DELIVERY TECHNOLOGIES



GLATT PHARMACEUTICAL SERVICES
20 Spear Road
Ramsey, NJ 07446
Phone: (201) 825-8700
www.glattpharmaceuticals.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
CPS™	Proprietary Drug Delivery Technology, High Potency Pellets, Uniformly Distributed Low Doses, Advantages over Extrusion/Spheronization, Dense, Spherical, Uniform Pellets	Not Disclosed
MicroPx™	Proprietary Drug Delivery Technology, High Potency Pellets, Pellets sizes of 50 microns and larger, Continuous Process, Dense, Spherical, Uniform	See Company Profile
ZRx™	Zero-Order Release Tablet System, Extended Release Tablet Matrix System, Zero or First-Order Release Characteristics	

Contact: Thomas M. Salus, (201) 818-3778

DRUG DELIVERY TECHNOLOGIES

HOSPIRA, INC.
One 2 One
D988, H1 275 Northfield Drive
Lake Forest, IL 60045
Phone: (224) 212-2267 Fax: (224) 212-3210
email: one2one@hospira.com
www.hospira.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Pre-filled Syringes	Plastic polymer and glass syringes available in luer cone, luer lock, and stacked in needle configurations	
i-Secure™	Pre-filled cartridge syringe designed for compatibility with IV sets or needles	
VisIV™	Ready-to-use IV medication delivery in a non-PVC/non-DEHP container	Multiple
ADD-Vantage System®	IV admixture system used when medication is not stable in a premix format	
Ansys Syringe®	Pre-filled plastic syringe compatible with IV systems	

Contact: Kevin Wess

DRUG DELIVERY TECHNOLOGIES



HOVIONE
40 Lake Drive
East Windsor, NJ 08520
Phone: 609-918-2600 Fax: 609-918-2615
email: helloovione.com
www.hovione.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Spray Drying	Encapsulation, Agglomeration, Reduction Residual Particle Sizing and shaping	Many
Micronization	Particle Size Control	
Freeze Drying	Processing Thermally Labile APIs	
Pipeline Technologies/Platforms:	Application(s):	
Sonocrystallization	Manipulate degree of crystallinity	
Other critical crystallization		

Contact: Mr. Doug Hecker



DRUG DELIVERY TECHNOLOGIES

INEOS FLUOR
The Heath - Runcorn
Cheshire, WA7 4QX UK
Phone: +44 (0)1928 515525 Fax: +44 (0)1928 511418
e-mail: info@ineosfluor.com
www.ineosfluor.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
HFA 134a and HFA 227ea	Medical Aerosols	Supply 80% of world market
Medical Propellants		

Contact: Dr. Tim Noakes

DRUG DELIVERY TECHNOLOGIES



INNERCAP TECHNOLOGIES, INC.
5420 Bay Center Drive, Suite 100
Tampa, FL 33609
Phone: (813) 837-0796 Fax: (813) 837-0207
email: fmiller@innercap.com
www.innercap.com

Pipeline Technologies/Platforms:	Application(s):	Development stage:
NOVACAPS™	Multi-Phase, Multi-Compartment Capsules Multiple Dual Drug Delivery Controlled and Site Specific Drug Delivery Incompatible combination drugs Pulsatile Drug Delivery	Actively seeking Licensees and partner

Contact: Fred H. Miller, (813) 837-0796

DRUG DELIVERY TECHNOLOGIES

INTELLIPHARMACEUTICS CORP.
30 Worcester Road
Toronto, Ontario M9W 5X2 - Canada
Phone: (416) 798-3001, ext. 128 - Fax: (416) 798-3007
e-mail: info@intellipharmaceutics.com
www.intellipharmaceutics.com

Current Technologies/Platforms:	Application(s):	Development stage:
HyperMatrix™ Technology Platforms	Oral Drug Delivery	Par Pharmaceuticals, ratiopharm, Elite, Larasan

Contact: Joe Quinto, Director of Business Development

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES



INTERNATIONAL SPECIALTY PRODUCTS

INTERNATIONAL SPECIALTY PRODUCTS (ISP)
1361 Alps Road
Wayne, NJ 07470
Phone: (973) 628-4000 Fax: (973) 628-4117
email: info@ispcorp.com
www.ispcorp.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Solid Dispersions</i>	Bioavailability Enhancement	Not Disclosed

Contact: Dr. Tim Bee

DRUG DELIVERY TECHNOLOGIES

INTRANASAL THERAPEUTICS, INC.
201 Summit Ave, Ste C-2
Montvale, NJ 07645
Phone: (201) 307-9450 Fax: (201) 307-9455
www.intranasal.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Nasal Drug Development</i> <i>Aseptic, Preservative Free</i>	Pain, CNS	Confidential

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Nasal Drug Development</i>	Metabolic	Preclinical

Contact: Ralph S. Johnston

DRUG DELIVERY TECHNOLOGIES

INXY, INC.
825 Third Avenue, 40th Floor
New York, NY 10022
Phone: (212) 838-1111 Fax: (212) 838-0060
e-mail: info@inxgroup.com
www.inyxgroup.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Metered Dose Inhalers (CFC & HFA)</i>	Asthma, Systemic	None
<i>Dry Powder Inhalers</i>	Asthma	None
<i>Nasal/Sublingual/Buccal Sprays</i>	Allergy, Systemic	None
<i>Topical Foams/Creams/Ointments/Gels</i>	Dermatological	None
<i>Aseptic Fill/Sterile Injectables</i>	Varied	None
<i>Solid Dose</i>	Varied	None

Contact: Marc Couturier, Senior Vice President, Global Business Development (416) 250-0091

DRUG DELIVERY TECHNOLOGIES



First in Iontophoresis

IOMED, INC.
2441 South 3850 West
Salt Lake City, Utah 84120
Phone: (800) 621-3347 Fax: (801) 972-9072
e-mail: info@iomed.com
www.iomed.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Iontophoresis (non-invasive method of drug delivery into and/or through biological membranes, such as skin, mucosal membrane of the body cavity, or ocular tissue for local or systemic applications)</i>	<ul style="list-style-type: none"> Physical therapy Local dermal anesthesia 	

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Transscleral Iontophoresis (non-invasive drug delivery into back of the eye)</i>	<ul style="list-style-type: none"> AMD Diabetic Retinopathy 	Preclinical

Contact: Jim Isaacson

See Company Profile

DRUG DELIVERY TECHNOLOGIES



KURVE TECHNOLOGY, INC
19805 North Creek Pkwy
Bothell, WA 98011
Phone: (425) 640-9249 Fax: (425) 673-5783
e-mail: info@kurvetech.com
www.kurvetech.com

Current Technologies/Platforms:	Application(s):	Development stage:
<i>Controlled Particle Dispersion™</i>	Nasal drug delivery	Confidential
<i>ViaNase ID</i>	Intelligent nasal drug delivery with electronic controls & lockouts	

Contact: Michael Rackley, VP Business Development, mrackley@kurvetech.com

See Company Profile

DRUG DELIVERY TECHNOLOGIES



LIPOCINE INC.
675 Arapeen Drive, Suite 202
Salt Lake City, UT 84103
Phone: (801) 994-7383 Fax: (801) 994-7388
email: GTS@lipocine.com
www.lipocine.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Lip'ra®</i>	Oral poorly water soluble compounds	Schwarz Pharma
<i>Lip'ra® SSR</i>	Oral extended release for poorly water soluble compounds	Schwarz Pharma
<i>Hydroance®</i>	Oral poorly permeable compounds	N/A
<i>Liliv™</i>	Parenteral delivery	N/A

Contact: Jerry Simmons, Corporate Business Development Officer

See Company Profile

DRUG DELIVERY TECHNOLOGIES

MACROMED, INC.
2417 S. 3850W, Suite 150
West Valley City, UT 84120
T: (801) 433-2560 Fax: (801) 433-2561
Website: www.macromed.com
e-mail: macromed@macromed.com - www.macromed.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>ReGel</i>	Parenteral Depot	
<i>HySolv</i>	Parenteral/Oral Solubilizer	Not Disclosed
<i>SQZgel</i>	Oral Sustained Release	

Contact: Alex S. Kim, Executive Vice President, (801) 433-2560

DRUG DELIVERY TECHNOLOGIES



MEDPHARM LTD
Business Centre - Sheep Street
Charlbury OX7 3RR
Oxfordshire, United Kingdom
Phone: +44 (0) 16 0881 9267 Fax: +44 (0) 16 0881 9268
email: busdev@medpharm.co.uk
www.medpharm.co.uk

Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>MedSpray™</i>	A novel topical/transdermal spray	Pre-clinical
<i>MedNail™</i>	A novel unguinal penetration system	Pre-clinical
<i>MedFoam™</i>	A novel cosmetically elegant stable/fast-breaking foam	Pre-clinical
<i>D3S™</i>	A device for dermal drug delivery	Seeking out-licensing partner

Contact: Carole Delauney, Head of Business Development

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

MERRION PHARMACEUTICALS, INC.
219 Racine Drive, Suite D
Wilmington, NC 28403-8702
Phone: (910) 799-1847 Fax: (910) 395-1843
email: info@merrionpharma.com
www.merrionpharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Gastrointestinal Permeation Enhancement Technology (GIPET™) for poorly permeable compounds	Applicable to solid and liquid-filled dosage forms. Enhancer-based technology for oral administration of small molecules, macromolecules, peptides, biologics, and polysaccharides	Confidential
Gastrointestinal Retention System (GIRESTM) - capsule containing a controlled-release tablet inside an inflatable pouch	Applicable to a wide range of drugs; there is no change in the chemical composition of API. Targeted at once-a-day dosing for compounds with short biological half-lives, narrow absorption windows, narrow therapeutic indices, or which require local delivery to GIT.	
Pipeline Technologies/Platforms:	Application(s):	Development stage:
Targeted Delivery Systems	Targeted Delivery	Preclinical
Oral Vaccine Delivery Systems	Oral	Preclinical

Contact: Thomas W. Leonard, PhD, VP & CSO

DRUG DELIVERY TECHNOLOGIES



MGLAS AG
Otto-Liebmann-Strasse 2
Münnerstadt, Germany 97702
Phone: +49(0)9733 808-0 Fax: +49(0)9733 808-160
email: info@mglas.de
www.mglas.de

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Containers made of tubular glass: Syringes, cartridges (one- and two-chamber), vials, ampoules, specialities upon on customer request	Parenteral Nasal Oral Diagnostic	Pharmcos, among others: Apotex, Aradigm, AstraZeneca, Biotage, Chiron, Sanofi Aventis, Sanofi Pasteur, Baxter, GSK, Roche Diagnostics, Schering-Plough, Vetter
Pipeline Technologies/Platforms:	Application(s):	Development stage:
Needle-free devices	Transdermal	Clinical Phase II
Innovative needles (V Bevel®/Spoon Point®/Spoon Point Plus®)	Parenteral	Market
Pre-washed/pre-sterilized cartridges for aseptic filling	Parenteral	Development
Laser technology	Manufacture of containers for parenterals	Market & Developmet

Contact: Mr. Wolfgang Heidl, +49(0)9733 808-125

DRUG DELIVERY TECHNOLOGIES

MISTRAL PHARMA INC.
2101 Halpern
St-Laurent, Quebec H4S 1S3 - Canada
Phone: (514) 920-0909 Fax: (514) 920-0404
www.mistralpharma.com
e-mail: info@mistralpharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Procise	Oral Drug Delivery	
Savit	Oral Drug Delivery	Confidential
Chronop	Oral Drug Delivery	

Contact: Alain Desjardins

DRUG DELIVERY TECHNOLOGIES

NASTECH PHARMACEUTICAL COMPANY, INC.
3450 Monte Ville Parkway Bothell, WA 98021
45 Adams Avenue
Hauppauge, NY 11788
Phone: (212) 845-4268
www.nastech.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
STAT-TM - Systemic Transnasal Absorption Technology	Intranasal	Pharmacia, Phol-Boskamp
PTSTM - Paracellular Transport System	Intranasal	Seeking additional partnerships for these technologies
JATM - Junction Activator Technology	Intranasal	

Contact: Robert Stanislaro, (212) 845-4268

DRUG DELIVERY TECHNOLOGIES



NEKTAR THERAPEUTICS
150 Industrial Road
San Carlos, CA 94070
Phone: (650) 631-3100
www.nektar.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
PEG-INTRON®	Parenteral	Schering-Plough
Neulasta™ (PEG-filgrastim)	Parenteral	Amgen
Pipeline Technologies/Platforms:	Application(s):	Development stage:
PEGASYS® (PEG-a-interferon)	Parenteral	Roche
Somavert® (PEG-hGHra)	Parenteral	Pharmacia
Exubera® (inhaled insulin)	Inhalation	Pfizer
EYEO01 (PEGylated aptamer)	Parenteral	Eyetech
SprayGel™ adhesion barrier system (PEG)	Gel	Confluent
CDP870 (PEGylated antibody fragment)	Parenteral	Pharmacia
Inhaled alpha 1	Inhalation	Phase I
Inhaled Forté (PTH)	Inhalation	Phase I
Inhaled tobramycin	Inhalation	Phase I
Inhaled leuprolide	Inhalation	Phase I
PEGylated interferon beta	Parenteral	Phase I
PEG-AXOKINE	Parenteral	Phase I
PEG-TPO	Parenteral	Pre-clinical
PEG-prostacyclin	Parenteral	Pre-clinical
PEG proteins	Parenteral	Pre-clinical
Inhaled dronabinol (MDI)	Inhalation	Pre-clinical
Inhaled small molecules	Inhalation	Pre-clinical
Single chain antibodies	Inhalation	Pre-clinical
PA2794	Inhalation	Pre-clinical

Contact: Joyce Strand, (650) 631-3138

NEW-ELECTRONIC EDITION

All advertisers appearing in our print edition will also appear in the electronic edition of *Drug Delivery Technology* with active links to their Web site. The electronic edition also provides advertisers with global distribution of their message.



DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

NEOPHARM INC.
1850 Lakeside Drive
Waukegan, IL 60085
Phone: (847) 887-0800 Fax: (847) 887-9281
email: ssheikh@neopharm.com
www.neopharm.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>NeoLipid® Technology</i>	Delivery of broad range of difficult to formulate drugs	
<i>NeoPhectin (In Vitro)</i>	Delivery of Nucleic acids (plasmid, antisense, siRNA)	
<i>NeoPhectin-AT (In Vivo)</i>	Delivery of Nucleic acids (plasmid, antisense, siRNA)	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>NeoLipid® Technology</i>	Easy to use Liposome based drugs for treatment of cancer	Liposome based SN-38 (LE-SN38), SN-38 is an active metabolite of Camptostar® - Phase II Liposome based Paclitaxel (LEP-ETU) - Phase I/II Liposome based raf antisense (LErafAONETU) - Phase I

DRUG DELIVERY TECHNOLOGIES



NOF CORPORATION
11 Martin Avenue, Suite 1170
White Plains, NY 10606
Phone: (914) 681-9790 Fax: (914) 681-9791
International: + 81-3-5424-6741
email: ddsinfo@nof.co.jp
www.nof.co.jp/dds



Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>PEG Derivatives</i>	Suitable & ideal for producing PEGylated drugs	N/A
<i>Phospholipids & Liposomes</i>	Ideal for screening tests and liposomal formulations	N/A
<i>Highly Purified Oleic Acid</i>	Formulation development	N/A
<i>Cholesterol Pullulan</i>	Encapsulated antigen or protein can be delivered to dendritic cells, so these nanoparticles can be suitable for stimulating immune system	N/A

Contact: ddsinfo@nof.co.jp

DRUG DELIVERY TECHNOLOGIES

NOVADEL PHARMA, INC.
25 Minneakoning Road, Suite 101
Flemington, New Jersey 08822
Phone: (908) 782-3431 Fax: (908) 782-2445
email: bcohen@novadel.com
www.novadel.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Oral spray technology platform applicable to a broad range of therapeutic areas & product categories:</i>	<ul style="list-style-type: none"> Oral spray technology potentially achieves: <ul style="list-style-type: none"> rapid delivery of drugs directly to bloodstream quick onset of action Lower doses Avoids the GI tract and first pass liver metabolism Strong patent position 	Par Pharmaceuticals - NitroMist™ (nitroglycerin lingual aerosol) Hanna Biosciences - Zensane™ (ondansetron oral spray) Manhattan Pharmaceuticals for Diprivan (Propofol)

Contact: Barry Cohen

DRUG DELIVERY TECHNOLOGIES

NU SIL TECHNOLOGY
1050 Cindy Lane
Carpinteria, CA 93013
Phone: (805) 684-8780 Fax: (805) 566-9905
email: silicone@nusil.com
www.nusil.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>silicone elastomers</i> <i>pressure sensitive adhesives</i> <i>silicone gels</i> <i>silicone fluids</i> <i>custom development</i>	transdermal, mucosal, in-vitro	

Contact: Mark Paulsen, (805) 684-8780

DRUG DELIVERY TECHNOLOGIES



OAKWOOD LABORATORIES, L.L.C.
7670 First Place, Suite A
Oakwood Village, OH 44146
Phone: (440) 359-0000 Fax: (440) 359-0001
email: info@oakwoodlabs.com
www.Oakwoodlabs.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>CHRONJECT™ Injectables</i> <i>Microsphere Technology</i>	Sustained Release of Parenteral Injectables NMEs, Peptides, Approved APIs	Domestic & International
<i>Sterile Lyophilized Dosage Forms</i>		
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Novel Advanced Drug Delivery Technologies</i>		

Contact: Mark T. Smith, President

DRUG DELIVERY TECHNOLOGIES

OSG NORWICH PHARMACEUTICALS, INC.
6826 State Highway 12
Norwich, NY 13815
Phone: (607) 335-3000 Fax: (607) 335-3100
email: Bob.Calabro@norwichpharma.com
www.norwichpharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Tablets</i> <i>Capsules</i> <i>Non-sterile liquids</i>		Numerous Numerous Numerous

Contact Person: Bob Calabro

DRUG DELIVERY TECHNOLOGIES

OWEN MUMFORD, LTD.
Brook Hill Woodstock
Oxford, OX20 1TU - England
Phone: +44 (0) 1993 812021 Fax: +44 (0) 1993 813473
e-mail: drugdelivery@owenmumford.co.uk
www.omdrugdelivery.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Customized Drug Delivery Devices</i> <i>Autoinjectors for plastic or glass-pre-filled syringes; Pen-cartridge injectors</i> <i>Re-usable/Re-loadable or Disposable Devices</i>	Subcutaneous Delivery	Abbott, Amgen, Sanofi-Aventis, Berlex-Schering AG, Genentech, Lilly, Serono, Teva, Cilag, many more

Contact Person: Sarah Massey

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

OXFORD LASERS INC.
29 King Street
Littleton, MA 01460-1528
Phone: (978) 742-9000 Fax: (978) 742-9100
email: EnVision@Oxfordlasers.com
www.oxfordlasers.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>EnVision System range (high quality high speed imaging system)</i> <i>EnVision QC system (information for FDA submissions)</i> <i>EnVision R&D (Full suite of capability to provide detailed information on the device)</i>	Automatic measurements systems: One system for Nasal, MDI, DPI and softmist devices. Information obtained: Spray Pattern, Plume geometry, Event duration and high speed imaging. R&D application: additional information on flow field velocity through the actuation of the device	Chiesi, Vectura, Bespak, GlaxoSmithKline
<i>Micro-Machining Systems</i> <i>Micro-Machining Application Labs</i>	For machining of small hole and feature in a wide range of material	

Contact Person: Dr. Seamus D. Murphy, (978) 742-9000, email: seamus.Murphy@oxfordlasers.com

DRUG DELIVERY TECHNOLOGIES

PARTICLE & COATING TECHNOLOGIES, INC
5445 Highland Park Drive
St. Louis, MO 63110
e-mail: ijacobs@pctincusa.com
Phone: (314) 535-1516 Fax: (314) 535-1514
www.pctincusa.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Spinning-disk coating</i>	Many	Several, confidential
<i>Micro-capacity spray dryer</i>	Preformulation Biotechnology Samples	
<i>Mini-Fluid-Bed</i>	Expensive Materials	
<i>Forming narrow-size distributions</i>	Many	
<i>Fluid-bed coating, spray-drying, spray-chilling</i>	Many	
<i>Bioavailability enhancement</i>	Hydrophobic drugs	
<i>Fast-melt tablets</i>	Pharmaceuticals	

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Coating liquid droplets</i>	Widely applicable	Successful initial applications
<i>Coating particles down to 1 micron</i>	Widely applicable	
<i>Extended-release technology</i>	Fragrance, flavor, etc.	

Contact: Person: Dr. Irwin Jacobs, ijacobs@pctincusa.com

DRUG DELIVERY TECHNOLOGIES

PENWEST PHARMACEUTICALS CO.
39 Old Ridgebury Road, Suite 11
Danbury, CT 06810
Phone: (203) 796-3700 Fax: (203) 794-1573
e-mail: Diane.dalessandro@penwest.com
www.penwest.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Timerex®</i>	Oral controlled release	Opana® ER – Endo Pharm Procardia® XL – Mylan Slofedipine® XL – Sanofi Synthelabo Cronodopin – E. Merck Procardia® – Ranbaxy Cystrin® CR – Leiras Internal projects
<i>Geminex®</i>	Dual Drug Release	Internal projects
<i>SyncroDose™</i>	Site and time specific release	Internal projects

Contact Person: Diane D'Alessandro

DRUG DELIVERY TECHNOLOGIES

PFEIFFER OF AMERICA
742 Alexander Road, Suite 201
Princeton, New Jersey 08540
Phone: (609) 987-0223 Fax: (609) 987-1511
e-mail: info@Pfeiffer-group.com
www.pfeiffer-group.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Metered Dose Dispensing Systems for Aqueous Solutions & Suspensions</i>	Nasal, Bucal, Topical & Dermal	N/A
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>Microhaler</i>	Pulmonary	Undisclosed

Contact: Richard Sica

DRUG DELIVERY TECHNOLOGIES

PHARMACEUTICAL PROFILES
Mere Way, Ruddington Fields, Ruddington
Nottingham, NG11 6JS, United Kingdom
Phone: +44 115 974 9000
www.pharmprofiles.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>ENTERION™ CAPSULE</i>	Oral drug development	Many
<i>TECHNECOAT™</i>	Pulmonary drug development	
<i>Gamma Scintigraphy</i>	Nasal, drug development, rectal drug development, vaginal drug development	

Contact: Dr. Gareth King, VP, Business Development

DRUG DELIVERY TECHNOLOGIES



PHARMAFORM L.L.C.
11400 Burnet Road, Bldg. 4 – Suite 4010
Austin, TX 78758
Phone: (512) 834-0449, ext. 201
Fax: (512) 834-2105
www.pharmaform.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Hot Melt Extrusion</i>	Controlled Release, Abuse Deterrent, Dosage Forms, Transmucosal Films, Enhanced Solubility	Confidential
<i>Liquid Fill Hard Gel Capsules – Sustained and Immediate Release</i>	Enhanced Solubility, Enhanced Bioavailability, Improved Stability, Extended Product Family	
<i>Novel Drug Delivery Systems</i>	Poorly Soluble Drugs, Expanded Product Lines, Target Drug Delivery, Improved Safety, Enhanced Patient Acceptance	
<i>Film Coating</i>	Tablets, Capsules, Multiparticulates, Improved Product Handling, Improved Stability, Aesthetics, Branding, Controlled Release	
<i>Powder Filled Capsules</i>	Capsules	
<i>Oral Suspensions</i>	Liquids	
<i>Sustained Release Matrix Tablets</i>	Tablets	
<i>Micronization – API</i>	All Dosage Forms	
<i>Immediate Release Tablets</i>	Tablets	
<i>Formulation Development</i>	All Dosage Forms	
<i>Preformulation Development</i>	All Dosage Forms	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>EDACS Abuse Deterrent Systems</i>	Controlled or abused substances	Confidential
<i>Films</i>	Transdermal and transmucosal drug delivery	
<i>Liquid Filled Hard Gelatin Capsules</i>	Sustained delivery	

Contact Person: Michael M. Crowley, PhD, VP Business Development

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

POLYGENETICS, INC.
PO Box 33115
Los Gatos, CA 95031
Phone: (408) 356-1815 Fax: (408) 356-7094
email: J-Benson@polygenetics.com
www.polygenetics.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Cavilink™ Porous Polymers</i>	Drug delivery, embolotherapy	Boston Scientific Corp.
<i>Cavilink™ Polymers</i>	Zero-order release	Boston Scientific
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Cavilink™</i>	Gene therapy	Intermediate
<i>Cavilink™</i>	Artificial organs	Preliminary

Contact: Dr. James Benson, (408) 356-1815

DRUG DELIVERY TECHNOLOGIES

RESPIRICS, INC.
6008 Triangle Drive, Suite 101
Raleigh, NC 27617
Phone: (919) 789-4220 Fax: (919) 789-4254
www.respirics.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>MD Turbo™</i>	Breath-triggered device with electronic dose counter for use with pMDIs	TEAMM Pharmaceuticals (U.S. Market Only)
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>Acu-Breathe™ Single Dose</i>	Pulmonary DPI; for infrequent dosing; single blister	Pre-Clinical
<i>Acu-Breathe™ 15-Dose</i>	Pulmonary DPI; for chronic dosing; replaceable cartridge	Pre-Clinical
<i>Acu-Breathe™ 30-Dose</i>	Pulmonary DPI; for chronic dosing; disposable	Pre-Clinical
<i>Acu-Breathe™ Twin</i>	Pulmonary DPI; for two or more drugs	Design Development

Contact: Gilbert S. Mott, Jr., President & CEO

DRUG DELIVERY TECHNOLOGIES

RESPIRONICS RESPIRATORY DRUG DELIVERY
41 Canfield Road
Cedar Grove, NJ 07009
Phone: (800) 962-1266 Fax: (724) 387- 5270
e-mail: mark.elphick@respiroics.com
www.respiroics.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>The I-neb® AAD® System</i> <i>The I-neb is the third generation AAD (Adaptive Aerosol Delivery) system. It is a small, battery-powered, lightweight, and virtually silent drug delivery device designed to significantly reduce the inconvenience of conventional nebulizer/compressor therapy while delivering a precise, reproducible dose of drug.</i>	Pulmonary Drug Delivery	CoTherix Inc, Schering AG, Profile Pharma Ltd

Contact: Mark Elphick

DRUG DELIVERY TECHNOLOGIES

REXAM
REXAM PHARMA
600 Deerfield Parkway
Buffalo Grove, IL 60089
Phone: (847) 541-9700 Fax: (847) 541-9201
e-mail: mailboxpharma@rexam.com
www.rexam.com/pharma

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>The Sof' Bag: 2 components delivered by Rexam: a multilayer bag in a plastic bottle combined a metering pump to guarantee a maximum protection against contamination and oxidation</i>	Dermal	N/A
<i>Pill jars & value added closures with or without tamper evidence, child resistance or desiccant</i>	Oral	N/A
<i>Patented Safe'n Sound safety system for prefilled syringes Transfer sets, veterinary syringes, auto-injectors, implanters, injectable vials</i>	Parenteral	N/A
<i>Diabolo: COC vials closed with a TPE cap in a class 100A room and sterilized to avoid any additional step before filling</i>	Parenteral	Aseptic Technologies
<i>DPIs and pMDIs</i>	Pulmonary	N/A
<i>Pumps, valves and applicators</i>	Nasal, Buccal & Auricular	N/A
<i>Medical Devices</i>	Various	N/A
<i>Diagnostic Disposables</i>	Various	N/A
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>Preservative Free solutions,</i>	Ophthalmics	

Contact: Michael Cullen

DRUG DELIVERY TECHNOLOGIES

SAFC
3050 Spruce Street
St. Louis, MO 63103
Phone: (800) 336-9719
www.sigmaaldrich.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Polyamineo Acids</i> <i>Lipids</i> <i>Liposomes</i> <i>Tween 20/80 GMP, Low Peroxide</i>	Carrier/excipient Liposomes Carrier/excipient Detergent/surfactant	
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>PEGylation</i>	Stability, solubility	Prototype

Contact: Tom Gelineau, (314) 301-2077, email: tgelineau@sial.com

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES



SAFETY SYRINGES
2875 Loker Avenue East
Carlsbad, CA 92010
Phone: (760) 918-9908 Fax: (760) 918-0565
e-mail: info@safetysyringes.com
www.safetysyringes.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>UltraSafe Passive® Delivery System</i>	Drug delivery devices for prefilled syringes; pharmaceutical presentations that offer passive safety features and improved drug delivery	Amgen, AstraZeneca Eisai, Johnson & Johnson (Ortho Clinical Diagnostics) Merck, Pfizer, Talecris Biotherapeutics
<i>Tamper-Evident UltraSafe Passive® Delivery System</i>	Anti-counterfeiting of drugs; tamper evidence	See Company Profile
<i>Ypsomed Autoinjector with the UltraSafe Passive® Delivery System</i>	Self-administration	

Contact: Matthew Klimjack, Director of Marketing

DRUG DELIVERY TECHNOLOGIES

SCIARRA LABORATORIES, INC.
485-09 S. Broadway
Hicksville, NY 11801
Phone: (516) 933-7853 Fax: (516) 933-7807
email: sciarralabs@att.net
www.sciarralabs.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Metered Dose Inhalers Pharmaceutical Aerosols</i>	Asthma Medication Foams, Solutions	

Contact: John J. Sciarra

DRUG DELIVERY TECHNOLOGIES



SCOLR Pharma, Inc.
3625 132nd Avenue SE, Suite 400
Bellevue, WA 98006
Phone: (425) 373-0171 Fax: (425) 373-0181
email: info@scolr.com
www.scolr.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>CDT® Controlled Delivery Technologies Platform consists of Four Issued Patents:</i>	Solid Oral Delivery, Small Molecule	See Company Profile
<i>"Dual Polymer" technology</i>	BCS class 1 & 2	
<i>"Salt" technology</i>	BCS class 1 & 2	
<i>"Amino Acid" technology</i>	BCS class 2, 3	Wyeth, Perrigo
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>CDT® "Asymmetrical" technology #4</i>	Combination, Cocktail Therapies, Gastric Retention and Site Specific	Pre-Clinical, Patent pending

Contact: Stephen Turner

DRUG DELIVERY TECHNOLOGIES

SENSIRION - THE SENSOR COMPANY
Laubisruetistr. 50
Staefa, Zurich CH-8712, Switzerland
Phone: +41 44 306 4000 Fax: +41 44 306 4030
email: info@sensirion.com
www.sensirion.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Microfluidic flow sensors and systems based on digital CMOS chips</i>	Dosing and metering of liquid drugs in the micro liter and nano liter range	Medical device manufacturers and bio-tech companies
<i>CMOSens Technology - The combination of sensor elements and digital signal processing on one single micro chip</i>	Calibrated, digital, ready to use sensor solutions	
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Disposable Flow Sensors</i>	Dosing and metering of liquid drugs in the micro liter and nano liter range	Functional samples available

Contact: Ulf Kanne +41 44 306 4000

DRUG DELIVERY TECHNOLOGIES

SHARMATEK, Inc.
12 Walnut Drive
Long Valley, NJ 07853
Phone: (908) 852-5087
email: vksharma@stk-inc.net
www.stk-inc.net

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Pulsatile Macroparticulate Drug Delivery System (PMDDST™)</i>	Diltiazem ER Capsules, qd (90,120 mg)	Marketed as Kaizem™ CD in India by Wockhardt
<i>Diffusion Controlled Drug Delivery System (DCDDST™)</i>	Diltiazem ER Capsules, qd (120, 180, 240, 300 360 mf); bioequivalent to Tiazac®, fasted	Available
<i>Hydrophilic Matrix Drug Delivery System (HMDDST™)</i>	Quinidine sulfate ER Tablets (300 mg); bioequivalent to Quinidex;	Currently manufactured and sold by TEVA Pharms
<i>Delayed Release Drug Delivery System (DRDDST™)</i>	Felodipine ER tablets, qd (2.5, 5, 10mg)	Available
<i>Micro Emulsion Drug Delivery System (MEDDST™)</i>	Ormeprazole EC capsules (10, 20, 40 mg), qd capsules, qd	Licensed to Wockhardt for international markets
<i>Predictive Modeling Tool (FRT/IVVC™)</i>	Cyclosporine	Marketed by Panacea Biotec in India
<i>Microfluidization Processing Technology (MPT™)</i>	RE: MR product design	Available
<i>Pipeline Technologies/Platforms:</i>	<i>Application(s):</i>	<i>Development stage:</i>
<i>Biphasic HMDDST™</i>	Low solubility, high permeability drugs, such as Cyclosporine	Available
<i>Programmable Tabsule™ Drug Delivery System (PTDDST™)</i>	Drugs absorbed at upper GI tract	Early stage development
	Oral, multi-phasic release, site-specific Tabsules™ (mini-tablets)	Early stage development

Contact: Vinay K. Sharma, PhD, Chairman, (908) 852-5087, Mobile: (908) 616-3319

DRUG DELIVERY TECHNOLOGIES

QUALICAPS
6505 Franz Warner Parkway
Whitsett, NC 27377
Phone: (336) 449-3900
www.qualicaps.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Quali-V® capsules</i>	Empty two-piece capsule of non-gelatin origin	
<i>F/S Machine</i>	Combination filling and sealing encapsulation	

Contact: Tamara Smith, (336) 449-3953

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

SMITHS MEDICAL ASD, INC,
2231 Rutherford Road
Carlsbad, CA 92008
Phone: (866) 286-6226 Fax: (760) 929-0147
www.smiths-medical.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Safety Devices for Hypodermic Injections</i>	Injection Medication Delivery	Many
<i>Syringe Pumps and Infusion Accessories</i>	Infusion Medication Delivery	Many

Contact: Mark Baumgartner, Business Development Manager

DRUG DELIVERY TECHNOLOGIES

SOLIQS
SOLIQS Business Unit
ABBOTT GmbH & Co. KG
PO Box 21 08 05
67008 Ludwigshafen, Germany
Phone: +49-621 589 2427 Fax: +49-621 589 3092
email: welcome@soliqs.com
www.soliqs.com

Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Meltrex™</i>	Melt extrusion technology	n/a
<i>Xellux™</i>	Polymeric film technology	n/a
<i>NanoMorph™</i>	Amorphous nanoparticle technology	n/a
<i>SoliScreen™</i>	Qualitative & quantitative screening systems	n/a

Contact: welcome@soliqs.com

DRUG DELIVERY TECHNOLOGIES

SPI PHARMA
321 Cherry Lane
New Castle, Delaware 19720
Phone: (302) 576-8500 x 8554
Fax: (302) 576-8567
www.spipharma.com



Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Pharmaburst™ Fast Melt Excipient System</i>	Oral Dispersible Tablet	Generic & Brand Rx
<i>Pharmafreeze™ Fast Melt Lyophilized System</i>	ODT, Sublingual Tablet	Brand Rx
<i>Pharmaspense™ Dry Powder Suspension</i>	Reconstitutable Syrup	Generic Rx, OTC
<i>Pharmagum™ DC Chewing Gum Powder</i>	Buccal Gum Tablet	Rx, OTC, Nutraceutical
<i>Taste-masking/Controlled release</i>	Solid Oral Dose	Rx, OTC
<i>Custom Processing</i>	Granulation, Chilsonation Micronizing, Extrusion	Rx, OTC
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>Pharmachew™ Excipient System</i>	Chewable Tablet Platform	OTC, Nutraceutical
<i>Pharmatab™ Excipient System</i>	Swallow Tablet Platform	Rx, OTC

Contact: Sarat Chandar

DRUG DELIVERY TECHNOLOGIES

TEXMAC INC.
3001 Stafford Drive
Charlotte, NC 28208
Phone: (704) 393-6555 Fax: (704) 392-1621
email: yosaka@texmacusa.com
www.texmac.com



Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>Soluble Microneedle Technology</i>	Drug delivery	Distribute sample micro-needles for customer's evaluation
	Cosmeceutical	Distribute sample micro-needles for customer's evaluation

Contact: Yashi Osaka

DRUG DELIVERY TECHNOLOGIES

TRANSPHARMA MEDICAL LTD.
2 Yodfat Street, Northern Industrial Zone
Lod, Israel 71291
Phone: +972-8-915-2201 Fax: +972-8-915-2202
e-mail: info@transpharma.co.il
www.transpharma-medical.com

Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>ViaDerm Drug Delivery System</i>	Transdermal	Teva Pharmaceutical Industries (undisclosed high molecular weight protein), seeking partner (hPTH (1-34) for osteoporosis)

Contact: Judith Kornfeld, Vice President, Business Development

DRUG DELIVERY TECHNOLOGIES

TRAVANTI PHARMA INC. (FORMERLY BIRCH POINT MEDICAL INC.)
2520 Pilot Knob Road, Suite 100
St. Paul, MN 55120
Phone: (651) 730-1008 Fax: (651) 730-1013
e-mail: rarnold@travantipharma.com
www.travantipharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>WEDD® (Wearable Electronic Disposable Drug Delivery) Technology - Proprietary active transdermal (iontophoretic) drug delivery system that is self-contained, portable & disposable</i>	Pain, Inflammation	Undisclosed

Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>WEDD® Active Transdermal Drug Delivery System</i>	Pain, Inflammation, Nausea/Emesis, Thrombosis, Osteoporosis, Cosmetics, among others	

Contact: Robert Arnold

DRUG DELIVERY TECHNOLOGIES

TRIS PHARMA, INC.
Brunswick Business Park - 2033 Route 130, Suite D
Monmouth Junction, NJ 08852
Phone: (732) 940-2800 - Fax: (732) 940-2855
e-mail: aparikh@trispharma.com - www.trispharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Lipisol™</i>	Bioavailability/Solubility Enhancement	Not Disclosed
<i>eXol™</i>	Bioavailability/Solubility Enhancement	
<i>maxsol™</i>	Bioavailability/Solubility Enhancement	
<i>PerpetuRate™</i>	Controlled Release	
<i>LiquiXR™</i>	Taste-masking/Controlled Release/Liquid Suspension	
<i>delibRate™</i>	Controlled Release	
<i>ProRate™</i>	Controlled Release	
<i>ODTXR™</i>	Orally Disintegrating Tablet /Controlled Release/ Fast Dissolve	

Contact: Anish Parikh

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES

UPM PHARMACEUTICALS, INC.
6200 Seaforth Street
Baltimore, MD 21224
Phone: (410) 843-3738 Fax: (410) 633-4438
askus@upm-inc.com
www.upm-inc.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Cushioning Beads™</i>	Pediatric, geriatric, HIV patients Accommodates high and low dose drugs, quick dissolve form	undisclosed
<i>Trap & Trigger™</i>	Pediatric, geriatric, HIV, cancer patients	undisclosed
Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Cushioning Beads™</i>	Oral quick dissolve tab	early
<i>Trap & Trigger™</i>	Oral SR suspension for electrolytic drugs	early

Contact: Rich Ryzenga

DRUG DELIVERY TECHNOLOGIES

VALERITAS
1000C Lake Street
Ramsey, NJ 07446
Phone: (847) 604-8005 Fax: (847) 604-8006
E-mail: plarsen@valeritas.com
Website: www.valeritas.com
Contact Person: Peter Larsen, VP Business Development

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Mini-Ject™</i>	Pre-Filled Needle-Free Delivery System	
<i>h-Patch™</i>	Single-Use, Disposable Basal-Bolus Delivery System	
<i>e-Patch™</i>	Control Release Disposable Micro Pump Delivery System	Undisclosed
<i>Micro-Trans™</i>	Microneedle Intradermal Delivery System	

Contact: Peter Larsen, VP, Business Development, (847) 604-8005, plarsen@valeritas.com

DRUG DELIVERY TECHNOLOGIES

VALOIS
50 Avenue de l'Europe
Marly-le-Roi, France 78164
Phone: +33 (0) 1 39 17 20 20 Fax: +33 (0) 1 39 58 12 98
www.valoispharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Metering Spray Pumps</i>	Nasal, Throat, Dermal/Transdermal, Ear	
<i>Metering Valves for pMDIs</i>	Pulmonary (Asthma, COPD)	
<i>Unit-Dose Nasal Spray Devices</i>	Nasal	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>Dose Indicator for pMDIs</i>		
<i>Dry Powder Inhaler</i>		
<i>Electronic Devices</i>		
<i>New Pumps, Valves and Unit-Doses</i>		

Contact: Pierre Carlotti - VP Marketing

DRUG DELIVERY TECHNOLOGIES

VECTURA GROUP PLC
1 Prospect West
Chippenham
Wiltshire, UK SN14 6FH
Phone: +44 1249 667700 Fax: +44 1249 667701
e-mail: enquiries@vectura.com
www.vectura.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>ASPIRAIR</i>	Pulmonary (Active DPI Device)	Available - Non-exclusive
<i>GYROHALER</i>	Pulmonary (Passive DPI Device)	Available - Non-exclusive
<i>POWDERHALE</i>	Pulmonary (Formulation System)	Available - Non-exclusive

Contact: Doug Smalley, Director of Business Development

DRUG DELIVERY TECHNOLOGIES

VENTAIRA PHARMACEUTICALS, INC.
1801 Watermark Drive, Suite 100
Columbus, OH 43215
Phone: (614) 340-2325 Fax: (614) 340-2320
email: Williams@ventaira.com
www.ventaira.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Mystic drug inhalation technology (uses electrostatic energy to form a uniform fine particle spray)</i>	Pulmonary	
<i>Drug formulation technology (allowing the company to optimize the delivery of drugs - small molecules and are expanding to biomolecules)</i>	Pulmonary	Seeking qualified strategic partners for co-develop opportunities
Internal Pipeline Technologies Partners:	Application(s):	Development stage:
<i>Fluticasone Propionate</i>	Asthma	Completed Phase I clinical trial
<i>Undisclosed</i>	Asthma	Formulation
<i>Undisclosed</i>	Pain	Formulation
<i>Undisclosed</i>	Undisclosed	Formulation

Contact: Leslie Williams, (614) 340-2338

DRUG DELIVERY TECHNOLOGIES

VYTERIS, INC.
13-01 Pollitt Drive
Fair Lawn, NJ 07410
Phone: (201) 703-2299
www.vyteris.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Active Transdermal Systems</i>	Transdermal	B. Braun
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Lidocaine System</i>	Transdermal	NDA filed on Lidocaine System

DRUG DELIVERY Technologies

DRUG DELIVERY TECHNOLOGIES



YPSOMED AG
Brunnmattstrasse 6
Burgdorf, Switzerland 3401
Phone: +41 34 424 41 11 Fax: +41 34 424 41 22
email: info@ypsomed.com
www.ypsomed.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Reusable injection pens</i>	Regular subcutaneous self-injections	Aventis (insulin), Dongbao (insulin), Pfizer (hGH), Eli Lilly (hGH), Genentech (hGH) and Roche (EPO and alfa-interferon)
<i>Disposable injection pens</i>	Regular subcutaneous self-injections	Aventis (insulin) and Serono (FSH)
<i>Semi-Disposable injection pens</i>	Regular subcutaneous self-injections	Aventis (insulin)
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Reusable and disposable auto-injector systems</i>	Subcutaneous and intramuscular self-injection of bio-molecules	Ongoing development programs with a number of partners

Contact: Ian Thompson, Manager Business Development

DRUG DELIVERY TECHNOLOGIES

DEGUSSA CORPORATION
Pharma Polymers
2 Turner Place
Piscataway, NJ 08855
T: (732) 981-5383 Option 4
F: (732) 981-5371
E: eudragit.usa@degussa.com

DEGUSSA AG - PHARMA POLYMERS
Röhm GmbH
Kirschenallee 45
64293 Darmstadt, Germany
T: +49-6151-18-4019
F: +49-6151-18-3520
E: eudragit.germany@degussa.com



Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>EURACOL™</i>	Colon-targeted-sustained-release oral drug delivery technology	See Company Profile
<i>EURAPULSE™</i>	Pulsatile oral drug delivery technology with variable lag times	
<i>EURAMODE™</i>	Oral drug delivery platform technology providing a broad range of release profiles	

Contact: Dr. Gerhard Renner, +49 6151 184810, gerhard.renner@degussa.com

DRUG DELIVERY TECHNOLOGIES



GENZYME PHARMACEUTICALS
675 West Kendall Street
Cambridge, MA 02142
Phone: (800) 868-8208 or (617) 374-7248
Fax: (617) 768-9765
E-mail: pharmaceuticals@genzyme.com
www.genzymepharmaceuticals.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>LipoBridge®</i>	CNS, blood brain barrier, Alzheimer's, stroke, trauma, Parkinson's, Multiple Sclerosis	Undisclosed
<i>LipoMask™</i>	Extended circulation time of drug particles in blood	Undisclosed
Pipeline Technologies/Platforms:	Application(s):	Development stage:
<i>Cerense™</i>	Deliver and assess poorly brain-penetrant drug compounds in the CNS	Undisclosed
<i>Design for Peptide Delivery™</i>	Customized solutions for peptide formulations	Undisclosed

See Company Profile

Check out the latest online issue of *Drug Delivery Technology* at
www.drugdeliverytech.com

Introducing Drug Delivery Technology...online!

- No special software required
- Table of contents navigation
- Click through to advertisers' sites and content
- Print, send, and share articles with colleagues
- Interactive correspondence with editors and advertisers
- Content searchable by keywords
- Faster online distribution



NEW- ELECTRONIC EDITION

All advertisers appearing in our print edition will also appear in the electronic edition of *Drug Delivery Technology* with active links to their Web site. The electronic edition also provides advertisers with global distribution of their message.

EXCIPIENTS, POLYMERS, Liposomes, Lipids, Coatings

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS



AKINA, INC.
Business & Technology Center
1291 Cumberland Avenue, E130
West Lafayette, IN 47906-1385
Phone: (765) 464-0501 Fax: (765) 464-0820
e-mail: kp@akinainc.com - www.akinainc.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
---------------------------------	-----------------	---------------------

Highly Plastic Granules	Fast melting tablets	Sanyang Corp.
-------------------------	----------------------	---------------

Contact: Yourong Fu, (765) 464-0501, ext. 1

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

A.P. PHARMA
123 Saginaw Drive
Redwood City, California 94063
Phone: (650) 366-2626 Fax: (650) 365-6490
E-mail: busdev@appharma.com
www.appharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
---------------------------------	-----------------	---------------------

MICROSPONGE [®]	Topical	J&J (Retin-A-Micro [®]), Aventis (Carac [™])
BIOCHROMER ^{™™} BIOERODIMER ^{™™} ALGINATES	Parenteral Parenteral Oral	Actively seeking partners Actively seeking partners Actively seeking partners

Pipeline Technologies/Platforms:	Application(s):	Development Stage:
----------------------------------	-----------------	--------------------

APF112 OSTEOARTHRITIS ANTI-NAUSEA/VOMITING ANTI-ADHESIONS	Parenteral, Post-operative Pain Relief Parenteral, Local Anti-inflammatory Parenteral, Post-chemotherapy Relief Parenteral, Post-surgical	
--	--	--

Contact: Mike O'Connell, (650) 366-2626

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

AQUALON DIVISION, HERCULES INCORPORATED
1313 North Market Street
Wilmington, DE 19894
Phone: (800) 345-0447
www.aqualon.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
---------------------------------	-----------------	---------------------

Klucel [®] hydroxypropylcellulose (HPC) Natrosol [®] hydroxyethylcellulose (HEC) Aqualon [®] ethylcellulose (EC) Aqualon [®] carboxymethylcellulose (CMC)	Applications for all 4 products/technologies: solid dosage (immediate and controlled release), film coatings, liquid system thickeners (oral, topical, nasal)	
--	--	--

Contact: Richard Salzstein, PhD, Pharmaceutical Sales Manager, (302) 995-3173

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS



The Chemical Company

BASF
100 Campus Drive
Florham Park, NJ 07932
Phone: (800) 443-0627, Fax: (973) 245-6763
email: pharماسolutions@basf.com
www.pharma-solutions.basf.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
---------------------------------	-----------------	---------------------

Kollicoat [®]	Coatings & Coating Systems	See Company Profile
Kollidon [®]	Binders & disintegrants	
Ludipress [®]	Direct compression aids	
Lutrol [®] & Lutrol [®] Micro	Solubilizers	
Solutol [®]	Solubilizer	
Cremophor [®]	Solubilizer & emulsifier	

Contact: BASF Pharma Solutions, (800) 443-0627

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS



BROOKWOOD PHARMACEUTICALS, INC.
756 Tom Martin Drive
Phone: (205) 917-2239
Fax: (205) 917-2205
www.brookwoodpharma.com



Current Technologies/Platforms:	Application(s):	Current Partner(s):
---------------------------------	-----------------	---------------------

Biodegradable poly(lactide-co-glycolide) (PLG) polymers	-cGMP commercial synthesis of PLGs at lot sizes up to 30 kg -cGMP contract manufacturing of other biodegradable biomaterials excipients	Undisclosed
---	--	-------------

Contract manufacturing and scale-up of custom biomaterials	Designed for companies developing the next generation of novel biomaterials that require technical expertise, synthesis, characterization, process development, and scale-up	Undisclosed
--	--	-------------

Modified Polymer Surfaces	-Covalently linking moieties, such as peptides, proteins, and polysaccharides, to biodegradable polymer matrices, such as microparticle rods, fibers, meshes, and other 3-D shapes -Applicable to drug delivery formulations or medical devices	Advanced Preclinical
---------------------------	--	----------------------

Pipeline Technologies/Platforms:	Application(s):	Development Stage:
----------------------------------	-----------------	--------------------

Injectable Microparticles	Wide range of therapeutic areas	Phase I, II and III
Injectable Solid Implants	Wide range of therapeutic areas	Phase I and II
Drug-eluting Devices	Local delivery	Advanced Preclinical

Contact: Kelly Ariant, (205) 917-2239

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS



CARDINAL HEALTH
14 Schoolhouse Road
Somerset, New Jersey 08873
Phone: (732) 537-6200 Fax: (732) 537-5949
email: pts@cardinal.com
www.cardinal.com/pts

Current Technologies/Platforms:	Application(s):	Current Partner(s):
---------------------------------	-----------------	---------------------

Matrix Tablets Tablet Coating Drug Layering Fine-Particle Coating	All are for oral applications for functional release	N/A N/A N/A N/A
--	--	--------------------------

Contact: (866) 720-3148, email: pts@cardinal.com

See Company Profile

NEW-ELECTRONIC EDITION

All advertisers appearing in our print edition will also appear in the electronic edition of *Drug Delivery Technology* with active links to their Web site. The electronic edition also provides advertisers with global distribution of their message.



EXCIPIENTS, POLYMERS, Liposomes, Lipids, Coatings

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

CHR. HANSEN
9015 W. Maple Street
Milwaukee, WI 53214
Phone: (800) 558-0802 Fax: (414) 607-5959
www.chr-hansen.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Pigmented and clear coating systems: Chroma-Tone™, Dri-Klear™, Chroma-Tone™, Chroma-Kote™, Chroma-Teric™, Chroma-SRF™, Chroma-GDF™, Chroma-Seal™, Gel-Klear™</i>	solid dosage forms	
<i>Compressible excipients: Foremos® Lactose, Nu-Tab®, Cal-Carb®, Pharma-Carb®</i>	solid dosage forms	

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

COLORCON
415 Mayer Boulevard
West Point, PA 19486-0024
Phone: (215) 699-7733
www.colorcon.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Acryl-EZE®</i>	Oral, Enteric, Modified Release, Film coating	
<i>Surelease®</i>	Oral, Modified Release, Film coating	
<i>Opaglos® 2</i>	Oral, High Gloss, complete film coating system	
<i>Opadry® II</i>	Oral, High Performance, complete film coating system	
<i>Opadry® AMB</i>	Oral, Aqueous Moisture Barrier, complete film coating system	
<i>Starch 1500®</i>	Partially Pregelatinized Maize Starch, excipient	

Contact: Donna Marano, (215) 661-2630

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS



CORIUM INTERNATIONAL, INC.
2686 Middlefield Road, Suite G
Redwood City, CA 94063
Phone: (650) 298-8255 Fax: (650) 298-8012
email: debfox@coriumtech.com
www.coriumgroup.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>CORPLEX™ Hydrogel</i>	Transdermal, mucosal, wound care, device, and diagnostic products	Pharma, specialty, generic, wound care, and device companies

Contact: Deb Fox, PhD, VP Business Development, (203) 775-7124, debfox@coriumtech.com

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

CP KELCO
8355 Aero Drive
San Diego, CA 92123
Phone: (858) 292-4900 Fax: (858) 292-4901
email: solutions@cpkelco.com
www.cpkelco.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>KELTROL® Xanthan gum</i>	Encapsulation	
<i>XANTURAL® Xanthan gum</i>	Tablet coatings	
<i>GELRITE® Gellan gum</i>	Pharmaceutical Emulsions	
<i>KELCOGEL® Gellan gum</i>	Ostomy & Wound Care Products	
<i>GENU® Pectin</i>	Ointments, Creams & Lotions	
<i>GENU® Carrageenan</i>		
<i>GENU® Gum Refined LBG</i>		
<i>NYMCEL® Carmellose Sodium</i>	Tablet Coating	

Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>KELCOGEL® Gellan Gum</i>	Ophthalmic Compositions	
<i>GENU® Pectin</i>	Edible Film Delivery Systems	

Contact: Anne Sinha, (858) 467-6615

EXIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

CRODA
Innovation you can build on™
CRODA INC.
300-A Columbus Circle
Edison, NJ 08837
Phone: (732) 417-0800 Fax: (732) 417-0804
email: pharmaceuticals@crodausa.com
www.crodausa.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Super Refined® Polysorbate 80</i>	Parenteral, Ophthalmic, Oral Topical, & Biotech	
<i>Super Refined® (High-Purity triglycerides)</i>	Topical, Oral, Parenteral	
<i>Super Refined® Oleic Acid NF</i>	Topical, Oral, Transdermal (TDD)	
<i>Super Refined® PEG 300 NF, Super Refined® PEG 400 NF, Super Refined® PEG 600 NF</i>	Topical, Oral, Parenteral	
<i>Crillet HP (High-purity polysorbate)</i>	Topical, Oral, Parenteral	
<i>Cholesterol HP (High-purity cholesterol)</i>	Parenteral	
<i>Medilan™ (Medium-Grade Lanolin)</i>	Topical	
<i>Crodamols (Fatty Esters)</i>	Topical, Oral, Parenteral	

Contact: Nigel Langley, (732) 417-0800, ext. 4281

EXIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

DEGUSSA CORPORATION
Pharma Polymers
2 Turner Place
Piscataway, NJ 08855
T: (732) 981-5383 Option 4
F: (732) 981-5371
E: eudragit.usa@degussa.com

DEGUSSA AG - PHARMA POLYMERS
Röhm GmbH
Kirschenallee 45
64293 Darmstadt, Germany
T: +49-6151-18-4019
F: +49-6151-18-3520
E: eudragit.germany@degussa.com

degussa.
creating essentials

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>EUDRAGIT® L/S and FS Polymers</i>	Enteric Coatings: Polymers for pH-dependent drug delivery from the duodenum to the colon.	
<i>EUDRAGIT® E Polymers</i>	Protective Coatings: Polymers for taste- and odor-masking, moisture protection.	N/A
<i>EUDRAGIT® RL / RS and NE an NM Polymers</i>	Sustained Release: Polymers for delayed, sustained, and pulsed release.	



*Add flexibility and power to your development process with EUDRAGIT®. Our wide range of polymers allows you to design your release profile.

Contact: USA: Andrew S. Honeycheck, (732) 981-5383; Germany: Jonas Ide, +49-6151-18-3567

EXCIPIENTS, POLYMERS, Liposomes, Lipids, Coatings

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

DELSITE BIOTECHNOLOGIES, INC.
1505 Walnut Hill Lane
Irving, TX 75038
Phone: (972) 717-5009 Fax: (972) 831-1132
email: info@delsite
www.delsite.com

Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>GelSite® Polymer</i>	Mucosal	DMF
<i>GelSite® Polymer</i>	Injectable	Preclinical

Contact: Jean Anne Mire - Director, Business Development, (972) 650-7320, email: jamire@delsite.com

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

DEPOMED, INC.
1360 O'Brien Drive
Menlo Park, CA 94025
Phone: (650) 462-5900
www.depomedinc.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Gastric Retention Diffusional Technology</i>	Oral, Liquid, Controlled release of soluble drugs	Biovail, Inc.
<i>Gastric Retention Erosional Technology</i>	Oral, Constant delivery rate of insoluble drugs	
<i>Gastric Retention Bi-Layer Technology</i>	Oral, Controlled release of 2 drugs with different characteristics	
<i>Gastric Retention Combination Technology</i>	Oral, Controlled release of 2 drugs simultaneously or in sequence	Biovail, Inc.

Contact: Thadd Vargas, (650) 462-5900

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

DOW CORNING CORPORATION
P.O. Box 994
Midland, MI 48686
Phone: (989) 496-6000 Fax: (989) 496-6731
e-mail: lifesciences@dowcorning.com
www.dowcorning.com

Current Technologies/Platforms:	Application(s):
<i>High-purity, Volatile Silicone Fluids</i>	Carrier for sprays, spreading agent, solvent, lubricant, emollient, skin protectant, and excipient for hydrophilic actives
<i>Blends</i>	Lubricant, emollient, carrier for sprays, spreading agent
<i>Gels</i>	Unique, silky aesthetics (smooth, dry feel); rheology modifier; thickener for silicone-containing formulations
<i>Waxes</i>	Semi-occlusive formulations, lubricant, detackifier, emollient, water-repellent, thickener, moisturizer
<i>Emulsifiers</i>	Room temperature emulsification
<i>Lipids</i>	Vegetable oil, evening primrose oil, camelina oil, borage oil, blackcurrent oil, shea butter, cocoa butter, jojoba oil, mango olein, mango butter, and several silicone and lipid blend emulsions
<i>Lecithin Stabilized Liposome Delivery Solution</i>	Based on a high content of diinoleic phosphatidylcholine

Contact: Stacey Chapin

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

EASTMAN CHEMICAL COMPANY
200 S. Wilcox Drive
Kingsport, TN 37662
Phone: (800) 327-8621
www.eastman.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Eastman CAP</i>	Enteric Coating	
<i>Eastman Eastacryl® 30D Acrylic Coating Material</i>	Enteric Coating	
<i>Eastman CA-398-10</i>	NF Sustained/Controlled Release; Taste Masking	
<i>Eastman CAB-171-15-PG</i>	Sustained/Controlled Release	
<i>Eastman Vitamin E TP6S</i>	Absorption Enhancer, Solubilizer, Bioavailability Enhancer	

Contact: Carolyn Baker, (423) 229-2987

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

ETHYPHARM
194 Bureaux de la Colline
92213 Saint-Cloud Cedex - France
Phone: +33 1 41 12 17 20
www.ethypharm.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Spherulites®</i>	Vaccines	
<i>Multiparticles, Sustained Release Forms</i>	Enhanced Absorption	

Contact: Bruno Delie, Senior VP - Business Development, +33 1 41 12 17 20

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

FLAMEL TECHNOLOGIES
33 Avenue Du Drive Georges Levy
Venissieux, France 69693
Phone: +33 472-783-434 Fax: +33 472-783-435
E-mail: simonin@flamel.com
www.flamel.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>MEDUSA</i>	Parenteral	Bristol-Myers Squibb & other undisclosed partners
<i>MICROPUMP</i>	Oral	Biovail, Merck, Servier GlaxoSmithKline & others undisclosed
Pipeline Technologies/Platforms:	Application(s):	Development Stage
<i>Genvir (MICROPUMP)</i>	Oral	Phase III
<i>Basulin (MEDUSA)</i>	Parenteral	Phase I
<i>Metformin XL (MICROPUMP)</i>	Oral	Phase I
<i>Augmentin SR (MICROPUMP)</i>	Oral	Confidential
<i>Ace Inhibitor (MICROPUMP)</i>	Oral	Confidential
<i>Various MEDUSA & MICROPUMP Projects</i>	Oral & Parenteral	Preclinical

Contact: Frederick Simonin, +33 472-783-434

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

GRAIN PROCESSING CORPORATION
1600 Oregon Street
Muscatine, IA 52761
Phone: (563) 264-4265
www.grainprocessing.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>MALTRIN® Maltodextrins NF</i>	Aqueous Film Coating, Bulking, Carrying, Blending, Capsules, Creams & Lotions, Dry Granulation, Film Forming, Liquid Pharmaceuticals, Medical Nutritionals, Soaps & Cleansers, Spray Drying, Tableting, Throat Lozenges, Wet Granulation	
<i>PURE-DENT® Corn Starches USP/NF</i>		
<i>PURE-COTE®, INSTANT PURE-COTE® Modified Starches</i>		
<i>Spres® Pregelatinized Starches NF</i>		
<i>WATER LOCK® Superabsorbent Polymers</i>		


Contact: Bob Bahn, (563) 264-4281

EXCIPIENTS, POLYMERS, Liposomes, Lipids, Coatings

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS



HUBER ENGINEERED MATERIALS, PART OF
J.M. HUBER CORPORATION
907 Revolution Street
Havre de Grace, MD 21078
T: (410) 939-7228
e-mail: hubermaterials@huber.com
www.rxciipients.com or www.hubermaterials.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
RxCIPIENTS® FM1000	Fast-dissolve excipient for oral dosage tablets	Various 
RxCIPIENTS® GL 100 & 200	Gildants	
HuberCal® calcium carbonate	Inert filler	
Hubersorb silica® & Zeopharm® calcium silicate	Carrier	

Contact: Karl Mattson-Boze

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

INEOS FLUOR
The Heath, Runcorn
Cheshire, UK WA7 4QX
Phone: +44 (0) 1928 51 5525 Fax: +44 (0) 1928 51 1418
email: info@ineosfluor.com
www.ineosfluor.com • www.zephex.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
ZEPHEX 134a and ZEPHEX 227ea HFA medical propellants	Metered Dose Inhalers, other medical aerosols and devices	Supply many of the World's leading MDI companies
CFC11 and CFC12 medical propellants	Made available to support the smooth transition from CFC propelled MDIs to HFA propelled ones	
Pipeline Technologies/Platforms:	Application(s):	Development Stage
Electrostatic effects from propellant interactions with can and drug	Enhancing reproducibility and delivery of pulmonary medications	Early research

Contact: Tim Noakes

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

INXX, INC.
825 Third Avenue, 40th Floor
New York, NY 10022
Phone: (212) 838-1111 Fax: (212) 838-0060
e-mail: info@inxgroup.com
www.inyxgroup.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Patented novel lipid-binding matrix technology	For delivering incompatible or unstable drug substances that enhance delivery of not only single molecule, but also combination inhalation therapy drugs	

Contact: Marc Couturier, Senior Vice President, Global Business Development (416) 250-0091

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS



International Specialty Products (ISP)
1361 Alps Road
Wayne, NJ 07470
Phone: (973) 628-4000 Fax: (973) 628-4117
email: info@ispcorp.com
www.ispcorp.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Advantia™ Coating Systems	Oral Solids	Not Disclosed

Contact: Ann Druffner

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

JRS PHARMA LP
2981 Route 22, Suite 1
Patterson, NY 12563
Phone: (800) 431-2457 Fax: (845) 878-3484
email: info@jrpharma.com
www.jrpharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
PROSOLV®	High Functionality Excipients	
PRUV® Sodium Stearyl Fumarate	Lubricant	
EXPLOTAB® Sodium Starch Glycolate	Superdisintegrant	
VIVASTAR® Sodium Starch Glycolate	Superdisintegrant	
EMCOCEL® Microcrystalline Cellulose	Tablet Binder	
VIVAPUR® Microcrystalline Cellulose	Tablet Binder	
LUBRITAB® Hydrogenated Vegetable Oil	Tablet Lubricant	

Contact: Renee Mill, (845) 878-8380

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

LOPAREX
7700 Griffin Way
Willowbrook, IL 60527
Phone: (630) 734-2700 Fax: (630) 734-2690
email: info@loporex.com
www.loporex.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Silicone-Coated Papers & Films	Release liners for medical devices	

Contact: Steve Saunders, Marketing Manager

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

MACROMED, INC.
2417 S. 3850W, Suite 150
West Valley City, UT 84120
T: (801) 433-2560 Fax: (801) 433-2561
Website: www.macromed.com
e-mail: macromed@macromed.com - www.macromed.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
HySolv™	Oral, Parenteral Solubilizer	Not Disclosed

Contact: Alex S. Kim, Executive Vice President, (801) 433-2560

NEW- ELECTRONIC EDITION

All advertisers appearing in our print edition will also appear in the electronic edition of *Drug Delivery Technology* with active links to their Web site. The electronic edition also provides advertisers with global distribution of their message.



EXCIPIENTS, POLYMERS, Liposomes, Lipids, Coatings

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

NEOPHARM INC.
150 Field Drive, Suite 195
Lake Forest, IL 60045
Phone: (847) 295-8678 Fax: (847) 295-8854
www.neopharm.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>NeoLipid™ Technology</i>	Delivery of broad range of difficult to formulate drugs	
<i>NeoPectin™ (In Vitro)</i>	Delivery of Nucleic acids (siRNA, plasmids, antisense)	
<i>NeoPectin-AT™ (In Vivo)</i>	Delivery of Nucleic acids (siRNA, plasmids, antisense)	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>NeoLipid™ Technology</i>	Easy to use Liposome-based drugs for treatment of Cancer	Liposome-based SN38 (LE-SN38), SN-38 is an active metabolite of Camptosar® - Phase I/II Liposome-based Paclitaxel (LEP-ETU) - Phase I/II Liposome-based raf anti-sense (LE-rafAON) - Phase I

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

NOVEON, INC.
9911 Brecksville Road
Cleveland, OH 44141
Phone: (216) 447-5000
www.pharma.noveon.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Carbopol® Polymers</i>	Controlled release solid dosage forms (tabs, caps); topical lotions, creams and gels	
<i>Pemulen® Polymeric Emulsifiers</i>	Topical lotions, creams and gels	
<i>Noveon® Polycarbophils</i>	Bioadhesion in vaginal, buccal and ophthalmic applications; taste masking	

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

OSG NORWICH PHARMACEUTICALS, INC.
6826 State Highway 12
Norwich, NY 13815
Phone: (607) 335-3000 Fax: (607) 335-3100
email: Bob.Calabro@norwichpharma.com
www.norwichpharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Aqueous and solvent tablet coating</i>	Tablets	Numerous

Contact: Bob Calabro

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

OXFORD LASERS INC.
2 Shaker Road, Unit D201
Shirley, MA 01464
Phone: (978) 425 0755 or (800) 222-3632 Fax: (978) 425-4487
www.oxfordlasers.com
e-mail: EnVision@Oxfordlasers.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>EnVision Pharma Systems - Short pulsed light source imaging</i>	MDI & nasal devices, generation of spray pattern and plume geometry information. Also development of DPI, nebulizer, and transdermal/needle-free devices	Bespak Vectura Chiesi GlaxoSmithKline
<i>VisiSizer System</i>	Particle size analysis for medical devices development	Bang & Olufsen Medicom
<i>Laser micro-machining</i>	Wide range of medical device and controlled/calibrated leak testing	

Contact: Dr. Séamus D Murphy, EnVision@Oxfordlasers.com, (978) 425 0755

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

PARTICLE AND COATING TECHNOLOGIES, INC.
5445 Highland Park Drive
St. Louis, MO 63110
Phone: (314) 535-1516 Fax: (314) 535-1514
email: rsparks@pctincusa.com
www.pctincusa.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Very viscous coatings</i> <i>Burst-release coatings</i>	Better barriers Delayed release	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>New barrier coatings</i>		

Contact: Robert Sparks

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS

PAULAU CORPORATION
105 Melrich road
Cranbury, NJ 08512
Phone: (609) 395-8844 Fax: (609) 395-8850
email: amartello@paulaur.com
www.paulaur.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Sugar Spheres USP/NF</i>	Oral, Solid Dosage, Sustained, Controlled & Extended Release	
<i>DURO-TAB®</i>	Direct Compacting & Tableting Sugar	
<i>MEGATAB®</i>	Direct Compacting & Tableting Sucrose	
<i>MEGADEX®</i>	Direct Compacting & Tableting Dextrose	

EXCIPIENTS, POLYMERS, LIPSOMES, LIPIDS, COATINGS


PHARMAFORM L.L.C.
11400 Burnet Road, Bldg. 4 - Suite 4010
Austin, TX 78758
Phone: (512) 834-0449, ext. 201 - Fax: (512) 834-2105
www.pharmaform.com
Excellence & Innovation in the Pharmaceutical Sciences

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Film Coating</i>	Controlled Release, Modified Release, Delayed Release	
<i>Hot Melt Extrusion</i>	Controlled Release, Abuse Deterrent, Dosage Forms, Transmucosal Films, Enhanced Solubility	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
<i>EDACS Abuse Deterrent Systems</i>	Controlled or abused substances	

Contact: Michael M. Crowley, PhD, VP Business Development

EXIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS

POLYMNUN SCIENTIFIC GMBH
Nussdorfer Laende 11
Vienna, Austria A-1190
Phone: +43-1-36006-6203 Fax: +43-1-3697615
e-mail: office@polymun.com
www.polymun.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
<i>Liposome Production Technology</i>	Continuous and aseptic one-step process resulting in sterile liposomes of defined size distribution and long-term stability. Allows scale-up to any desired production size at high drug incorporation rates and excellent batch-to-batch consistency in GMP-compliant quality.	

Contact: Dr. Dietmar Katinger

EXCIPIENTS, POLYMERS, Liposomes, Lipids, Coatings

EXCIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS

PURAC AMERICA, INC
111 Barclay Boulevard
Lincolnshire, IL 60069
Phone: (847) 634-6330 Fax: (847) 634-1992
www.purac.com or www.puracbiomaterials.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
PURAC® PURASAL® PURASORB® (Biodegradable Polymers)	Oral Parenteral Parenteral, Implants, Microspheres	Many
Contact: Claudia Bratrude		

EXCIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS

SAFC
3050 Spruce Street
St. Louis, MO 63103
Phone: (800) 244-1173 (314-534-4900) Fax: (800) 368-4661 (314-652-0000)
email: safcglobal@sial.com
www.safcglobal.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Polyamino Acids Lipids Liposomes Tween 20/80 GMP, Low Peroxide Synthetic Cholesterol Keyhole limpet hemocyanin (KLH)	Carrier/excipient Liposomes Carrier/excipient Detergent/surfactant Emulsifier/liposomes Carrier/adjuvant	
Pipeline Technologies/Platforms:	Application(s):	Development Stage:
PEGylation Conjugation	Stability, solubility	Prototype
Contact: Tom Gelineau, (314) 301-2077, email: tgelineau@sial.com		

EXCIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS



SPI PHARMA
321 Cherry Lane
New Castle, Delaware 19720
Phone: (302) 576-8500 x 8554
Fax: (302) 576-8567
www.spipharma.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Mannogem™ EZ, 2080, Granular, Powder Mannitol	Solid Oral Dose	Rx, OTC Nutraceutical
Sorbogem™ Spray-dried Sorbitol Powder	Solid Oral Dose	Rx, OTC Nutraceutical
Contact: Sarat Chandar		

EXCIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS

STEPAN COMPANY
100 West Hunter Avenue
Maywood, NJ 07607
Phone: (201) 712-7642 Fax: (201) 712-7648
email: jbutterwick@stepan.com
www.stepan.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
NEOBEE® Medium Chain Triglycerides	Solvent, carrier	
WECOBEE® Triglycerides	Suppository base	
Contact: James M. Butterwick		

EXCIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS

TEXMAC INC.
3001 Stafford Drive
Charlotte, NC 28208
Phone: (704) 393-6555 Fax: (704) 392-1621
email: yosaka@texmacusa.com
www.texmac.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
Micro-/Nan particle surface coating, modification	Drug delivery, cosmetics	Nara Machinery
Contact: James M. Butterwick		

EXCIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS

THE DOW CHEMICAL COMPANY
P.O. Box 1206
Midland, Michigan 48642
Phone: (898) 832-1560 Fax: (898) 832-1465
www.dowexcipients.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
ETHOCEL™ Ethylcellulose	Controlled release, tablet coating	
METHOCEL™ Cellulose Ethers	Controlled release, tablet coating, granulation, oral films, hot-melt extrusion	
POLYOX™ Water-Soluble Resins NF	Controlled release, hot-melt extrusion	
Contact: Melissa Bressette		

EXCIPIENTS, POLYMERS, LIPOSOMES, LIPIDS, COATINGS



GENZYME PHARMACEUTICALS
675 West Kendall Street
Cambridge, MA 02142
Phone: (800) 868-8208 or (617) 374-7248
Fax: (617) 768-9765
E-mail: pharmaceuticals@genzyme.com
www.genzymepharmaceuticals.com

Current Technologies/Platforms:	Application(s):	Current Partner(s):
LipoBridge®	CNS, blood brain barrier, Alzheimer's, stroke, trauma, Parkinson's, Multiple Sclerosis	Undisclosed
LipoMask™	Extended circulation time of partners in blood	Undisclosed
Custom manufactured and standard lipids available		

See Company
Profile

NEW- ELECTRONIC EDITION

All advertisers appearing in our print edition will also appear in the electronic edition of *Drug Delivery Technology* with active links to their Web site. The electronic edition also provides advertisers with global distribution of their message.



CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



3M Drug Delivery Systems

Bldg 275-3E-10
St. Paul, MN 55110
Phone: (800) 643-8086 Fax: 651-737-5265
www.3m.com/ddsadv

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other:

Contact: Brian Gabrio; bjgabrio@mmm.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



AKINA, INC.
Business & Technology Center
1291 Cumberland Avenue, E130
West Lafayette, IN 47906-1385
Phone: (765) 464-0501 - Fax: (765) 464-0820
e-mail: kp@akinainc.com - www.akinainc.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Current Partnerships: Samyang Corp., Boston Scientific, Endovasc

Contact: Kinam Park, PhD, (765) 464-0390, kp@akinainc.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

AAIPHARMA INC.
2320 Scientific Park Drive
Wilmington, NC 28405
Phone: (800) 575-4224 or (910) 254-7000
Fax: (910) 815-2300
e: services@aaipharma.com - www.aaipharma.com/aiportal/

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Phase I-IV Clinical Trials, Clinical trial packaging and distribution

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

AKORN, INC.
2500 Millbrook Drive
Buffalo Grove, IL 60089
Phone: (800) 932-5676 Fax: 800-943-3694
Website: www.akorn.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing Other:

Current Partnerships:

Contact: JAY STERN VP SALES & MARKETING

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

ABC LABORATORIES, INC.
7200 East ABC Lane
Columbia, MO 65202
Phone: (573) 443-9000 Fax: (573) 443-9033
email: abc@abclabs.com
www.abclabs.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Nancy Berrey

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

Alcoa Flexible Packaging
6603 West Broad Street
Richmond, VA 23230
Phone: (804) 281-2603 Fax: (804) 281-2238
www.alcoa.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Victoria C. Welch, (804) 281-2262

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

ADVION BIOSCIENCES
15 Catherwood Road
Ithaca, New York 14850
Phone: (607) 266-0665 Fax: (607) 266-0749
email: CROinfo@advion.com
www.advion.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis
 Other: LC/MS Bioanalytical Services; Sample Management Services

Contact: Gaye Martin

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

American Peptide Company, Inc.
777 East Evelyn Avenue
Sunnyvale, CA 94086
Phone: (408) 733-7604, x204
www.americanpeptide.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Peptides, cGMP, Process Development

Contact: Gary Hu, (800) 926-8272, ext. 204

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



ASSA INTERNATIONAL INC
3B East Lake Road
Danbury, CT 06811
Phone: (203) 312-0682 Fax: (203) 312-0722
email: assa.info@assainternational.com
www.assainternational.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Other: Education & Training:

assa*international*® is a training and consulting company specialized on pharmaceutical applications of solid-state analytical techniques. Specifically, assa:

- organizes in-depth [International Workshops](#) and Conferences on Solid State Characterization in the Pharmaceutical area.
- offers specialized courses for pharmaceutical applications on Polymorph Screening, X-Ray Powder Diffraction, Near IR and Terahertz Spectroscopy, and Patent related issues.
- Also offers a wide range of [Analytical Services](#) for Pharmaceutical Solid State problems, including four Polymorph Screening programs. We are available for Expert Witness services.

Contact: Dr. Angeline Zakrzewski, email: Angeline@assainternational.com 203-312-0682



CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



BESPAK PLC
Blackhill Drive, Featherstone Road,
Wolverton Mill South
Milton Keynes, Buckinghamshire MK12 5TS
United Kingdom
Phone: +44(0)1908 552600 - Fax: +44(0)1908 552613
e-mail: bizdev@bespak.com - www.bespak.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Joe Keenan, joe.keenan@bespak.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



BIOCONVERGENCE LLC
4320 West Zenith Drive
Bloomington, IN 47404
Phone: (812) 961-1700 Fax: (812) 961-1733
email: info@bioc.us
www.bioc.us



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: cGMP materials management (storage, dispensing, sampling, logistics), consulting

Contact: Jennifer Winders

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

AZOPHARMA, CONTRACT PHARMACEUTICAL SERVICES
10320 USA Today Way
Miramar, FL 33025
Phone: (954) 433-7480 Fax: (954) 432-9015
email: development@azopharma.com
www.azopharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Other: Characterization Services, Synthesis, Preformulation

Contact: David Greeley, VP Sales and Marketing

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



BIOSCREEN TESTING SERVICES, INC.
3904 Del Amo Blvd
Torrance, CA 90503
Phone: (310) 214-0043 Fax: (310) 370-3642
e-mail: info@bioscreen.com
www.bioscreen.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Laboratory Testing Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Analytical Chemistry & Microbiological Testing Services

Contact: Sales

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



BASF
100 Campus Drive
Florham Park, NJ 07932
Phone: (800) 443-0627, Fax: (973) 245-6763
email: pharmasolutions@basf.com
www.pharma-solutions.basf.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Other: Solid and semi-solid dosage form contract manufacturing

Contact: BASF Pharma, (800) 443-0627

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

BIOSEV CORPORATION
5340 Eastgate Mall
San Diego, California 92121
Phone: (858) 450-34123 Fax: (858) 450-0785
email: info@bioservcorp.com
www.bioservcorp.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development
 Other: Lyophilization

Contact: Lee Starr, (858) 450-4676

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



BAXTER HEALTHCARE CORPORATION
Route 120 & Wilson Roads
Round Lake, IL 60073
T: (800) 422-9837 (domestic) or (847) 948-4770
F: (847) 948-3642
e-mail: onebaxter@baxter.com
www.baxterbiopharmasolutions.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Kim Thomas, (847) 270-5072



CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

BIOVAIL CONTRACT RESEARCH
460 Comstock Road
Toronto, Ontario, Canada M1L4S4
Phone: (416) 752-3636 Fax: (416) 752-7610
email: clientserv@biovail.com
www.biovail-cro.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other: Clinical Trials & Bioanalysis, Analytical Testing & Analysis

Contact: Tamar Aghamanoukian, Director, Marketing & Sales

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CAPSUGEL
535 North Emerald Road
Greenwood, SC 29646
Phone: (888) 783-6361 Fax: (888) 783-6360
email: Glenda.oliver-smith@pfizer.com
www.capsugel.com



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Laboratory Testing

Contact: Glenda Oliver-Smith

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



BROOKWOOD PHARMACEUTICALS, INC.
756 Tom Martin Drive
Phone: (205) 917-2239
Fax: (205) 917-2205
www.brookwoodpharma.com



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Kelly Arlint, (205) 917-2239

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CELSION CORPORATION
10220-L Old Columbia Road
Columbia, MD 21046
Phone: (410) 290-5390 Fax: (410) 290-5394
email: celsion@celsion.com
www.celsion.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development
 Other: Cancer Drug Development

Contact: Anthony P. Deasey, EVP & COO, (410) 290-5390 x4899

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CALORIMETRY SCIENCES CORPORATION
890 West 410 North, Suite A
Lindon, UT 84042
Phone: (801) 763-1500 Fax: (801) 763-1414
email: info@calscorp.com
www.calorimetrisciences.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Peter Zumbrennen

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CENTER FOR ADVANCED DRUG DEVELOPMENT
100 Oakdale Campus Room 1 PRL
Iowa City, Iowa 52242-5000
Phone: (319) 335-4096 Fax: (319) 335-4374
email: alta-botha@uiowa.edu
www.pharmacy.uiowa.edu/rxserve/index.htm

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Method development and validation according to ICH guidelines, development of dissolution procedures and validation of the analytical method, pre-formulation, development of formulations, API, excipient and drug product testing according to official monographs.

Contact: Dr. Alta Botha

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



CARDINAL HEALTH
14 Schoolhouse Road
Somerset, New Jersey 08873
Phone: (732) 537-6200 Fax: (732) 537-5949
email: pts@cardinal.com
www.cardinal.com/pts

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development
 Other: Product Launch Services, Medical Education, Post-Launch Services

Contact: (866) 720-3148 (toll-free) or pts@cardinal.com



CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CERILLIANT CORPORATION
811 Paloma Drive
Round Rock, Texas 78664
Phone: (800) 848-7837 Fax: (800) 654-1458
email: custserv@cerilliant.com
www.cerilliant.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development

Contact: Debbie Palmon, Account Manager/Tradeshow Coordinator

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CHR. HANSEN
9015 W. Maple Street
Milwaukee, WI 53214
Phone: (800) 558-0802 Fax: (414) 607-5959
email: Innovations@chr-hansen-us.com
www.chr-hansen.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Supplies probiotics (capsules, tablets and powders), phytonutrients, colors, flavors and maskants

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



CORIUM INTERNATIONAL, INC.
2686 Middlefield Road, Suite G
Redwood City, CA 94063
Phone: (650) 298-8255 Fax: (650) 298-8012
email: debfox@coriumtech.com
www.coriumgroup.com

Please check the categories in which your company provides the service.

- Laboratory Testing Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: (Co-Development, Contract Development, Product Re-engineering)
 Current Partnerships:

Contact: Deb Fox, PhD, VP Business Development, (203) 775-7124, debfox@coriumtech.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CIBA® EXPERT SERVICES
540 White Plains Road
Tarrytown, NY 10591
Phone: (914) 785-2533 Fax: (914) 785-4241
email: cxs_nafta@cibasc.com
www.cibasc.com/cxs

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Leachables and Extractables Analysis, Quality Management, Life Cycle Consultation, EH&S testing and Consulting

Contact: Miles Hutchings and Dean Hamel

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

COVANCE LABORATORIES
3301 Kinsman Blvd.
Madison, WI 53704
Phone: (888) COVANCE Fax: (608) 241-7227
e-mail: info@covance.com
www.covance.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CIRRUS PHARMACEUTICALS, INC.
P.O. Box 14748
Research Triangle Park, NC 27709-4748
Phone: (919) 884-2064 Fax: (919) 884-2075
email: info@cirruspharm.com
www.cirruspharm.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other: Physical & Chemical Characterization, Particle Size Analysis, Fine Particle Generation, Analytical Method Development & Validation

Contact: Michael Branciforti (919) 321-4043

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CP KELCO
8355 Aero Drive
San Diego, CA 92123
Phone: (858) 292-4900 Fax: (858) 292-4901
email: solutions@cpkelco.com
www.cpkelco.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Fermentation Capability
 Current Partnerships:

Contact: Anne Sinha, (858) 467-6615

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

COATING PLACE, INC.
200 Paoli Street, PO Box 930310
Verona, WI 53593
Phone: (608) 845-9521
www.encap.com



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Fred Schulze, (817) 477-2766

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

CYDEX, INC.
10513 West 84th Terrace
Lenexa, KS 66214
Phone: (913) 685-8850 Fax: (913) 685-8856
email: cd_info@cydexinc.com
www.cydexinc.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Jose L. Rodriguez

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



COOK PHARMICA LLC
1300 S. Paterson Drive
Bloomington, IN 47403
Phone: (877) 312-COOK Fax: (812) 336-7167
email: busdev@cookpharmica.com
www.cookpharmica.com

Please check the categories in which your company provides the service.

- Analytical Testing Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Process Development Manufacturing Packaging
 Other: Mammalian cell culture services, Cell line development, Cell banking, Process Development

Contact: April Ladd, Manager of Sales & Marketing

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

DE DIETRICH PROCESS SYSTEMS, INC.
244 Sheffield Street
Mountainside, NJ 07092
Phone: (908) 317-2585 Fax: 908-889-4960
e-mail: sales@ddpsinc.com
www.ddpsinc.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Jennifer Kubiak

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

DEGUSSA CORPORATION
Pharma Polymers
2 Turner Place
Piscataway, NJ 08855
T: (732) 981-5383 Option 4
F: (732) 981-5371
E: eudragit.usa@degussa.com

DEGUSSA AG - PHARMA POLYMERS
Röhm GmbH
Kirschenallee 45
64293 Darmstadt, Germany
T: +49-6151-18-4019
F: +49-6151-18-3520
E: eudragit.germany@degussa.com

degussa.
creating essentials



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: USA: Dr. Nasser Nyamweya, (732) 981-5366; Germany: Dr. Thomas Furst, +49-6151-18-4452

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

DELSITE BIOTECHNOLOGIES, INC.
1505 Walnut Hill Lane
Irving, TX 75038
Phone: (972) 717-5009 Fax: (972) 831-1132
email: info@delsite
www.delsite.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Jean Anne Mire, (972) 650-7320, email: jamire@delsite.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

DEPOMED, INC.
1360 O'Brien Drive
Menlo Park, CA 94025
Phone: (650) 462-5900
www.depomedinc.com


Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Current Partnerships: Biovail, Inc., ActivBiotics, AVI Biopharma

Contact: Thadd Vargas, (650) 462-5900

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



DOW PHARMACEUTICAL SCIENCES, INC.
1330 Redwood Way
Petaluma, CA 94954
Phone: (707) 793-2600
Fax: (707) 793-0145
www.dowpharmsci.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other: *In vitro* permeation studies; human skin, bovine eye, sheep vaginal, and porcine buccal tissues, clinical labeling (any dosage form), regulatory consulting and submissions, and dermatology and vaccine clinical trials.

Contact: Steve Smith, VP Marketing & Business Development (707) 793-2600

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



DPT LABORATORIES, LTD.
307 East Josephine Street
San Antonio, TX 78215
Phone: (210) 476-8159 - Fax: (210) 829-8733
e-mail: confidence@dptlabs.com
www.dptlabs.com



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Roxanne Barr

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

EGALET
Lejrvej 37- 41 Kirke Vaerlose
DK - 3500 Vaerlose - Denmark
Phone: +45 4447 8080 Fax: +45 4447 2425
www.egalet.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Ken Downie

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

ELAN DRUG TECHNOLOGIES
Monksland
Athlone, Co Westmeath, Ireland
Phone: +353 90 64 95000 Fax: +353 90 64 95807
www.elan.com/EDT

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Sarah Carty, Associate Director, European Business Development, +353 1 7094046

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

E.I. DUPONT DE NEMOURS COMPANY
DuPont Fluorochemicals, Chestnut Run Plaza
Wilmington, DE 19880-0711
Phone: +1-302-224-0426 Fax: +1-302-224-0427 www.dupont.com/dymel

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Mr. Joseph Creazzo, Technical Service Manager, email: Joseph.A.Creazzo@usa.dupont.com

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

EMERSON RESOURCES, INC.
600 Markley Street
Norristown, PA 19401
Phone: (610) 279-7450 Fax: (610) 292-9722
email: info@emersonresources.com
www.emersonresources.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Walter Strathy

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



EURAND, INC.
845 Center Drive
Vandalia, OH 45377
Phone: (937) 898-9669 Fax: (937) 898-1093
email: bizdev@eurand.com
www.eurand.com

See Company Profile

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

FACET TECHNOLOGIES
1850 Parkway Place, Suite 900
Marietta, GA 30067
Phone: (770) 767-8344 Fax: (770) 767-7320
email: info@facettechnologies.com
www.facettechnologies.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development
 Other: Dosage Device Development and Mfg.

Contact: Michael Flater

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

FERRIS PHARMACEUTICALS INC.
16W300 83rd Street
Burr Ridge, IL 60527-5848
Phone: (630) 734-7810 Fax: (630) 887-1008
email: info@ferrispolymem.com
www.FerrisCares.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Transdermal and mucosal patches/pads/inserts, with/without adhesive. Materials added to foam or gel formulas without heat/shear degradation. Quality system accredited to international requirements.

Contact: Paul Kay

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



FILTERTEK INC.
11411 Price Road
Hebron, IL 60034
Phone: (800) 648-0791 Fax: (815) 648-2929
www.filtertek.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Bruce Daniels, VP Medical Marketing

See Company Profile

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

FLAMEL TECHNOLOGIES S.A.
Parc Club Du Moulin à Vent
33, Avenue du Docteur Georges Lévy
69693 Vénissieux Cedex - France
Phone: (+33) 472-783-434 Fax: (+33) 472-783-435
email: simonin@flamel.com / website: www.flamel.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Process Development
 Other: Drug Delivery

Current Partnerships: Biovail (Genvir), Bristol-Myers Squibb (Basulin), GlaxoSmithKline (2 Products), Merck & Co. (1 Product), Servier (Ace Inhibitor)

Contact: Frederick Simonin, (+33) 472-783-434

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

FLUID AIR, INC.
2550 White Oak Circle
SAurora, Illinois 60504
Phone: (630) 851-1200 Fax: (630) 851-1244
E-mail: sales@fluidair.com
Website: pharmproservices.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

FORMATECH, INC.
200 Bulfinch Drive
Andover, MA 01810
Phone: (978) 725-9077 Fax: 978-725-9078
e-mail: info@formatech.com
www.formatech.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
Contact: Jeffrey Bernard, Director of Business Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

GENEREX BIOTECHNOLOGY CORPORATION
33 Harbour Square, Suite 202
Toronto, ON, Canada M5J 2G2
Phone: (800) 391-6755 Fax: (416) 364-9363
email: info@generex.com
www.generex.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Drug delivery feasibility studies

Contact: Business Development, (800) 391-6755, info@generex.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



GLATT PHARMACEUTICAL SERVICES
20 Spear Road
Ramsey, NJ 07446
Phone: (201) 825-8700
www.glattpharmaceuticals.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Thomas M. Salus, (201) 818-3778

See Company Profile

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

HAUSER CONTRACT RESEARCH ORGANIZATION
6880 N. Broadway, Suite H
Denver, CO 80221
Phone: (720) 406-4700
www.hausercro.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Compliance Consulting

Contact: Rod McKeever, (720) 406-4700

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

HILL TOP RESEARCH
P.O. Box 429501
Cincinnati, OH 45242
Phone: (800) 785-2693 Fax: (513) 831-1217
email: info@hill-top.com
www.hill-top.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Clinical Research

Contact: Bryan Reynolds

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



HOVIONE
40 Lake Drive
East Windsor, NJ 08520
Phone: 609-918-2600 Fax: 609-918-2615
email: helloovione.com
www.hovione.com



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

HOSPIRA, INC.
One 2 One
D988, H1 275 Northfield Drive
Lake Forest, IL 60045
Phone: (224) 212-2267 Fax: (224) 212-3210
email: one2one@hospira.com
www.hospira.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development
 Other: Parenteral Manufacturing: vials, cartridges, pre-filled syringes, IV containers, and ampoules. Impurity Identification, Lyophilization Cycle Development, and Sterilization Cycle Development.

Contact: Kevin Wess

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

INEOS FLUOR
The Heath, Runcorn
Cheshire, UK WA7 4QX
Phone: +44 (0) 1928 51 5525 Fax: +44 (0) 1928 51 1418
email: info@ineosfluor.com
www.ineosfluor.com • www.zephex.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other: Specialized medical propellant testing

Contact: Tim Noakes

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

INTELLIPHARMACEUTICS CORP.
30 Worcester Road
Toronto, Ontario M9W 5X2
Canada
Phone: (416) 798-3001, ext. 128 Fax: (416) 798-3007
e-mail: info@intellipharmaceutics.com
www.intellipharmaceutics.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other:

Contact: Joe Quinto, Director of Business Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



INTERNATIONAL SPECIALTY PRODUCTS (ISP)
1361 Alps Road
Wayne, NJ 07470
Phone: (973) 628-4000 Fax: (973) 628-4117
email: info@ispcorp.com
www.ispcorp.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Ann Druffner

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

INTRANASAL THERAPEUTICS, INC.
201 Summit Ave, Ste C-2
Montvale, NJ 07645
Phone: (201) 307-9450 Fax: (201) 307-9455
www.intranasal.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development Other: Provided as a service to ITI partners

Contact: Ralph S. Johnston

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

INX, INC.
825 Third Avenue, 40th Floor
New York, NY 10022
Phone: (212) 838-1111 Fax: (212) 838-0060
e-mail: info@inxgroup.com
www.inxgroup.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development Other:

Contact: Marc Couturier, Senior Vice President, Global Business Development (416) 250-0091

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

JRS PHARMA LP
2981 Route 22, Suite 1
Patterson, NY 12563
Phone: (800) 431-2457 Fax: (845) 878-3484
email: info@jrpharma.com
www.jrpharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other: Excipients, Binders, Disintegrants, Lubricant, High Functionality Excipient

Contact: Renee Mill

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

MACROMED, INC.
2417 S. 3850W, Suite 150
West Valley City, UT 84120
T: (801) 433-2560 Fax: (801) 433-2561
Website: www.macromed.com
e-mail: macromed@macromed.com - www.macromed.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Drug Delivery

Contact: Alex S. Kim, Executive Vice President, (801) 433-2560

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

LANCASTER LABORATORIES, INC.
2425 New Holland Pike
Lancaster, PA 17601
Phone: (717) 656-2300 Fax: (717) 656-3772
email: pha@lancasterlabs.com
www.lancasterlabs.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Doug Hostetler

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



MEDPHARM LTD
Business Centre, Sheep Street
Charlbury OX7 3RR
Oxfordshire
Phone: +44 (0) 16 0881 9267 Fax: +44 (0) 16 0881 9268
email: busdev@medpharm.co.uk
www.medpharm.co.uk

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Mathematical modeling of Drug Absorption, predictive model for formulation optimization and screening, in vitro efficacy and performance testing

Contact: Carole Delauney, Head of Business Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

LIPOCINE INC.
675 Arapen Drive, Suite 202
Salt Lake City, UT 84103
Phone: (801) 994-87383 Fax: (801) 994-7388
email: GTS@lipocine.com
www.lipocine.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Jerry Simmons

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

MERRION PHARMACEUTICALS, INC.
219 Racine Drive, Suite D
Wilmington, NC 28403-8702
Phone: (910) 799-1847 Fax: (910) 395-1843
email: info@merrionpharma.com
www.merrionpharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Thomas W. Leonard, PhD, VP & CSO

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



LOPAREX
7700 Griffin Way
Willowbrook, IL 60527
Phone: (630) 734-2700 Fax: (630) 734-2690
email: info@loporex.com
www.loporex.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Steve Saunders, Marketing Manager

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

METRICS, INC.
1240 Sugg Parkway
Greenville, North Carolina
Phone: (252) 752-3800 Fax: (252) 758-8522
email: marketing@metricsinc.com
www.metricsinc.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development

Contact: Jeffrey Basham, jeff@metricsinc.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

LYOPHILIZATION TECHNOLOGY, INC.
30 Indian Drive
Ivyland, PA 18974
Phone: (215) 396-8373 Fax: (215) 396-8375
email: frzdry@lyo-t.com
www.lyotechnology.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Lyophilization, Thermal Analysis Services, Validation-Manufacturing, Development Services, Process Engineering, Process Optimization, Clinical Material Preparation, Finished Product Testing, Consulting, Troubleshooting, Quality and Regulatory Services, On-site Training

Contact: Christine Adams

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



MGLAS AG
Otto-Liebmann-Strasse 2
Münnerstadt, Germany 97702
Phone: +49(0)9733 808-0 Fax: +49(0)9733 808-160
email: info@mglas.de
www.mglas.de

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Mr. Wolfgang Heidl, +49(0)9733 808-125

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

MICRON TECHNOLOGIES INC.
435 Creamery Way
Exton, PA 19341
Phone: (610) 425-5100 Fax: (610) 425-5104
www.microntech.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Analytical Testing & Analysis

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

MISTRAL PHARMA INC.
2101 Halpern
St-Laurent, Quebec H4S 1S3 - Canada
Phone: (514) 920-0909 Fax: (514) 920-0404
www.mistralpharma.com
e-mail: info@mistralpharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Bertrand Bolduc

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

MYLAN TECHNOLOGIES, INC.
110 Lake Street
St. Albans, Vermont 05478
Phone: (800) 532-5226 (U.S.) International: 1-802-527-7792
Fax: (802) 527-8151
email: mtiinfo@mylantech.com
www.mylantech.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development

Contact: Tom Campbell

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

NEXT BREATH LLC
1450 South Rolling Road
Baltimore, MD 21227
Phone: (410) 455-5904
www.nextbreath.net

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Nasal, Pulmonary Development, & Analytical Testing

Contact: Julie Suman, PhD, (410) 455-5904

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

NORTHWEST KINETICS INC.
3615 Pacific Avenue
Tacoma, Washington 98418
Phone: (253) 593-5304 Fax: (253) 593-5181
BusinessDevelopment@nwkinetics.com
www.nwkinetics.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development
 Other: Phase I & II Clinical Trials

Contact: Lisa Rehberger

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



OAKWOOD LABORATORIES, L.L.C.
7670 First Place, Suite A
Oakwood Village, OH 44146
Phone: (440) 359-0000 Fax: (440) 359-0001
email: info@oakwoodlabs.com
www.Oakwoodlabs.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Mark T. Smith, President

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

OCTOPLUS
Zernikedreef 12
2333 CL Leiden Netherlands
Phone: +31 71 5244044 Fax: +31 71 5244043
email: info@octoplus.nl
www.octoplus.nl

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Special expertise in pharmaceutical development and cGMP clinical trial manufacturing of biopharmaceuticals and low-soluble compounds

Contact: Dr. Henrik Luessen, Director Business Development, +31 71 5244044

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

OSG NORWICH PHARMACEUTICALS, INC.
6826 State Highway 12
Norwich, NY 13815
Phone: (607) 335-3000 Fax: (607) 335-3100
email: Bob.Calabro@norwichpharma.com
www.norwichpharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Bob Calabro

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

OWEN MUMFORD, LTD.
Brook Hill Woodstock
Oxford, OX20 1TU - England
Phone: +44 (0) 1993 812021 Fax: +44 (0) 1993 813473
e-mail: drugdelivery@owenmumford.co.uk
www.omdrugdelivery.com

Please check the categories in which your company provides the service.

- | | | | |
|--|---|---|--|
| <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Analytical Development | <input type="checkbox"/> Formulation Development | <input type="checkbox"/> Stability Testing |
| <input type="checkbox"/> Clinical Trial MFG/Scale-up | <input type="checkbox"/> Technology/Transfer | <input checked="" type="checkbox"/> Manufacturing | <input type="checkbox"/> Packaging |
| <input type="checkbox"/> Laboratory Testing | | | |

Contact: Sarah Massey

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PENWEST PHARMACEUTICALS CO.
39 Old Ridgebury Road, Suite 11
Danbury, CT 06810
Phone: (203) 796-3700 Fax: (203) 794-1573
e-mail: Diane.dalessandro@penwest.com
www.penwest.com

Please check the categories in which your company provides the service.

- | | | | |
|--|---|---|--|
| <input type="checkbox"/> Drug Discovery | <input checked="" type="checkbox"/> Analytical Development | <input checked="" type="checkbox"/> Formulation Development | <input type="checkbox"/> Stability Testing |
| <input type="checkbox"/> Clinical Trial MFG/Scale-up | <input checked="" type="checkbox"/> Technology/Transfer | <input type="checkbox"/> Manufacturing | <input type="checkbox"/> Packaging |
| <input type="checkbox"/> Laboratory Testing | <input type="checkbox"/> Other: Out-licensing proprietary drug delivery technologies for product formulations | | |

Contact: Diane D'Alessandro

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

OXFORD LASERS INC.
29 King Street
Littleton, MA 01460-1528
Phone: (978) 742-9000 Fax: (978) 742-9100
email: EnVision@Oxfordlasers.com
www.oxfordlasers.com

Please check the categories in which your company provides the service.

- | | | | |
|---|---|--|--|
| <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Analytical Development | <input type="checkbox"/> Formulation Development | <input type="checkbox"/> Stability Testing |
| <input type="checkbox"/> Clinical Trial MFG/Scale-up | <input type="checkbox"/> Technology/Transfer | <input type="checkbox"/> Manufacturing | <input type="checkbox"/> Packaging |
| <input checked="" type="checkbox"/> Other: Imaging, Micromachining, Photonics | | | |

Contact: Dr. Seamus D. Murphy, (978) 742-9000, email: seamus.Murphy@oxfordlasers.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PFEIFFER OF AMERICA
742 Alexander Road, Suite 201
Princeton, New Jersey 08540
Phone: (609) 987-0223 Fax: (609) 987-1511
e-mail: info@Pfeiffer-group.com
www.pfeiffer-group.com

Please check the categories in which your company provides the service.

- | | | | |
|---|---|--|---|
| <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Analytical Development | <input type="checkbox"/> Formulation Development | <input type="checkbox"/> Stability Testing |
| <input type="checkbox"/> Clinical Trial MFG/Scale-up | <input type="checkbox"/> Technology/Transfer | <input type="checkbox"/> Manufacturing | <input checked="" type="checkbox"/> Packaging |
| <input checked="" type="checkbox"/> Other: Mechanical and electronic devices for multidose and unitdose drug dispensing applications, for use in nasal, oral and topical drug administration. | | | |

Contact: Richard Sica

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PARTICLE AND COATING TECHNOLOGIES, INC.
5445 Highland Park Drive
St. Louis, MO 63110
Phone: (314) 535-1516 Fax: (314) 535-1514
email: rsparks@pctincusa.com
www.pctincusa.com

Please check the categories in which your company provides the service.

- | | | | |
|--|---|---|--|
| <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Analytical Development | <input checked="" type="checkbox"/> Formulation Development | <input type="checkbox"/> Stability Testing |
| <input type="checkbox"/> Clinical Trial MFG/Scale-up | <input checked="" type="checkbox"/> Technology/Transfer | <input checked="" type="checkbox"/> Manufacturing | <input type="checkbox"/> Packaging |
| <input checked="" type="checkbox"/> Laboratory Testing | | | |

Contact: Robert Sparks

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PHARMACEUTICAL PROFILES
Mere Way, Ruddington Fields, Ruddington
Nottingham, NG11 6JS, United Kingdom
Phone: +44 115 974 9000
www.pharmprofiles.com

Please check the categories in which your company provides the service.

- | | | | |
|---|---|---|--|
| <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Analytical Development | <input checked="" type="checkbox"/> Formulation Development | <input type="checkbox"/> Stability Testing |
| <input checked="" type="checkbox"/> Clinical Trial MFG/Scale-up | <input type="checkbox"/> Technology/Transfer | <input checked="" type="checkbox"/> Manufacturing | <input type="checkbox"/> Packaging |
| <input type="checkbox"/> Other: | | | |
| <input type="checkbox"/> Current Partnerships: | | | |

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PATHEON INC.
7070 Mississauga Road, Suite 350
Mississauga, ON, Canada L5N 7J8
Phone: (905) 821-4001 Fax: (905) 812-6709
email: patheon@patheon.com
www.patheon.com

Please check the categories in which your company provides the service.

- | | | | |
|--|--|---|---|
| <input checked="" type="checkbox"/> Drug Discovery | <input checked="" type="checkbox"/> Analytical Development | <input checked="" type="checkbox"/> Formulation Development | <input checked="" type="checkbox"/> Stability Testing |
| <input checked="" type="checkbox"/> Clinical Trial MFG/Scale-up | <input checked="" type="checkbox"/> Technology/Transfer | <input checked="" type="checkbox"/> Manufacturing | <input checked="" type="checkbox"/> Packaging |
| <input checked="" type="checkbox"/> Other: High-potency manufacturing, Controlled Release products, Controlled substances, Over-encapsulation, Lyophilization, Sterile injectables, Nasal Spray delivery | | | |

Contact: Pam Shirto

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



PHARMAFORM L.L.C.
11400 Burnet Road, Bldg. 4 - Suite 4010
Austin, TX 78758
Phone: (512) 834-0449, ext. 201 Fax: (512) 834-2105
www.pharmaform.com

Please check the categories in which your company provides the service.

- | | | | |
|---|--|---|---|
| <input type="checkbox"/> Drug Discovery | <input checked="" type="checkbox"/> Analytical Development | <input checked="" type="checkbox"/> Formulation Development | <input checked="" type="checkbox"/> Stability Testing |
| <input checked="" type="checkbox"/> Clinical Trial MFG/Scale-up | <input checked="" type="checkbox"/> Technology/Transfer | <input checked="" type="checkbox"/> Manufacturing | <input checked="" type="checkbox"/> Packaging |
| <input type="checkbox"/> Other: | | | |
| <input type="checkbox"/> Current Partnerships: | | | |

Contact: Michael M. Crowley, PhD, VP Business Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PAULAU CORPORATION
105 Melrich road
Cranbury, NJ 08512
Phone: (609) 395-8844 Fax: (609) 395-8850
email: amartello@paulaur.com
www.paulaur.com

Please check the categories in which your company provides the service.

- | | | | |
|--|---|---|--|
| <input type="checkbox"/> Drug Discovery | <input type="checkbox"/> Analytical Development | <input checked="" type="checkbox"/> Formulation Development | <input type="checkbox"/> Stability Testing |
| <input type="checkbox"/> Clinical Trial MFG/Scale-up | <input type="checkbox"/> Technology/Transfer | <input type="checkbox"/> Manufacturing | <input type="checkbox"/> Packaging |
| <input type="checkbox"/> Laboratory Testing | | | |

Contact: Larry Toscano

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PHARMATEK LABORATORIES INC.
5626 Oberlin Drive, Suite 100
San Diego, CA 92121
Phone: (858) 587-8783 Fax: (858) 587-8771
email: info@pharmatek.com
www.pharmatek.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing
 Other:

Contact: Elizabeth Hickman, ehickman@pharmatek.com, (858) 587-8783

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PRECISION PHARMA SERVICES
155 Duryea Road
Melville, New York 11747
T: 631-845-6244 F: 631-752-7354
www.precisionpharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development
 Other: Aseptic parenteral manufacturing

Contact: Neil L. Coles

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PHARMPRO® (DIVISION OF FLUID AIR)
2550 White Oak Circle
Aurora, IL 60504
Phone: (630) 851-1200
www.pharmpro.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Tom Tappen, (630) 851-1200

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

REMMELE ENGINEERING, INC. - AUTOMATION DIVISION
677 Transfer Road
St. Paul, MN 55114
Phone: (651) 643-3700 Fax: (651) 642-5665
email: automation@remmele.com
www.remmeleautomation.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Brian Raehsler

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

POLY MUN SCIENTIFIC GMBH
Nussdorfer Laende 11
Vienna, Austria A-1190
Phone: +43-1-36006-6203 Fax: +43-1-3697615
e-mail: office@polymun.com
www.polymun.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other:

Contact: Dr. Dietmar Katinger

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

RESPIRONICS RESPIRATORY DRUG DELIVERY
41 Canfield Road
Cedar Grove, NJ 07009
Phone: (800) 962-1266 Fax: (724) 387-5270
e-mail: mark.elphick@respiroics.com
www.respiroics.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Aerosol Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Mark Elphick

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

POLYPEPTIDE LABORATORIES
365 Maple Avenue
Torrance, California 90503
Phone: (800) 770-0557 or (310) 782-3569
Fax: (310) 782-3645
www.polypeptide.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development Other: Peptide API Manufacturing

Contact: Jane Salik, (310) 782-3569

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

REXAM PHARMA
600 Deerfield Parkway
Buffalo Grove, IL 60089
Phone: (847) 541-9700 Fax: (847) 541-9201
e-mail: mailboxpharma@rexam.com
www.rexam.com/pharma

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Michael Cullen

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

PRACS INSTITUTE, LTD.
4801 Amber Valley Parkway
Fargo, North Dakota 58104
Phone: (701) 239-4750 Fax: (701) 239-4955
Email: pracsbd@pracs.com
Website: www.pracs.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development

Other: Clinical Research Services

Contact: John Pottier, Director, Business Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

SAFC
3050 Spruce Street
St. Louis, MO 63103
Phone: (800) 244-1173 (314-534-4900) Fax: (800) 368-4661 (314-652-0000)
email: safcglobal@sial.com
www.safcglobal.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Tom Gelineau, (314) 301-2077, email: tgelineau@sial.com

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

SCIARRA LABORATORIES, INC.
485-09 S. Broadway
Hicksville, NY 11801
Phone: (516) 933-7853 Fax: (516) 933-7807
email: sciarralabs@att.net
www.sciarralabs.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: John J. Sciarra

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



SCOLR Pharma, Inc.

SCOLR Pharma, Inc.
3625 132nd Avenue SE, Suite 400
Bellevue, WA 98006
Phone: (425) 373-0171 Fax: (425)-373-0181
email: info@scolr.com
www.scolr.com



Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Stephen Turner

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

SMITHS MEDICAL ASD, INC,
2231 Rutherford Road
Carlsbad, CA 92008
Phone: (866) 286-6226 Fax: (760) 929-0147
www.smiths-medical.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Safety Devices for Injection, Syringe Pumps & Accessories for Infusion

Contact: Mark Baumgartner, Business Development Manager

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



SPI PHARMA
321 Cherry Lane
New Castle, Delaware 19720
Phone: (302) 576-8500 x 8554
Fax: (302) 576-8567
www.spipharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Sarat Chandar

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



Spray Analysis
and Research Services

SPRAY ANALYSIS AND RESEARCH SERVICES
P.O. Box 7900
Wheaton, IL 60187
Phone: (800) 95-Spray Fax: (630) 260-7593
e-mail: info@sprayconsultants.com
www.sprayconsultants.com

Please check the categories in which your company provides the service.

- Drug Discovery Laboratory Testing Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Elizabeth Kucharz

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

SRI INTERNATIONAL
333 Ravenswood Avenue
Menlo Park, CA 94025
Phone: (866-451-5998) Fax: (650) 859-3041
email: biosciences@sri.com
www.sri.com/biosciences

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Client Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

STEPAN COMPANY
100 West Hunter Avenue
Maywood, NJ 07607
Phone: (201) 712-7642 Fax: (201) 712-7648
email: jbutterwick@stepan.com
www.stepan.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Analytical Testing & Analysis Process Development

Contact: James M. Butterwick

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

TEXMAC

TEXMAC INC.
3001 Stafford Drive
Charlotte, NC 28208
Phone: (704) 393-6555 Fax: (704) 392-1621
email: yosaka@texmacusa.com
www.texmac.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Other: Machinery distribution - Transdermal patch film coating - Hirano Coating machine distribution

Contact: Yashi Osaka

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



TUNNELL CONSULTING, INC.
900 East Eighth Avenue, Suite 106
King of Prussia, PA 19406
Phone: (610) 337-0820 Fax: (610) 337-1884
e-mail: tunnell@tunnellconsulting.com
www.tunnellconsulting.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Stephanie A. Haase

CONTRACT PHARMACEUTICAL & Biological Development Services

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

UNIVERSITY OF IOWA/COLLEGE OF PHARMACY/
CENTER FOR ADVANCED DRUG DEVELOPMENT
100 Oakdale Campus, Room 1 PRL
Iowa City, IA 52242-5000
Phone: (319) 335-4096 Fax: (319) 335-4374
e-mail: alta-botha@uiowa.edu
www.pharmacy.uiowa.edu/service/index.htm

Please check the categories in which your company provides the service.

- Laboratory Testing Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Other: Manufacturing of tablets, capsules, injectables and lyophilized drug products, clinical trial blinding or over-encapsulation; capable of handling potent material, licensed to handle controlled substances; method development, validation according to ICH guidelines, development of dissolution procedures and validation of the analytical method, preformulation, development of formulations, API, excipients and drug product testing according to official monographs

Contact: Alta Botha, D.Sc.

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

VETTER PHARMA-FERTIGUNG GMBH & Co. KG
Schuetzenstr. 87
Ravensburg, Germany 88212
Phone: +49 751 3700 0 Fax: +49 751 3700 4000
email: info@vetter-pharma.com
www.vetter-pharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Other: Contract Manufacturing, Process Development/Scale-Up, Aseptic Filling of Syringes/Vials/Cartridges, Lyophilization

Contact: Suzan Frohmann

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

UPM PHARMACEUTICALS, INC.
6200 Seaforth Street
Baltimore, Maryland 21224
Phone: (410) 843-3738 Fax: (410) 633-4438
email: info@upm-inc.com
www.upm-inc.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Contact: Rich Ryzenka

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

WEST PHARMACEUTICAL SERVICES, INC.
101 Grodon Drive
Lionville, PA 19341
Phone: (800) 231-3000 Fax: (610) 594-3000
www.westpharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Analytical Testing & Analysis Process Development

Other:

Refillable Syringe Systems – Vinod.vilivalam@westpharma.com

Custom Injection Molding for drug delivery systems: Mike.Treadaway@techgroup.com

Package Testing: West Monarch Analytical Laboratories, jennifer.riter@westpharma.com

Reconstitution Systems: Medimop Projects Ltd; graham.reynolds@westpharma.com

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

VALOIS
50 Avenue de l'Europe
Marly-le-Roi, France 78164
Phone: +33 (0) 1 39 17 20 20 Fax: +33 (0) 1 39 58 12 98
www.valoispharma.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging
 Laboratory Testing

Contact: Guillaume Brouet - Lab Manager

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

XEMPLAR PHARMACEUTICALS, LLC
200 Riegenbach Road
Fall River, MA 02720
Phone: (508) 676-6726 Fax: (508) 676-6546
email: charles.eck@xemplarpharm.com
www.xemplarpharm.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Analytical Testing & Analysis Process Development

Other: Aerosol Delivery Systems, Double Blind Masking Devices

Contact: Charles R. Eck

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES

VECTURA LIMITED
One Prospect West
Chippenham
Wiltshire, SN14 6FH
United Kingdom
Phone: (+44) (0)1249 667667
www.vectura.co.uk

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Other: Inhalers

Current Partnerships: Various

Contact: Doug Smalley, Director of Business Development, (+) 44 (0) 1249 667667

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



YPSOMED AG
Brunnmattstrasse 6
Burgdorf, Switzerland 3401
T: +41 34 424 41 11 Fax: +41 34 424 41 22
www.ypsomed.com
e-mail: info@ypsomed.com

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Analytical Testing & Analysis Process Development

Other:

Contact: Ian Thompson, Manager Business Development

CONTRACT PHARMACEUTICAL & BIOLOGICAL DEVELOPMENT SERVICES



Genzyme Pharmaceuticals
675 West Kendall Street - Cambridge, MA 02142
Phone: (800) 868-8208 or (617) 374-7248
Fax: (617) 768-9765
E-mail: pharmaceuticals@genzyme.com
www.genzymepharmaceuticals.com

See Company Profile

Please check the categories in which your company provides the service.

- Drug Discovery Analytical Development Formulation Development Stability Testing
 Clinical Trial MFG/Scale-up Technology/Transfer Manufacturing Packaging

Analytical Testing & Analysis Process Development

Other:

MACHINERY & LABORATORY

Equipment and Software

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

THE AEGIS TECHNOLOGIES GROUP
13062 Highway 290 West
Austin, TX 78737
Phone: (800) 647-2275 Fax: (512) 615-3574
email: sales@aegisxcellon.com
www.aegisxcellon.com

Type of Software & Brand Name:	Application(s):
acslXtreme	acslXtreme is a modeling, execution and analysis environment for continuous dynamic systems and processes. Versatile and powerful enough to address the most challenging simulation problems.
asciXtreme	acslXtreme is a powerful application for fast, efficient simulation execution and analysis. It allows users to conduct sophisticated model analysis without having to be a model developer.

Contact: Mark Green

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

ARIZONA INSTRUMENT
1912 West 4th Street
Tempe, AZ 85281
Phone: (602) 470-1414 Fax: (480) 804-0656
email: azi@azic.com
www.azic.com

Type & Brand Name of Instrument/System:	Application:
Moisture/Solids/Ash Analyzer - Computrac MAX, Computrac Vappor Pro	Used in R&D, quality control, and industrial process control. Durable and easy to use, these analyzers are equally suitable for production floor or laboratory environments.

Contact: Julie Driver or Terri Thomas

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

ASSURX INC.
305 Vineyard Town Center, Suite 374
Morgan Hill, CA 95037
Phone: (408) 778-1376 Fax: (408) 776-1267
email: tamar@assurx.com
www.assurx.com

Type of Software & Brand Name:	Application(s):
Enterprise Quality Tracking-CATSWeb	AssurX offers CATSWeb, a browser-based corrective-action tracking system that complies to FDA 21 CFR Part 11 regulations. The software helps manufacturers track and manage issues, customer complaints, supplier returns, and other corrective actions. Customization and extensibility features have been designed into the core of the program, which is accessible from remote systems running a variety of operating systems.

Contact: Tamar June

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE



CAPSUGEL
535 North Emerald Road
Greenwood, SC 29646
Phone: (888) 783-6361 Fax: (888) 783-6360
email: Glenda.oliver-smith@pfizer.com
www.capsugel.com

Type & Brand Name of Instrument/System:	Application:
Xcelodose®	Precision micro-filling system eliminates the need for formulation or excipients for first-in-man trials. Precise from 100 micrograms to 100 milligrams with an RSD of less than 2%
CFS 1000	Liquid filling and sealing system for up to 1200 capsules per hour for R&D
Profill 300	Bench-top capsule filling system for up to 7,000 capsules per hour
Ultra 8 II	Semi-automatic production scale capsule filling machine



Contact: Glenda Oliver-Smith

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

EMERSON RESOURCES, INC.
600 Markley Street
Norristown, PA 19401
Phone: (610) 279-7450 Fax: (610) 292-9722
email: info@emersonresources.com
www.emersonresources.com

Type & Brand Name of Instrument/System:	Application:
HPLC TOC GC IR UV Dissolution Texture analyzer DSC	Formulation Development Analytical Methods Development & Testing

Contact: Walter Strathy

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

ERWEKA AMERICA CORP.
70 Church Street, Suite 102
Flemington, NJ 08822
Phone: (908) 788-4666 Fax: (908) 788-4667
email: sales.usa@erweka.com
www.erweka.com

Type & Brand Name of Instrument/System:	Application:
Inhaler Testers	MDI and DPI models consisting of Anderson Type Cascade, Astra Draco Multi-Stage Liquid Impinger, as well as Single Stage Impinger's are available, in accordance with all testing procedures within the USP.
DT Series Dissolution Testers	Complete range of apparatus in two versions, standard High Head and Low Head model designed to reduce evaporation loss. Complete on-line & off-line systems, in addition to integration with external HPLC units.
ZT Series Disintegration Testers	From manually controlled units to fully automated systems, available with either single or multiple test baskets, either 6 cell and 3 cell test basket configurations.
TBH Series & MC Series Tablet Tester	Commencing with a hand-held unit designed for hardness measurement; up to fully automated units which can be integrated with an external computer for compliance with CFR 21 Part 11.
Friability Testers	Three different models, available with either a single or dual drum configuration. The TA operates with a fixed speed of 25 RPM, whereas the TAR and TDR is variable from 20-4000 RPM.
CWS Check Weigher	Modular check weighing system permits up to 50 different test samples. Unit automatically individualizes the samples and transport them to a balance, then displays & transports samples to a container.
Powder and Granulate Tester	Three different models designed to offer measurement of flow time according to specified amount (weight or volume) or amount (weight).
Suppository Testers	Four different units designed to measure sample hardness and disintegration. Single and multiple test cells are available.
All Purpose Drive	The AR 402 is the drive system which permits the use of twenty-one different attachments. Some modules include wet or dry granulator, planetary stirrer, sieve analysis, pelletizer, homogenizer & tablet press.
Fluid Bed Tester	Lab unit designed to accommodate all aspects of fluidizing (i.e. powder, crystals, granules, extrudates, pellets, etc.) Two sizes are 50-300 grams, as well as 250-1000 grams.
VDT Blister Tester	Vacuum blister density checker permitting samples in an external pressurized container (-1200 to -800 mbar) which is then filled with liquid; then tested within a range of up to 99 minutes and 50 seconds.

Contact: JR Alicea

MACHINERY & LABORATORY

Equipment and Software

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

FLEXICON AMERICA INC.
156 College Street
Burlington, VT 05401
Phone: (802) 657-3232 Fax: (802) 657-3202
www.flexiconamerica.com

Type & Brand Name of Instrument/System:	Application:
Peristaltic Liquid Filling Dispenser	BioPharma small to medium scale liquid fillings
Liquid filling machinery: semi-automatic to fully automatic	Liquid filling for labs, R&D pilot and production manufacturing.

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

HORIBA INSTRUMENTS, INC.
17671 Armstrong Avenue
Irvine, CA 92614
Phone: (949) 250-4811 Fax: (949) 250-0924
email: labinfo@horiba.com
www.horiba.com

Type & Brand Name of Instrument/System:	Application:
Particle Size Analyzer - LA 930	Full range particle size analyzer, measuring dispersions or dry powders from 0.02-2000 microns, with complete accuracy and resolution, with a full range of accessories.
Particle Size Analyzer - LB 550	DLS particle size analyzer measuring 1nm - 6 microns over a wide range of concentrations. Accurate measurement of distribution shape and modes without operator input.

Contact: Duncan Griffiths

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

IMAGETHERM
142 North Road
Sudbury, MA 01776
Phone: (978) 443-1989 Fax: (978) 443-8942
email: info@imagetherm.com
www.imagetherm.com

Type & Brand Name of Instrument/System:	Application:
SprayVIEW® Measurement System	Automated measurement system for pharmaceutical drug nasal sprays, metered dose inhalers and oral spray for the testing of spray pattern and plume geometry.
SprayVIEW® Actuation System	Automated actuation system for pharmaceutical drug nasal sprays, metered dose inhalers and oral spray for automated device actuation.

Contact: Dino Farina

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

INNOVASYSTEMS, INC.
840 Lenola Road, Unit 8
Moorestown, NJ 08057
Phone: (856) 722-0410 Fax: (856) 722-0042
email: info@InnovaSystemsInc.com
www.innovasystems.com

Type & Brand Name of Instrument/System:	Application:
<ul style="list-style-type: none"> - MightyRunT Actuation Station, Force-Controlled - NSP VA Actuation Station, Velocity-Controlled - PAWS - Pump Actuation & Weight Station - OSA - Optical Spray Analyzer - NSP DW - Dose Weight Station - NSP DWC - Dose Weight with Collection Station 	Automation Supporting Testing of Nasal Spray Products, Dosing Devices and Ophthalmic Solutions to include: <ul style="list-style-type: none"> • Wasting • Droplet Size • Dose Weights/Content Uniformity • Spray Pattern • Plume Geometry
MDI AC2 - Automated Canister Cutter MDI AS - Actuation, Collection Station MDI FD-10 - Fire-Down Station MDI DW - Dose Weight Station	Automation to Support Testing of Inhalers to include: <ul style="list-style-type: none"> • Cutting Cans - Total Can Content • Wasting • Priming/Repriming • Tail-Off Profile • Leak Rate • Particle Sizing • Dose Weights
Automated Extraction Station	Automation to Support Sample Preparation of Ointments, Creams and Pastes. Weighs, dispenses sample to target weight, dilutes, caps and mixes in preparation for analysis.
Type of Software & Brand Name:	Application(s):
EZ Spray™	Low-cost alternative to optical spray pattern analysis via easy-to-use, desktop scanner based technology. EZ Spray™ scans patterns on TLC plates and computes FDA-recommended Spray Pattern Test parameters.

Contact: Loren Wagner

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

LCI CORPORATION
PO Box 16348
Charlotte, NC 28297-8804
Phone: (704) 394-8341 Fax: (704) 392-8507
email: info@lccorp.com
www.lccorp.com

Type & Brand Name of Instrument/System:	Application:
Multi Granulator MG-55	Allows formulation/product developers to evaluate three low pressure granulation techniques—dome, radial, and axial extrusion—and determine which one best suits their product.
Laboratory Marumerizer QJ-230T	Easily evaluates the effectiveness of spheronization on extruded products; converts moist cylindrical extruded granules into smooth, uniform spheres in a variety of applications.

Contact: Sam Habash

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

MALVERN INSTRUMENTS
10 Southville Road
Southborough, MA 01772
Phone: (508) 480-0200 Fax: (508) 460-9692
email: info@malvernusa.com
www.malverninstruments.com

Type & Brand Name of Instrument/System:	Application:
Laser Diffraction Systems, Mastersizer 2000, Spraytec, Also on-line particle sizing with Insittec	For particle size in solids, liquids, slurries and aerosols
Pipeline Technologies/Platforms	Application(s):
Zeta Potential and sub-micron particle size, Zetasizer Nano	For comprehensive analysis of suspensions and emulsions

Contact: Mansa Fraser, (508) 480-0200

NEW-ELECTRONIC EDITION

All advertisers appearing in our print edition will also appear in the electronic edition of *Drug Delivery Technology* with active links to their Web site. The electronic edition also provides advertisers with global distribution of their message.



MACHINERY & LABORATORY

Equipment and Software

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

MISTRAL PHARMA INC.
2101 Halpern
St-Laurent, Quebec H4S 1S3 - Canada
Phone: (514) 920-0909 Fax: (514) 920-0404
www.mistralpharma.com
e-mail: info@mistralpharma.com

Type & Brand Name of Instrument/System:	Application:
Dissolution Tester – VARIAN/SOTAX	Test drug release from solid dosage forms at different predetermined time intervals. Different methods can be used: paddle or baskets depending of tablet design. Dissolution bath is coupled to a pump (for sample withdrawal) and then to a UV/visible spectrophotometer.
Disintegration Tester – Globe Pharma	Tablets are subjected to up and down movement at a constant frequency rate (29-32 cycles/min) and time for complete disintegration is recorded.
Hardnes Tester (Pharma Test)	Test tablet hardness. Pressure parallel to tab diameter is applied until tab breaks.
Friabilator (Globe Pharma)	Test tab friability. Tablets are subjected to an upward circular motion & downward drops (25/min). Differences of weight (before and after) should not exceed 1%.
Infrared Balance (Mettler Toledo)	Test humidity of powders & granules.
Tap Density Tester (Globe Pharma)	For powders & granules. To test tapped density. Known mass is placed in a cylinder and volume is measured. Then cylinder is subjected to predetermined taps (vertical) process is continued till volume no longer changes.
Sonic Sifter (ATM Corporation)	To measure particle size distribution. Powders/granules are placed on top of a series of screens. The set is subjected to vibration & shocks

Contact: Alain Desjardins

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

NATOLI ENGINEERING
28 Research Park Circle
St. Charles, Missouri 63304
Phone: (636) 926-8900 Fax: (636) 926-8910
email: sales@natoli.com
www.natoli.com

Type & Brand Name of Instrument/System:	Application:
Manufacturing and Tablet Compression, Tablet Presses, and Replacement Parts	Production & Quality Control
Type of Software & Brand Name:	Application(s):
Tablet CAD	Tablet design
Tool Management II (TMII) New Version 4.1	Inspections & tool record keeping

Contact: Dale Natoli

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

OSG NORWICH PHARMACEUTICALS, INC.
6826 State Highway 12
Norwich, NY 13815
Phone: (607) 335-3000 Fax: (607) 335-3100
email: Bob.Calabro@norwichpharma.com
www.norwichpharma.com

Type of Software & Brand Name:	Application:
SAP	Full version of SAP to run the business
Type & Brand Name of Instrument/System:	Application(s):
Complete analytical, micro, and stability labs including but not limited to HPLC, GC, UV/Vis Spec, FTIR Spec, Dissolution (manual and automated), Auto-titration, Complete wet chemistry, Bacteria/Yeast/Fungal ID, Method development and transfer, Product screening using Steri-Screen, Sterile products testing, Autoturb, Biolog, Bioluminescence. Full ICH Chambers available: 30°C/65%RH, 25°C/60%RH, 30°C/60%RH, 40°C/75%RH 30°C/70%RH, (Zone IV), 30°C/ambient	Provide outsourcing services to our clients to support the manufacturer and packaging of products for them

Contact: Bob Calabro

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

OXFORD LASERS INC.
2 Shaker Road, Unit D201
Shirley, MA 01464
Phone: (978) 425 0755 or (800) 222-3632 Fax: (978) 425-4487
www.oxfordlasers.com
e-mail: EnVision@Oxfordlasers.com

Type & Brand Name of Instrument/System:	Application:
EnVision Pharma Software	Software to determine spray pattern data (shape, size and orientation) and plume geometry (angle, width, orientation, and length) in accordance with FDA guidelines for MDI and nasal devices.
VisiSizer Software	Image-based particle size analysis software
Vector analysis software	Used to determine velocity vectors over defined region. When used in combination with EnVision system, will report velocity changes over event duration.
EnVision Pharma QC system	Imaging system provides plume geometry and spray pattern information in accordance with FDA guidelines, system configured for nasal and MDI devices, 21CFR Pt 11, automated analysis
EnVision Pharma R&D system	Advanced imaging system for R&D environment for device development provides standard plume geometry and spray pattern information, also, particle size, velocity vector analysis and high-speed imaging.
Micro-Machining Systems	Advance machining system, for small hole and features, in a wide range of materials, product and R&D systems available.
Micro-Machining Job shop	Advanced machining labs for product development and batch processing. Machine features to +/- 1 micron and hole size down to 1 micron. Range of pinholes available for calibrated leak testing.

Contact: Dr Séamus D. Murphy, EnVision@Oxfordlasers.com, (978) 425 0755

MACHINERY & LABORATORY

Equipment and Software

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

PARTICLE AND COATING TECHNOLOGIES, INC.
5445 Highland Park Drive
St. Louis, MO 63110
Phone: (314) 535-1516 Fax: (314) 535-1514
email: rsparks@pctincusa.com
www.pctincusa.com

Type & Brand Name of Instrument/System:	Application:
Micro-Capacity Spray Dryer	Can dry samples from 25 mg. to grams. Special handling for highly unstable molecules (peptides, hormones, etc.) On market early 2006.
Mini-Fluid-Bed	Successful in coating samples down to 5 grams. On market early 2006.

Contact: Robert Sparks, email: rsparks@pctincusa.com

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

PHARMATEK LABORATORIES INC.
5626 Oberlin Drive, Suite 100
San Diego, CA 92121
Phone: (858) 587-8783 Fax: (858) 587-8771
email: info@pharmatek.com
www.pharmatek.com

Type & Brand Name of Instrument/System:	Application:
Hot Road Chemistry® (HRC) Formulation Screening Kit	Designed to solubilize even the most difficult drug compounds for <i>in vivo</i> animal testing. The kit contains eight non-toxic, FDA-approved, orally available formulations.

Contact: Elizabeth Hickman, ehickman@pharmatek.com, (858) 587-8783

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

RESPIRONICS RESPIRATORY DRUG DELIVERY
41 Canfield Road
Cedar Grove, NJ 07009
Phone: (800) 962-1266 Fax: (724) 387- 5270
e-mail: mark.elphick@respironics.com
www.respironics.com

Type & Brand Name of Instrument/System:	Application:
Adaptive Aerosol Delivery (AAD)	AAD was designed to deliver the right amount of medication to the patient regardless of size or breathing patterns. It monitors a patient's breathing pattern throughout the treatment. I-neb AAD delivers the medication only when a patient breathes in. This timing gives the medication the best opportunity to reach deep into the lungs and greatly reduces exhaled or escaped medication, minimizing waste of drug to the environment. By monitoring breathing patterns, the I-neb AAD system can also provide valuable patient feedback to ensure optimal patient technique and compliance to therapy.
I-neb Target Inhalation Mode (TIM)	In TIM mode, the patient is guided to a slow and deep inspiration. With each breath, the patient is trained to lengthen inspiration via a vibration feedback. The TIM mode is based on the assumption that aerosol deposition in the lungs is mainly dependent on airway geometry, particle size, and the patient's breathing pattern, and of these three variables, particle size and breathing pattern are variables that can be altered to increase the deposition of drug in the lungs.
I-neb Insight	I-neb Insight™ was developed for the I-neb AAD system to provide a tool for data monitoring and a tool for training patients to optimize their inhalation cycle. For data monitoring, Insight is used to download the data stored in the patient logging system (PLS). The I-neb Insight functionality has been tested in patients with cystic fibrosis. The data analysis indicates the combination of the PLS function, and Insight can provide a very useful tool for the analysis of adherence and compliance information. This analysis can then be used by healthcare professionals to identify patients who might have problems that could lead to treatment failures. The analysis might also be an important part of a telemedicine network, which increasingly uses computer technology and telecommunication equipment to provide continuous vital sign monitoring and facilitate patient care at home, rather than solely relying on in-person care.

Contact: Mark Elphick

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

SOTAX
411 Caredean Drive, Suite A
Horsham, PA 19044
Phone: (215) 442-1500 Fax: (215) 442-1514
email: sotaxusa@sotax.ch
www.sotax.com

Type & Brand Name of Instrument/System:	Application:
Dissolution Tester: SOTAX AT 7 <i>smart</i>	Ideal for USP 1/2/5/6 Methods and every dissolution laboratory. Designed with the Autocompliance concept, eliminating daily routine validation. Stand-alone unit or upgraded to automatic system.
Dissolution Tester: SOTAX AT 70 <i>smart</i>	Fully automated serial release testing for up to 15 USP 2 tests. High sample throughput combined with efficient cleaning system. Easy to validate.
Dissolution Tester: SOTAX AT 70 BS 60	Fully automated serial release testing for USP 1/2 tests with basket station. Maximum flexibility and sample throughput combined with efficient cleaning system. Easy to validate.
Dissolution Tester: SOTAX CE 7 <i>smart</i>	Automated system for flow-through method tests (USP 4). Suitable for all dosage forms with easy media/pH changes for simple in-vivo simulation. Available online, offline, on-offline.
Disintegration Tester: SOTAX DT 2	Detection of disintegration end point – the most efficient way of testing the disintegration time, either manually or automated.
Hardness Tester: SOTAX HT 1	Testing of four essential physical parameters: hardness/thickness/diameter/weight of a tablet. Revolutionary Auto Alignment device rapidly aligns all common tablet forms for testing.
Hardness Tester: SOTAX HT 10	Semi-automated testing of four essential physical parameters: hardness/thickness/diameter/weight of a batch (up to 20 tablets). With the revolutionary Auto Alignment device.
Hardness Tester: SOTAX: HT 100	Fasted Automated tablet testing system with revolutionary Auto Alignment/Auto Separator devices ensures, consistent, trouble-free results for all shapes and sizes of tablets batch after batch.
Flowability Tester: SOTAX FT 300	Performs a variety of test conditions including mixing and vibration settings. Produces precise and reproducible results on the flowability characteristics of powders and granulates.
Friability Tester: SOTAX F 1 / F 2	The friability testers built with unique front loading and automatic discharge system.
Tap Density Tester: SOTAX TD 2	Compact microcontroller-based tap density tester for simple measuring of the tapped density. Testing of powders, granulates, pellets, flakes and other bulk substances.

Type of Software & Brand Name:	Application(s)
Dissolution software: WinSOTAX	This advanced, menu-driven dissolution software was developed under the latest regulations (GAMP, GALP, ISO 9001) and completely complies with 21 CFR Part 11.
Physical testing software: Q-Doc	Q-Doc physical testing software is a validated Windows (98/NT/2000/XP) software which fully complies with 21 CFR Part 11. Q-Doc is also available with LIMS capabilities.

Contact: Bates Stuart, Finn Marc, Majeski Ray

MACHINERY & LABORATORY Equipment and Software

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE



SPRAY ANALYSIS AND RESEARCH SERVICES
P.O. Box 7900
Wheaton, IL 60187
Phone: (800) 95-Spray Fax: (630) 260-7593
e-mail: info@sprayconsultants.com
www.sprayconsultants.com

Type & Brand Name of Instrument/System:

State-of-the-art spray laboratories capable of characterizing sprays, designing and fabricating prototype spray nozzles and headers, and optimizing spray conditions.

Phase Doppler Particle Analyzers

Laser Diffraction Particle Analyzer

Particle Image Analyzer

Computational Fluid Dynamics software

Application:

Used to measure drop size and velocity of liquid sprays

Used to measure drop size distribution of liquid or powder sprays

Used to measure the size and shape of drops emitted from both opaque and transparent liquid sprays

Used to simulate and predict spray performance using actual customer process conditions

Contact: Elizabeth Kucharz

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

WATERS CORPORATION
34 Maple Street
Milford, MA 01757
Phone: (508) 478-2000 Fax: (508) 872-1990
email: Brian_J_Murphy@waters.com
www.waters.com

Type & Brand Name of Instrument/System:

ACQUITY Ultra Performance Liquid Chromatography™

The Waters® Protein Expression System

SunFire™ columns

The Waters Micromass® Q-ToF Premier Mass Spectrometer

Application:

First-of-its-kind LC system designed to take full advantage of the potential of proprietary, sub two-micron particles. Provides chromatographic run times up to 9X shorter than today's fastest HPLC systems, up to 2X better peak capacity or resolution, and 3X better routine sensitivity.

Industry's first multiplexed system to quantitatively assess changes in protein expression while performing enhanced qualitative protein identification - all within the same LC/MS run.

State-of-the-art reversed-phase C18 bonded silica, which provides the best peak shape, low-pH stability and efficiency.

Hybrid quadrupole, orthogonal acceleration time-of-flight mass spectrometer that enables automated exact mass measurement of precursor and fragment ions to yield the highest confidence for metabolism studies, proteomics and structural analyses.

Type of Software & Brand Name:

MetaboLynx™ software

eLab Notebook™ Software

Application(s):

Features advanced tools for mining complex LC/MS data sets and accelerating the process of identifying drug metabolites.

Allows companies to digitally capture and store scientific information — graphical, mathematical, and textual information of all types — that, today, researchers enter manually into paper laboratory notebooks.

Contact: Brian J. Murphy, (508) 482-2614

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE



WEILER ENGINEERING, INC.
1395 Gateway Drive
Elgin, IL 60123
Phone: (847) 697-4900 Fax: (847) 697-4915
email: solutions@weilerengineering.com
www.weilerengineering.com

Type & Brand Name of Instrument/System:

ASEP-TECH®

Model 640
Model 624
Model 628
Model 603



Application:

Oral, parenteral (Injectable), Respiratory Therapy, Ophthalmic, Nutraceutical

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

WEST PHARMACEUTICAL SERVICES, INC.
101 Gordon Drive
Lionville, PA 19341
Phone: (800) 231-3000 Fax: (610) 594-3000
www.westpharma.com

Type & Brand Name of Instrument/System:

Extractable Leachables Testing

Application:

Tests and evaluates the compatibility of drug products with their packaging or delivery system for the pharmaceutical, biotechnology and medical device industries.

Contact: Jennifer Riter, Jennifer.riter@westpharma.com

MACHINERY & LABORATORY EQUIPMENT AND SOFTWARE

WYATT TECHNOLOGY
6300 Hollister Avenue
Santa Barbara, CA 93117
Phone: (805) 681-9009 Fax: (805) 681-0123
email: info@wyatt.com
www.wyatt.com

Type & Brand Name of Instrument/System:

DAWN light scattering detectors

DynaPro Titan Light Scattering instrument

DynaPro Titan Plate Reader

Application:

Multi-angle light scattering instruments for determining absolute molar masses and sizes of polymers and biopolymers in solution

Dynamic light scattering instruments for determining solution properties of proteins and nanoparticles in solution

Automates the dynamic light scattering to use standard 96 and 384-well plates. Reduces sample preparation and analysis time by a factor of 10.

Contact: Geoffrey Wyatt

DRUG DELIVERY Spotlight

ADVANCED DELIVERY TECHNOLOGIES



Cardinal Health is the global leader in providing outsourced pharmaceutical development services, drug delivery technologies, contract manufacturing, packaging, and product commercialization services, serving the worldwide pharmaceutical and biotechnology industries. The company offers the broadest range of dose-form development and

manufacturing options in the industry - from traditional and proprietary oral forms to sterile products, from inhaled forms to topicals. Cardinal Health holds more than 1,500 patents and patent applications for drug delivery systems. Technologies include soft gelatin capsules; Zydis® fast-dissolve dosage form; EnCirc®, EnVel®, and EnSolv® for oral modified-release products; lyophilization; inhaled technologies; and topical Microsponge® for timed-release and DelPouch® for unit dosing. For more information, contact Cardinal Health at (866) 720-3148 or e-mail pts@cardinal.com; or visit www.cardinal.com/pts.

POLYMERS & DELIVERY TECHNOLOGIES



Pharma Polymers is one of the world leaders in the manufacturing and supplying of functional coatings for the pharmaceutical industry. EUDRAGIT® polymers are ideal for Enteric Delivery, Controlled Release, and Protective Coatings. Based on more than 50 years of experience in EUDRAGIT® polymer design and formulation know-how for pharmaceutical applications, Pharma Polymers has developed intellectual property on advanced oral drug delivery technologies. The different brands of EUDRAPULSE™, EUDRACOL™, and EUDRAMODE™ are the achievements of this intensive research and development effort so far. Pharma Polymers' business models for commercialization of these drug delivery technologies range from the development of customer-specific solutions to out-licensing strategies. For more information, contact Degussa Corporation, Rohm America LLC at (877) 764-6872 (Option 4) or visit www.pharma-polymers.com

DRUG DEVELOPMENT SERVICES



DPT is the source for semi-solids and liquids — from concept to commercialization and beyond. Combining decades of expertise with unlimited production capabilities, DPT provides fully integrated development, manufacturing, and packaging solutions for biopharmaceutical and pharmaceutical products in semi-solid and liquid dosage forms. Drug development services range from

preformulation, formulation and biopharmaceutical development, analytical development and validation, through process development. Specialized production capabilities include four cGMP facilities, clinical trial materials, full-scale commercial production, controlled substance registration Class II-IV, and complete supply chain management. Packaging services encompass engineering and procurement resources necessary for both conventional and specialized packaging. For more information, contact DPT at (866) CALL-DPT or visit www.dptlabs.com.

ORALLY DISINTEGRATING TABLETS



Advatab® is a new generation of ODT technology that offers distinct advantages and unique applications – unparalleled taste, flexible dosing, modified release, and a robust tablet. Advatab can be combined with Eurand's leading Microcaps® taste-masking technology to provide an ODT with superior taste and

mouth-feel. Advatab tablets dissolve rapidly in the mouth within 15 to 30 seconds, and the smooth mixture of carrier excipients and taste-masked drug granules is suitable for delivering high drug doses. Modified-release drug granules can also be incorporated into the Advatab dosage form to provide a fast-dissolve tablet with sustained-release properties. Advatab tablets can be packaged in either bottles or push-through blisters. For more information, contact Eurand at (937) 898-9669 or at bizdev@eurand.com.

DRUG DELIVERY Spotlight

INHALATION & TRANSDERMAL DELIVERY



3M Drug Delivery Systems is a global leader and innovator for inhalation and transdermal drug delivery. From drug discovery to commercialization, 3M offers innovative and proven technology,


product development services, global regulatory expertise, commercial manufacturing, and a broad range of customizable system components. 3M's technology, expertise, and experience can provide pharmaceutical and biotech companies with differentiated products, speed to market, and increased probability of technical and commercial success. 3M's proven track record includes development of the first MDI, HFA MDI, and the first stand-alone 7-day transdermal system. Products manufactured by 3M Drug Delivery Systems are currently sold in more than 60 countries on 6 continents. The company combines the agility of a leading drug delivery company with the resources of a major, multinational corporation, providing expertise in product development, regulatory, and manufacturing to get its partners to market sooner. For more information, contact 3M Drug Delivery Systems at (800) 643-8086 or visit www.3m.com/dds.

OSMOTIC TECHNOLOGY



OROS® technology employs osmosis to provide precise, controlled drug delivery for up to 24 hours and can be used with a range of compounds, including poorly soluble or highly soluble drugs. OROS can be used to deliver high drug doses meeting high-drug loading requirements. L-OROS™ technology, adapted for liquid formulations, can enhance the bioavailability of drugs with low solubility. Targeting specific areas of the GI tract, OROS technology may provide more efficient drug absorption and enhanced bioavailability. L-OROS can also enhance the bioavailability of drugs with low solubility. For many drugs, zero-order is not the optimal delivery profile. OROS can be tailored to meet patterned delivery profiles to optimize a drug's therapeutic efficacy. For more information, contact ALZA Corp. at (650) 564-5000 or visit www.alza.com.

PULMONARY FORMULATION



PROMAXX, Baxter Healthcare Corporation's proprietary drug delivery technology, is designed to enhance formulation success. The protein microsphere technology offers narrow particle size distribution ideal for

delivery to and through the lung. This versatile platform can be applied to a variety of drug classes and has the potential to improve stability of the starting material. Baxter's experience with technology transfer offers clients the option to integrate formulation processing equipment with their manufacturing process. The PROMAXX manufacturing process consists of a simple, robust, gentle process that is water-based whenever possible. This has been shown to preserve the drug's protein structure and activity. Pulmonary formulation challenges? Let Baxter help you overcome them. For more information, contact Baxter Healthcare Corporation at (781) 440-0100 ext. 281 or visit www.baxterbiopharmasolutions.com.

PREFILLABLE DELIVERY SYSTEMS



BD Medical - Pharmaceutical Systems is dedicated to developing prefilled drug delivery systems designed to fit the needs of the pharmaceutical industry. Whether a glass or plastic prefilled syringe, a nasal spray system, a

dry drug reconstitution system, an injection or self-injection device, BD Medical - Pharmaceutical Systems provides the expertise and experience required by the pharmaceutical industry in a packaging partner. We deliver cost-effective alternatives to conventional drug delivery methods, which differentiate pharmaceutical products and contribute to the optimization of drug therapy. All of its prefilled devices are designed to meet healthcare professionals' demands for safety and convenience and to fulfill patients' needs for comfort. BD's worldwide presence, market awareness, and pharmaceutical packaging know-how allow it to propose suitable solutions for all regional markets and parenteral drug delivery needs. For more information, contact BD Medical - Pharmaceutical Systems at (201) 847-4017 or visit www.bdpharma.com.

DRUG DELIVERY Spotlight


PHYSICAL CHARACTERIZATION WORKSHOP



IWPCPS-9 Ninth International Workshop on Physical Characterization of Pharmaceutical Solids, June 24-20, 2007, in Boston, MA, will be presenting information about cutting-edge methods for solid-state characterization, reviewing most recent regulatory issues, and presenting the latest research results in drug development and future outlooks. There will be 5 days of a Commercial Industry Exhibition with vendors of

analytical, state-of-the-art pharmaceutical equipment who will introduce their newest instrumentation and software. Supporting companies include GSK; Boehringer Ingelheim; Amgen Inc; AstraZeneca; Sanofi-Aventis; Setaram; Teraview, UK; Panalytical; Lederer & Keller, Germany; Otago University, New Zealand; University of Toho, Japan; PerkinElmer; TA Instruments and more. For detailed information and abstract submission, visit our [website www.assainternational.com/workshops/IWPCPS_9/IWPCPS_9.cfm](http://www.assainternational.com/workshops/IWPCPS_9/IWPCPS_9.cfm) or contact us at workshops@assainternational.com or +1 203 312 0682.

SOLID-LIPID DISPERSIONS



For diseases requiring rapid and superior therapy, drug absorption from a conventional solid dosage form of drugs with poor absorption potential is often slow and suboptimal. Nanosplode expands the dosage form options of Lipocine's Lipral (for optimal oral bioavailability) and Hydroance (for optimal non-invasive delivery of hydrophilic drugs with poor oral absorption potential) delivery technologies, while preserving their respective performance attributes. Nanosplode offers novel compositions and processes to produce practical solid dosage forms utilizing a broad spectrum of lipid materials. These materials are generally accepted lipid and other formulation excipients already in approved food or drug products. For more information, contact Lipocine, Inc., at (801) 994-7383 or visit www.lipocine.com.

NEW DDS FACILITY



NOF CORPORATION has been supplying Activated PEGs, high-purity phospholipids, and high-performance Polysorbate to pharmaceutical companies throughout the world. Its Activated

PEGs have been used to conjugate with protein drugs so that PEG-stabilized drugs can circulate longer in the bloodstream with improved efficacy. NOF's new DDS plant for manufacturing Activated PEGs has started commercial operation under cGMP since October 2005. The new three-story, 200,000-sq-ft DDS plant now offers a five-fold increase in production capacity. The company's Activated PEGs and new plant have been attracting increasing attention from pharmaceutical companies across the globe. In addition, a new DDS Research Laboratory has just been established in the new building next to the DDS plant to accelerate the development of new products for DDS and satisfy customers. For more information, contact NOF Corporation at (914) 681-9790 or visit www.nof.co.jp/dds.

CONTROLLED DELIVERY PLATFORM




SCOLR Pharma applies its patented CDT® Controlled Delivery Technologies to develop formulations for companies with pharmaceutical, OTC, and nutraceutical products. These elegantly simple technologies can be used for controlled-release periods for up to 24 hours and can be manufactured using readily available standard materials and conventional production equipment.

SCOLR Pharma partners with companies under contractual arrangements that include licensing fees, royalties, manufacturing contracts, or other mutually agreed upon financial arrangements. SCOLR Pharma's CDT® has the many distinct advantages, including highly programmable (capable of a wide range of release profiles), easy to manufacture (employs conventional manufacturing equipment), cost effective (utilizes standard tableting excipients), higher payload (when compared to other technologies), and strong patent protection (full patent life and easy enforcement). For more information, visit SCOLR Pharma at www.scolr.com.

DRUG DELIVERY Spotlight

BBB TRANSPORTER



Lipobridge™ compounds facilitate transport of drugs across the blood-brain-barrier (BBB) and into the CNS. Short chain oligoglycerolipids have been shown to facilitate the delivery, distribution, and uptake of pharmaceutical actives into the CNS and thereby permeate the BBB. Data shows that some of these molecules can increase drug concentration reaching the CNS by a factor up to

100 without toxic side effects. Demonstrated in several laboratories, intracarotid injections of a simple mixture of Lipobridge and model compounds or pharmaceutical actives can be delivered into one or both hemispheres of the brain allowing for increased concentration in a selected hemisphere. This permeability has been shown to be reversible and has been demonstrated that the carrier itself is excreted unmetabolized. For more information, contact Genzyme Pharmaceuticals at (800) 868-8208 or visit www.genzymepharmaceuticals.com.

SUB-Q PROTEIN DELIVERY



Would you like to convert your drugs from IV to subcutaneous (Sub-Q) delivery or enhance the dispersion of your existing Sub-Q compounds? With Enhanze™ Technology, microgram quantities of a fully human recombinant enzyme act as a “molecular machete” to clear the subcutaneous “jungle.” Based upon this mechanism of action, co-delivery with Enhanze is anticipated to permit the Sub-Q administration of large volumes (up to 10 cc) of antibody drugs, speed onset of action relative to Sub-Q delivery without Enhanze, and improve patient comfort. For more information, contact Mark Wilson, Vice President of Business Development (Halozyme Therapeutics) at mwilson@halozyme.com or (858) 794-8889; or visit www.halozyme.com.

MANUFACTURER & API SPECIALIST



Hovione is a fine chemicals company that specializes in the process development and manufacture of active pharmaceutical ingredients and regulated intermediates. Dedicated to solving the problems associated with the industrial production of

complex chemical entities, the company's expertise in process chemistry and regulatory compliance to cGMP standards is based on more than 40 years of experience. Over that time, its ability to provide customers with timely solutions that are dependable and economical has given them a worldwide reputation for superior customer service. Hovione's business is 50% custom synthesis for large pharma and biotech companies and 50% generic products. More than half of today's sales consists of products launched less than 5 years ago. For more information, visit Hovione at www.hovione.com.

IONTOPHORESIS TECHNOLOGIES



IOMED is a leader in the development, manufacture, and sale of active drug delivery systems that employ iontophoresis. IOMED's versatile transdermal and trans-scleral technology allows for custom delivery profiles for local and systemic applications. The company is actively pursuing opportunities to utilize its non-invasive drug delivery systems in combination with specialty pharmaceuticals to offer unique products designed to satisfy unmet medical needs. Licensing, co-development, and marketing agreements are available. For more information, contact IOMED at (801) 975-1191 or visit www.iomed.com.

DRUG DELIVERY Spotlight

DEVICE DEVELOPMENT & MANUFACTURING



Throughout the past 9 years, BC Tech has grown to be one of the most comprehensive contract Medical Product Design, Development, and Manufacturing companies in California. It is established medical equipment manufacturing company with more than 100 medical

devices completed for its satisfied national & international customers. BC Tech designed and developed its 20,000-square-foot facility to facilitate the flow of its multidisciplinary teams and their specialized equipment. BC Tech's seasoned teams have fine-tuned a development process that consistently yields highly effective medical products for its customers. BC Tech's medical equipment development and medical product manufacturing teams provide a highly effective outsourcing solution for companies seeking FDA-registered and ISO 9001-compliant medical equipment. For more information, contact BC Technology, Inc. at (831) 459-6464 or visit www.bctechinc.com.

NASAL DELIVERY DEVICE



The ViaNase ID™ electronic atomizer is the first nasal drug delivery device that incorporates drug pedigree confirmation, lock-out technology, and an electronic display – features that curb counterfeit/competitor drug use and abuse while improving patient compliance. By combining Controlled Particle Dispersion™ and intelligent nasal drug delivery technologies, ViaNase ID intranasally delivers

topical, systemic, and nose-to-brain medical therapies with greater efficacy and efficiency than traditional nasal delivery devices. For more information, contact Kurve Technology at (425) 640-9249; info@kurvetech.com or visit www.kurvetech.com.

SPECIALTY MEDICAL DEVICES



Founded more than 40 years ago, Bespak is a leading supplier of specialty medical devices for the pharmaceutical, healthcare, and diagnostics industries. Bespak's scientific expertise and world-class facilities support the production of products, such as metered dose inhalers (pMDIs), dry powder inhalers (DPIs), actuators, compliance aids,

and medical check valves. As both facilitator and partner, Bespak also offers complete device development services in line with customer requirements. The company has the experience and expertise to manage development programs from concept to full-scale manufacture at a design and engineering level. Each stage of device evolution is supported by regulatory documentation. For more information, visit Bespak at www.bespak.com.

CONTRACT SERVICES



BioConvergence helps clients move products to the clinic and market with speed and quality. The company does this by providing such services as pharmaceutical product development, storage and logistics, and engineering and supply chain consulting. BioConvergence is one of the first companies to offer secure electronic transparency (e-transparency) to its clients, so that they have the data they

need on a real-time basis. To do so, the firm has implemented back-end systems that electronically track all work performed, such as its Electronic Laboratory Notebook (ELN) system used by its scientists, and its Enterprise Resource Planning (ERP) system used by the entire staff. Specific services include Parenteral Development (lyophilization cycle development/optimization), Formulation Development, Analytical Development/Validation, and GLP Toxicology Batch Manufacturing, Storage & Logistics, and Consulting Services. For more information, contact BioConvergence at (800) 978-2462 or visit www.bioc.us.

DRUG DELIVERY Spotlight

SILICONE-COATED PAPERS & FILMS



Loparex specializes in thin coatings on flexible webs in the manufacture of release liners for medical pressure sensitive adhesive (PSA) products. The major categories that define the medical PSA market include: Transdermal Drug Delivery Systems, EKG/ECG Electrodes and Electro-Medical Devices, and Wound Dressings. Key performance characteristics of release liners for medical PSA products include: complete traceability, cleanliness, moisture resistance, and die-cutability. Manufacturing release

liners that satisfy the requirements of both manufacturer and end user is critical. Because of our continuing commitment to leading-edge technologies in chemistry and substrate development, Loparex is uniquely qualified to develop a release liner designed for your unique application. Look to Loparex for all your medical device release liner needs. For more information, contact Loparex, Inc., at (888) 327-5454, ext. 2671 or visit www.loparex.com.

PRODUCT & DEVELOPMENT SERVICES



Given that the capsule dosage form had its genesis in pharmaceutical products, it is easy to understand why CAPSUGEL strives to go far beyond supplying high-

quality capsules. CAPSUGEL's main mission is to assist its customers in the development of new products and line extensions. The company offers a wide range of specialized services to its pharmaceutical customers, for example, it can help provide appropriate technical information on a wide array of topics, such as formulating products for immediate or modified release. Also, its most recent technology can help experts in pharmaceutical development to formulate poorly soluble products. CAPSUGEL can assist in the technical transfer issues associated with scale-up and validation, and it has successfully proven its ability to design the best capsule and packaging that assures the highest level of customer satisfaction. For more information, visit Capsugel at www.capsugel.com.

SPECIALTY EXCIPIENTS



Developed by Huber Engineered Materials, a trusted name in calcium carbonate, silica, silicates, and other specialty excipients, RxCIPIENTS® FM1000 is a fast-melt technology with numerous benefits to formulators and brand managers. RxCIPIENTS® FM1000 is an excipient that enhances tablet disintegration. It's fast, with tablet disintegration in 5 to 30

seconds, and strong, with a low tablet friability allows for standard packaging. It provides consistent tablet disintegration and is the excipient you can formulate in house without the need for a drug delivery company. Formulation scientists who are bringing new products to the market or brand managers who are forecasting line extensions of existing products can begin test formulations with RxCIPIENTS® FM1000 today. For more information, visit Huber Engineered Materials at www.rxcipients.com.

LABORATORY TESTING SERVICES



BioScreen is a full-service laboratory in industrial microbiology and analytical chemistry. The company is US FDA registered, ISO 9001:2000 Certified, DEA registered, and California State Certified to test drinking water. It now offers analytical reports direct from the Internet with

electronic signature, and a blend of science and business with a service-oriented approach. BioScreen is capable of executing USP methods when required as well as designing or researching specialized methods for a unique product or process. The company has also participated in numerous projects for IND, NDA, and ANDA submissions to the FDA. There are four corporate divisions: Pharmaceutical & Biotechnology Services; Medical Device; Cosmetic, Household & Industrial Products; and Midwest Clinical Trials (Human Clinical & Claim Substantiations). For more information, contact BioScreen Testing Services, Inc., at (800) 229-9057 or visit www.bioscreen.com.

DRUG DELIVERY Spotlight

TOPICAL PRODUCT DEVELOPMENT



Dow Pharmaceutical Sciences creates and develops superior topical products for its clients. Dow's vision is to be the best topical product development

company in the world. Since 1977, it has become a full-scope topical product development company able to design, develop, and optimize its clients' topical formulation, utilizing skin-penetration studies from its Skin Biology Laboratory. Dow provides analytical method development and validation, stability testing, clinical materials manufacturing, and labeling and distribution of clinical trial materials. To meet client dermatology needs, the company provides expert staff within regulatory, clinical affairs, and dermatology clinical trial sites to conduct the regulatory planning and filings as well as the non-clinical and clinical testing needed to take products through NDA approval. For more information, contact Dow Pharmaceutical Sciences at (707) 793-2600 or visit www.dowpharmsci.com.

COMBINATION CAPSULE TECHNOLOGY



InnerCap offers an advanced patent-pending multi-phased, multi-compartmentalized capsular-based delivery system. The system can be used to enhance the value and benefits of pharmaceutical and biopharmaceutical products. Utilizing two-piece hard shell capsules, the technology offers the industry solutions to problems affecting pharmaceutical companies, patients, and healthcare providers. The delivery system will be licensed to enhance pharmaceutical and

biopharmaceutical products. It is a very effective way to deliver multiple active chemical compounds in different physical phases with controlled-release profiles. The delivery system provides the pharmaceutical and biopharmaceutical industries with beneficial solutions to the industry's highly publicized need to repackage and reformulate existing patented blockbuster drugs with expiring patents over the next 5 years. For more information, contact InnerCap Technologies, Inc., at (813) 837-0796 or visit www.innercap.com.

FILTRATION & FLUID CONTROL




TO STAY AHEAD OF YOUR COMPETITION,
IT PAYS TO HAVE THE
RIGHT CONNECTIONS.

Filtertek understands how filtration and fluid control ultimately affect a medical product's success. More importantly, the company knows how these devices affect safety for the end user. With medical technology rapidly evolving, Filtertek realizes the knowledge behind the manufacture of these devices has to keep pace with new medical applications and scientific discoveries. With so much riding on performance, designing and developing components for critical medical

applications takes design ingenuity, technical knowledge, and manufacturing precision. By choosing Filtertek to produce medical filtration and fluid control devices, customers are assured of partnering with a source that puts as much into the development of their products as they do. For more information, contact Filtertek at (800) 648-0791 or visit www.filtertek.com.

PRECISION MICRO-FILLING



With the Xcelodose™ system, creating manufacturing batches for clinical trials and small-scale production has never been easier or more precise. That's because this unique technology allows companies to fill capsules with drug substances alone, thereby eliminating the need for excipient compatibility and

preformulation activities. By implementing the Xcelodose system, pharmaceutical companies benefit from a shorter drug development process by reducing the need for costly and time-consuming stability studies, not to mention the avoidance of labor costs and possible inaccuracies associated with hand-filling. This in turn reduces the time taken to reach the "first-in-man" clinical trial decision point, which allows an increase in throughput of candidate compounds for development. For more information, contact Xcelience at (813) 286-0404 or visit www.xcelience.com.

Tech Conference & Pharma Expo

EXCIPIENT FEST Puerto Rico

Excipient Technology for Pharma Formulation & New Drug Application

The Science...

is the Fun!

April 24-25, 2007
The Ritz Carlton
San Juan, Puerto Rico

PLATINUM SPONSOR

MEDIA SPONSOR

JRS PHARMA



Drug Delivery Technology

GOLD SPONSORS



SILVER SPONSORS



excipientfest.com

tel (787) 746-5080

fax (787) 746-8000

info@excipientfest.com

NOVEMBER/DECEMBER 2006

Advertiser Index

<i>Company</i>	<i>Pg</i>	<i>Phone</i>	<i>Web Site</i>
3M Drug Delivery Systems	5, 16,17	800-643-8086	www.3m.com/dds
ALZA Corporation	2, 3		www.alza.com
ASSA International	12	203-312-0682	www.assainternational.com
BASF	18, 19	800-443-0627	www.pharma-solutions.basf.com
Baxter BioPharma Solutions	11,20, 21	800-422-9837	www.baxterbiopharmasolutions.com
BC Technology	4	(831) 459-6464	www.bctechinc.com
Bespak	13, 22	+44 1553 691000	www.bespak.com
BD	24, 25, 123	800-225-3310	www.bdpharma.com
BioScreen Testing Service	6	800-229-9057	www.bioscreen.com
BioConvergence	15, 26	800-978-2462	www.bioc.com
Capsugel	28, 29		www.capsugel.com
Cardinal Health	30, 31, 124	866-720-3148	www.cardinal.com/pts
Coating Place Inc.	32, 33	608-854-9521	www.encap.com
Controlled Release Society	27	651-994-3817	www.controlledrelease.org
Degussa	34, 35		www.pharma-polymers.com
DPT Laboratories	36, 37	866-CALL-DPT	www.dptlabs.com
Drug Delivery Partnerships	38,39		www.drugdeliverypartnerships.com
Eurand	7, 40, 41	937-898-9669	www.eurand.com
ExcipientFest	121	787-746-5080	www.excipientfest.com
Filtertek Inc.	42, 43	1-800-648-0791	www.filtertek.com
Genzyme Pharmaceuticals	44, 45	800-868-8208	www.genzyme pharmaceuticals.com
Glatt Pharmaceutical Services	46, 47	201-825-8700	www.glattpharmaceuticals.com
Halozyme	48, 49	858-794-8889	www.halozyme.com
Hovione	50, 51	609-918-2600	www.hovione.com
Huber Engineering	52, 53	866-881-6480	www.rxipients.com
Iomed	54, 55	801-975-1191	www.iomed.com
Kurve Technologies	56, 57	425-640-9249	www.kurvetech.com
Lipocine	58, 59	801-994-7383	www.lipocine.com
Loparex Inc.	60, 61	888-327-5454	www.loparex.com
NOF Corporation	62, 63	914-6819790	www.nof.co.jp/dds
PharmaCircle	14	847-729-2960	www.pharmacircle.com
PharmaMed Device	70		www.pharmameddevice.com
RDD Europe	25		www.rddonline.com
Safety Syringes	64,65	760-918-9908	www.safetysyringe.com
Scolr Pharma, Inc	9, 66, 67	425-373-0171	www.scolr.com
Weiler Engineering	68, 69	847-697-4900	www.weilerengineering.com

BD™ Self-Injection Systems

Bringing you solutions for the home care market



Helping all people
live healthy lives

BD Pen II and BD Liquid-Dry Pen

While most patients can use the traditional vial and syringe effectively, it can also prove to be complicated and inaccurate for those who are young, elderly and/or physically/visually impaired¹. Self-Injection pens are easy to use and help deliver a more precise dosage². BD offers a broad array of self-administration system designs to help meet your product and patient needs.

BD also offers a line of pen needles, which come in a variety of lengths and gauges and are among the thinnest and sharpest needles available on the market.

- Customizable body designs and colors
- Adaptable for liquid or lyophilized drugs
- Reusable and disposable systems
- Adjustable or fixed doses

**For more information, please call
800-225-3310 or visit www.bdpharma.com**

¹ Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. *Clin Ther*. 1998;20(3):486-496.

² Weiss, PM., http://www.femalepatient.com/html/aru/sig/pharma/articles/028_07_031.asp

Reduce stress. Eliminate worry. Increase relaxation.



Oral Solids Manufacturing

Our technical expertise and commitment to customer service will put your manufacturing worries to rest.

You've invested hundreds of millions of dollars, years of research and untold amounts of effort into developing your product. It's about time you took some of the stress out of the manufacturing process.

Cardinal Health has the technical expertise, infrastructure and resources to help you do just that. Our advanced oral solids manufacturing facilities and dedicated project management systems can help you commercialize your product.

We provide:

- **First-class manufacturing services that meet your needs for scale, breadth and value**
- **Consistent, on-time delivery and reliable customer service**
- **A strong commitment to your commercial objectives**

Essential Facts

Serving Size: Multiple manufacturing sites to meet any need from clinical to commercial scale.

	% DV*
Quality	100%
Reliability	100%
Customer Service	100%
Capacity	100%
Consistency	100%

*Percent Daily Values (DV) are based on a healthy business plan and intelligent outsourcing.



Delivering quality, capacity and peace of mind.

As a world leader in the manufacture of oral dosage forms, Cardinal Health can deliver the one result you value most: getting your product to market without costly delays... or unnecessary anxiety.

www.cardinal.com/pts

1.866.720.3148 U.S.

+44 (0) 1793 864000 Europe

pts@cardinal.com e-mail


CardinalHealth
Working together. For life.™